original_id,original_type,normalized_id,normalized_type,PubMedID
nonsmallcell lung cancer,class_id,nonsmallcell lung cancer,class_id,34339292
epidermal growth factor receptor,class_id,epidermal growth factor receptor,class_id,34339292
egfr exon 20 insertion mutation,class_id,egfr exon 20 insertion mutation,class_id,34339292
tyrosine kinase inhibitor,class_id,tyrosine kinase inhibitor,class_id,34339292
amivantamab,class_id,amivantamab,class_id,34339292
chrysalis,class_id,chrysalis,class_id,34339292
phase i,class_id,phase i,class_id,34339292
dose escalation,class_id,dose escalation,class_id,34339292
dose expansion,class_id,dose expansion,class_id,34339292
egfr exon20ins nsclc,class_id,egfr exon20ins nsclc,class_id,34339292
overall response rate,class_id,overall response rate,class_id,34339292
recommended phase ii dose,class_id,recommended phase ii dose,class_id,34339292
infusion-related reaction,class_id,infusion-related reaction,class_id,34339292
paronychia,class_id,paronychia,class_id,34339292
hypokalemia,class_id,hypokalemia,class_id,34339292
pulmonary embolism,class_id,pulmonary embolism,class_id,34339292
diarrhea,class_id,diarrhea,class_id,34339292
neutropenia,class_id,neutropenia,class_id,34339292
platinum-based chemotherapy,class_id,platinum-based chemotherapy,class_id,34339292
mitochondrial unfolded protein response,preferred_label,mitochondrial unfolded protein response,preferred_label,34338986
breast cancer,preferred_label,breast cancer,preferred_label,34338986
cisplatin,preferred_label,cisplatin,preferred_label,34338986
clpp,preferred_label,clpp,preferred_label,34338986
hsp,preferred_label,hsp,preferred_label,34338986
lonp1,preferred_label,lonp1,preferred_label,34338986
sirt3,preferred_label,sirt3,preferred_label,34338986
nicotinamide ribose,preferred_label,nicotinamide ribose,preferred_label,34338986
photothermal therapy,preferred_label,photothermal therapy,preferred_label,34338525
inflammation,preferred_label,inflammation,preferred_label,34338525
immune escape,preferred_label,immune escape,preferred_label,34338525
metastasis,preferred_label,metastasis,preferred_label,34338525
normal cell,preferred_label,normal cell,preferred_label,34338525
mildtemperature ptt,preferred_label,mildtemperature ptt,preferred_label,34338525
nanosystem,preferred_label,nanosystem,preferred_label,34338525
hepg2 cancer cell,preferred_label,hepg2 cancer cell,preferred_label,34338525
zinc glutamatemodified prussian blue nanoparticles,preferred_label,zinc glutamatemodified prussian blue nanoparticles,preferred_label,34338525
triphenylphosphineconjugated lonidamine,preferred_label,triphenylphosphineconjugated lonidamine,preferred_label,34338525
heat shock protein,preferred_label,heat shock protein,preferred_label,34338525
physicochemical property,preferred_label,physicochemical property,preferred_label,34338525
antitumor efficacy,preferred_label,antitumor efficacy,preferred_label,34338525
nanoparticles,preferred_label,nanoparticles,preferred_label,34338525
hepg2 cell membrane,preferred_label,hepg2 cell membrane,preferred_label,34338525
circulation time,preferred_label,circulation time,preferred_label,34338525
cancer cell,preferred_label,cancer cell,preferred_label,34338525
atp,preferred_label,atp,preferred_label,34338525
nanocomposites,preferred_label,nanocomposites,preferred_label,34338525
biomedical application,preferred_label,biomedical application,preferred_label,34338525
Posttransplant lymphoproliferative disorder,class_id,Posttransplant lymphoproliferative disorder,class_id,34338127
Brentuximab vedotin,class_id,Brentuximab vedotin,class_id,34338127
Rituximab,class_id,Rituximab,class_id,34338127
Neutropenia,class_id,Neutropenia,class_id,34338127
Hypertension,class_id,Hypertension,class_id,34338127
Infection,class_id,Infection,class_id,34338127
Peripheral neuropathy,class_id,Peripheral neuropathy,class_id,34338127
Fluorouracil,drug,Fluorouracil,drug,34337082
Curcumin,drug,Curcumin,drug,34337082
Intestinal mucositis,disease,Intestinal mucositis,disease,34337082
Cancer,disease,Cancer,disease,34337082
Inflammation,biological process,Inflammation,biological process,34337082
Intestinal epithelial cells,cell type,Intestinal epithelial cells,cell type,34337082
IL-STAT3 signaling pathway,biological pathway,IL-STAT3 signaling pathway,biological pathway,34337082
portal vein tumor thrombosis,class_id,portal vein tumor thrombosis,class_id,34337041
transarterial chemoembolization,class_id,transarterial chemoembolization,class_id,34337041
hepatic arterial infusion chemotherapy,class_id,hepatic arterial infusion chemotherapy,class_id,34337041
Hepatocellular carcinoma,class_id,Hepatocellular carcinoma,class_id,34337041
fluoropyrimidines,class_id,fluoropyrimidines,class_id,34331561
cancer patient,class_id,cancer patient,class_id,34331561
toxicity,class_id,toxicity,class_id,34331561
pharmacogenes,class_id,pharmacogenes,class_id,34331561
gastrointestinal cancer patient,class_id,gastrointestinal cancer patient,class_id,34331561
polymorphism,class_id,polymorphism,class_id,34331561
genotyping technology,class_id,genotyping technology,class_id,34331561
ancestry analysis,class_id,ancestry analysis,class_id,34331561
gene,class_id,gene,class_id,34331561
brazilian amazon,class_id,brazilian amazon,class_id,34331561
population,class_id,population,class_id,34331561
biomarkers,class_id,biomarkers,class_id,34331561
cyclophosphamide,drug,cyclophosphamide,drug,34331111
bortezomib,drug,bortezomib,drug,34331111
fludarabine,drug,fludarabine,drug,34331111
mcl,disease,mcl,disease,34331111
neutropenia,adverse event,neutropenia,adverse event,34331111
thrombocytopenia,adverse event,thrombocytopenia,adverse event,34331111
Therapeutic Drug Management,may_treat,Therapeutic Drug Management,may_treat,34330885
Colorectal Cancer,has disease,Colorectal Cancer,has disease,34330885
Fluorouracil-based Chemotherapy,may_treat,Fluorouracil-based Chemotherapy,may_treat,34330885
Chemotherapy Toxicity,adverse event occurs in,Chemotherapy Toxicity,adverse event occurs in,34330885
Chemotherapy Efficacy,adverse event outcome,Chemotherapy Efficacy,adverse event outcome,34330885
soft tissue sarcoma,class_id,soft tissue sarcoma,class_id,34330766
talimogene laherparepvec,preferred_label,talimogene laherparepvec,preferred_label,34330766
oncolytic virotherapy,preferred_label,oncolytic virotherapy,preferred_label,34330766
melanoma,preferred_label,melanoma,preferred_label,34330766
sarcoma,preferred_label,sarcoma,preferred_label,34330766
radiation therapy,preferred_label,radiation therapy,preferred_label,34330766
herpes simplex virus type 1,preferred_label,herpes simplex virus type 1,preferred_label,34330766
caspase-3,preferred_label,caspase-3,preferred_label,34330766
neoadjuvant folfirinox,treatment,neoadjuvant folfirinox,treatment,34330715
chemoradiation with carboplatinpaclitaxel,treatment,chemoradiation with carboplatinpaclitaxel,treatment,34330715
gastric cancer,disease,gastric cancer,disease,34330715
gastroesophageal cancer,disease,gastroesophageal cancer,disease,34330715
ctdna,biomarker,ctdna,biomarker,34330715
olaparib,drug,olaparib,drug,34329939
platinum-resistant ovarian cancer,disease,platinum-resistant ovarian cancer,disease,34329939
BRCA,gene,BRCA,gene,34329939
high-grade serous or endometrioid ovarian carcinoma,disease,high-grade serous or endometrioid ovarian carcinoma,disease,34329939
pegylated liposomal doxorubicin (PLD),drug,pegylated liposomal doxorubicin (PLD),drug,34329939
progressive multifocal leukoencephalopathy,class_id,progressive multifocal leukoencephalopathy,class_id,34329579
john cunningham virus,class_id,john cunningham virus,class_id,34329579
CD4,class_id,CD4,class_id,34329579
HIV infection,class_id,HIV infection,class_id,34329579
chemotherapy,class_id,chemotherapy,class_id,34329579
immunosuppressive therapy,class_id,immunosuppressive therapy,class_id,34329579
rituximab,class_id,rituximab,class_id,34329579
non-hodgkin lymphoma,class_id,non-hodgkin lymphoma,class_id,34329579
rheumatoid arthritis,class_id,rheumatoid arthritis,class_id,34329579
chronic lymphocytic leukaemia,class_id,chronic lymphocytic leukaemia,class_id,34329579
granulomatosis with polyangiitis,class_id,granulomatosis with polyangiitis,class_id,34329579
microscopic polyangiitis,class_id,microscopic polyangiitis,class_id,34329579
pemphigus vulagris,class_id,pemphigus vulagris,class_id,34329579
classical hodgkin lymphoma,preferred_label,classical hodgkin lymphoma,preferred_label,34329577
brentuximab vedotin,preferred_label,brentuximab vedotin,preferred_label,34329577
ifosfamide,preferred_label,ifosfamide,preferred_label,34329577
carboplatin,preferred_label,carboplatin,preferred_label,34329577
etoposide,preferred_label,etoposide,preferred_label,34329577
autologous haematopoietic stemcell transplantation,preferred_label,autologous haematopoietic stemcell transplantation,preferred_label,34329577
dosedense bvice,preferred_label,dosedense bvice,preferred_label,34329577
Seattle Cancer Care Alliance,preferred_label,Seattle Cancer Care Alliance,preferred_label,34329577
University of Washington,preferred_label,University of Washington,preferred_label,34329577
vascular wall,class_id,vascular wall,class_id,34328715
nanoparticles,class_id,nanoparticles,class_id,34328715
cancer drug delivery,class_id,cancer drug delivery,class_id,34328715
pselectin,class_id,pselectin,class_id,34328715
drug nanocrystals,class_id,drug nanocrystals,class_id,34328715
cupric diethyldithiocarbamate nanocrystals,class_id,cupric diethyldithiocarbamate nanocrystals,class_id,34328715
fucoidan,class_id,fucoidan,class_id,34328715
human umbilical vein endothelial cell,class_id,human umbilical vein endothelial cell,class_id,34328715
melanoma,class_id,melanoma,class_id,34328715
sirolimus,drug,sirolimus,drug,34328215
mammalian target of rapamycin inhibitor,drug class,mammalian target of rapamycin inhibitor,drug class,34328215
mtori,protein,mtori,protein,34328215
antiproliferative,property,antiproliferative,property,34328215
antiangiogenic,property,antiangiogenic,property,34328215
immunosuppressive,property,immunosuppressive,property,34328215
renal transplant patient,patient population,renal transplant patient,patient population,34328215
dermatological condition,medical condition,dermatological condition,medical condition,34328215
tuberous sclerosis complex,medical condition,tuberous sclerosis complex,medical condition,34328215
gvhd prophylaxis,medical condition,gvhd prophylaxis,medical condition,34328215
side effects,medical condition,side effects,medical condition,34328215
skin irritation,medical condition,skin irritation,medical condition,34328215
neurological complication,preferred_label,neurological complication,preferred_label,34328206
haematopoietic stem cell transplantation,preferred_label,haematopoietic stem cell transplantation,preferred_label,34328206
central nervous system infection,preferred_label,central nervous system infection,preferred_label,34328206
vascular complication,preferred_label,vascular complication,preferred_label,34328206
pharmacological toxicity,preferred_label,pharmacological toxicity,preferred_label,34328206
metabolic complication,preferred_label,metabolic complication,preferred_label,34328206
immune-mediated disorder,preferred_label,immune-mediated disorder,preferred_label,34328206
post-hsct carcinogenesis,preferred_label,post-hsct carcinogenesis,preferred_label,34328206
graft-versus-host disease,preferred_label,graft-versus-host disease,preferred_label,34328206
thrombotic microangiopathy,preferred_label,thrombotic microangiopathy,preferred_label,34328206
lactobacillus casei 21l10,class_id,lactobacillus casei 21l10,class_id,34327573
ht29 cell line,class_id,ht29 cell line,class_id,34327573
lipopolysaccharide,class_id,lipopolysaccharide,class_id,34327573
annexin vpi,class_id,annexin vpi,class_id,34327573
inflammation,semantic_types,inflammation,semantic_types,34327573
apoptosis,semantic_types,apoptosis,semantic_types,34327573
glucocorticoid excess,semantic_types,glucocorticoid excess,semantic_types,34325494
metabolic dysfunction,semantic_types,metabolic dysfunction,semantic_types,34325494
offspring,semantic_types,offspring,semantic_types,34325494
mouse,semantic_types,mouse,semantic_types,34325494
dexamethasone,drug associated with AE,dexamethasone,drug associated with AE,34325494
streptozotocin,drug associated with AE,streptozotocin,drug associated with AE,34325494
hyperglycemia,semantic_types,hyperglycemia,semantic_types,34325494
glucose intolerance,semantic_types,glucose intolerance,semantic_types,34325494
insulin,semantic_types,insulin,semantic_types,34325494
glucagon,semantic_types,glucagon,semantic_types,34325494
HNF4,semantic_types,HNF4,semantic_types,34325494
brentuximab vedotin,drug,brentuximab vedotin,drug,34323643
classical Hodgkin lymphoma,disease,classical Hodgkin lymphoma,disease,34323643
observational study,research study,observational study,research study,34323643
overall response rate,clinical outcome,overall response rate,clinical outcome,34323643
complete response rate,clinical outcome,complete response rate,clinical outcome,34323643
progression-free survival,clinical outcome,progression-free survival,clinical outcome,34323643
overall survival,clinical outcome,overall survival,clinical outcome,34323643
hematological toxicity,adverse event,hematological toxicity,adverse event,34323643
neutropenia,adverse event,neutropenia,adverse event,34323643
anemia,adverse event,anemia,adverse event,34323643
thrombocytopenia,adverse event,thrombocytopenia,adverse event,34323643
peripheral neuropathy,adverse event,peripheral neuropathy,adverse event,34323643
phosphatidylinositol3 kinase pathway,preferred_label,phosphatidylinositol3 kinase pathway,preferred_label,34322775
head and neck squamous cell carcinoma,preferred_label,head and neck squamous cell carcinoma,preferred_label,34322775
copanlisib,preferred_label,copanlisib,preferred_label,34322775
antiegfr monoclonal antibody cetuximab,preferred_label,antiegfr monoclonal antibody cetuximab,preferred_label,34322775
hyperglycemia,preferred_label,hyperglycemia,preferred_label,34322775
pembrolizumab,drug,pembrolizumab,drug,34321417
toxic epidermal necrolysis,adverse event,toxic epidermal necrolysis,adverse event,34321417
nonsmall cell lung cancer,disease,nonsmall cell lung cancer,disease,34321417
intravenous immunoglobulin,drug,intravenous immunoglobulin,drug,34321417
pexidartinib,drug,pexidartinib,drug,34321280
sirolimus,drug,sirolimus,drug,34321280
soft tissue sarcoma,disease,soft tissue sarcoma,disease,34321280
colony-stimulating factor 1 receptor,protein,colony-stimulating factor 1 receptor,protein,34321280
tumor-associated macrophage,cell type,tumor-associated macrophage,cell type,34321280
sarcoma,disease,sarcoma,disease,34321280
malignant peripheral nerve sheath tumor,disease,malignant peripheral nerve sheath tumor,disease,34321280
tenosynovial giant cell tumor,disease,tenosynovial giant cell tumor,disease,34321280
leiomyosarcoma,disease,leiomyosarcoma,disease,34321280
activated m2 macrophage,cell type,activated m2 macrophage,cell type,34321280
ceritinib,drug,ceritinib,drug,34319586
gemcitabine,drug,gemcitabine,drug,34319586
ALK,gene,ALK,gene,34319586
cMET,gene,cMET,gene,34319586
JNK,gene,JNK,gene,34319586
cholangiocarcinoma,disease,cholangiocarcinoma,disease,34319586
paclitaxel,drug,paclitaxel,drug,34319435
cisplatin,drug,cisplatin,drug,34319435
fluorouracil,drug,fluorouracil,drug,34319435
esophageal squamous cell carcinoma,disease,esophageal squamous cell carcinoma,disease,34319435
chemotherapy,treatment,chemotherapy,treatment,34319435
surgery,treatment,surgery,treatment,34319435
chemoradiotherapy,treatment,chemoradiotherapy,treatment,34319435
neutropenia,adverse event,neutropenia,adverse event,34319435
leucopenia,adverse event,leucopenia,adverse event,34319435
stomatitis,adverse event,stomatitis,adverse event,34319435
photodynamic therapy,treatment,photodynamic therapy,treatment,34319255
immunotherapy,treatment,immunotherapy,treatment,34319255
nanoparticles,material,nanoparticles,material,34319255
hernanobody nb,protein,hernanobody nb,protein,34319255
human serum albumin hsa,protein,human serum albumin hsa,protein,34319255
chlorin ce6,compound,chlorin ce6,compound,34319255
catalase cat,enzyme,catalase cat,enzyme,34319255
hypoxia inducible factor1hif1,protein,hypoxia inducible factor1hif1,protein,34319255
reactive oxygen specie,compound,reactive oxygen specie,compound,34319255
apoptosis,process,apoptosis,process,34319255
danger-associated molecular pattern damp,biomarker,danger-associated molecular pattern damp,biomarker,34319255
dendritic cell,cell,dendritic cell,cell,34319255
t cell,cell,t cell,cell,34319255
idelalisib,drug associated with AE,idelalisib,drug associated with AE,34319205
immune-related adverse event iraes,adverse event occurs in,immune-related adverse event iraes,adverse event occurs in,34319205
immune checkpoint inhibitor-induced iraes,adverse event occurs in,immune checkpoint inhibitor-induced iraes,adverse event occurs in,34319205
survival outcome,adverse event outcome,survival outcome,adverse event outcome,34319205
solid tumor,has disease,solid tumor,has disease,34319205
grade 3 diarrheacolitis,drug AE occurs in,grade 3 diarrheacolitis,drug AE occurs in,34319205
alanine/aspartate transaminase (ALT/AST) elevation,drug AE occurs in,alanine/aspartate transaminase (ALT/AST) elevation,drug AE occurs in,34319205
indolent non-hodgkin lymphoma (INHL),has disease,indolent non-hodgkin lymphoma (INHL),has disease,34319205
follicular lymphoma (FL),has disease,follicular lymphoma (FL),has disease,34319205
chronic lymphocytic leukemia,has disease,chronic lymphocytic leukemia,has disease,34319205
overall response rate (ORR),adverse event outcome,overall response rate (ORR),adverse event outcome,34319205
progression-free survival (PFS),adverse event outcome,progression-free survival (PFS),adverse event outcome,34319205
high-dose methotrexate,drug,high-dose methotrexate,drug,34319023
blood methotrexate level,clinical parameter,blood methotrexate level,clinical parameter,34319023
leucovorin rescue,drug,leucovorin rescue,drug,34319023
urine alkalinization,clinical intervention,urine alkalinization,clinical intervention,34319023
childhood acute lymphoblastic leukemia patients,patient population,childhood acute lymphoblastic leukemia patients,patient population,34319023
hepatotoxicity,adverse event,hepatotoxicity,adverse event,34319023
neutropenia,adverse event,neutropenia,adverse event,34319023
chemoradiotherapy,may_treat,chemoradiotherapy,may_treat,34318389
rectal cancer,has disease,rectal cancer,has disease,34318389
local excision,may_treat,local excision,may_treat,34318389
adjuvant CRT,may_treat,adjuvant CRT,may_treat,34318389
limited surgery,may_treat,limited surgery,may_treat,34318389
anal canal cancer,has disease,anal canal cancer,has disease,34318389
adenocarcinoma,has disease,adenocarcinoma,has disease,34318389
stomatitis,adverse event occurs in,stomatitis,adverse event occurs in,34318389
diarrhea,adverse event occurs in,diarrhea,adverse event occurs in,34318389
anal function,has part,anal function,has part,34318389
immune-related adverse event,adverse event,immune-related adverse event,adverse event,34316029
immune checkpoint inhibitor,drug,immune checkpoint inhibitor,drug,34316029
biomarkers,biomarker,biomarkers,biomarker,34316029
trial,clinical trial,trial,clinical trial,34316029
toxicity,adverse event outcome,toxicity,adverse event outcome,34316029
mechanism,mechanism,mechanism,mechanism,34316029
strategy,intervention strategy,strategy,intervention strategy,34316029
neoadjuvant everolimus plus letrozole,drug,neoadjuvant everolimus plus letrozole,drug,34315439
chemotherapy,drug,chemotherapy,drug,34315439
postmenopausal patient with erpositive hernegative breast cancer,disease,postmenopausal patient with erpositive hernegative breast cancer,disease,34315439
primary tumor,anatomical entity,primary tumor,anatomical entity,34315439
axillary lymph node,anatomical entity,axillary lymph node,anatomical entity,34315439
tregs,cell type,tregs,cell type,34315439
cd t cell,cell type,cd t cell,cell type,34315439
pd-l1,protein,pd-l1,protein,34315439
ki67,protein,ki67,protein,34315439
tumor-infiltrating tregs,cell type,tumor-infiltrating tregs,cell type,34315439
tumor-specific ctls,cell type,tumor-specific ctls,cell type,34315439
nanovesicle delivery system,class_id,nanovesicle delivery system,class_id,34313109
superparamagnetic iron oxide nanoparticles,class_id,superparamagnetic iron oxide nanoparticles,class_id,34313109
ultrasound contrast agent perfluorohexane,class_id,ultrasound contrast agent perfluorohexane,class_id,34313109
cisplatin,class_id,cisplatin,class_id,34313109
silicate-polyaniline vesicle,class_id,silicate-polyaniline vesicle,class_id,34313109
tumor,class_id,tumor,class_id,34313109
nanodrug delivery system,class_id,nanodrug delivery system,class_id,34313104
tumor cell,class_id,tumor cell,class_id,34313104
drug delivery performance,class_id,drug delivery performance,class_id,34313104
cancer therapy,class_id,cancer therapy,class_id,34313104
phh2o2 dual-responsive chiral mesoporous silica nanorods,class_id,phh2o2 dual-responsive chiral mesoporous silica nanorods,class_id,34313104
phenylboronic acid pinacol ester,class_id,phenylboronic acid pinacol ester,class_id,34313104
doxorubicin,class_id,doxorubicin,class_id,34313104
cyclodextrin-modified hyaluronic acid conjugate,class_id,cyclodextrin-modified hyaluronic acid conjugate,class_id,34313104
tumor microenvironment,class_id,tumor microenvironment,class_id,34313104
tumor region,class_id,tumor region,class_id,34313104
cd44 receptor-mediated endocytosis,class_id,cd44 receptor-mediated endocytosis,class_id,34313104
antitumor efficacy,class_id,antitumor efficacy,class_id,34313104
biocompatibility,class_id,biocompatibility,class_id,34313104
trastuzumab,drug,trastuzumab,drug,34312098
anthracycline chemotherapy drug,drug,anthracycline chemotherapy drug,drug,34312098
neoadjuvant chemotherapy regimen,treatment,neoadjuvant chemotherapy regimen,treatment,34312098
paclitaxel,drug,paclitaxel,drug,34312098
fluorouracil,drug,fluorouracil,drug,34312098
epirubicin,drug,epirubicin,drug,34312098
cyclophosphamide,drug,cyclophosphamide,drug,34312098
docetaxel,drug,docetaxel,drug,34312098
carboplatin,drug,carboplatin,drug,34312098
human epidermal growth factor receptor positive (HER) breast cancer,disease,human epidermal growth factor receptor positive (HER) breast cancer,disease,34312098
cardiotoxicity,adverse event,cardiotoxicity,adverse event,34312098
late-onset cardiotoxicity,adverse event,late-onset cardiotoxicity,adverse event,34312098
cardiac event,adverse event,cardiac event,adverse event,34312098
hypertension,disease,hypertension,disease,34312098
esophageal squamous cell carcinoma,class_id,esophageal squamous cell carcinoma,class_id,34311300
docetaxel,preferred_label,docetaxel,preferred_label,34311300
paclitaxel,preferred_label,paclitaxel,preferred_label,34311300
fluoropyrimidine,preferred_label,fluoropyrimidine,preferred_label,34311300
platinumbased chemotherapy,preferred_label,platinumbased chemotherapy,preferred_label,34311300
neutropenia,preferred_label,neutropenia,preferred_label,34311300
leukopenia,preferred_label,leukopenia,preferred_label,34311300
febrile neutropenia,preferred_label,febrile neutropenia,preferred_label,34311300
dextranpolylactide,class_id,dextranpolylactide,class_id,34310998
doxorubicin,class_id,doxorubicin,class_id,34310998
NIR dye,class_id,NIR dye,class_id,34310998
dir doxdexpla micelle,class_id,dir doxdexpla micelle,class_id,34310998
tumor,class_id,tumor,class_id,34310998
mouse model,class_id,mouse model,class_id,34310998
laser irradiation,class_id,laser irradiation,class_id,34310998
nabpaclitaxel chemoradiotherapy,preferred_label,nabpaclitaxel chemoradiotherapy,preferred_label,34310350
fluorouracil or gemcitabine chemoradiotherapy,preferred_label,fluorouracil or gemcitabine chemoradiotherapy,preferred_label,34310350
pancreatic adenocarcinoma,preferred_label,pancreatic adenocarcinoma,preferred_label,34310350
patient,preferred_label,patient,preferred_label,34310350
surgery,preferred_label,surgery,preferred_label,34310350
mammalian target of rapamycin,class_id,mammalian target of rapamycin,class_id,34310349
temsirolimus,preferred_label,temsirolimus,preferred_label,34310349
docetaxel,preferred_label,docetaxel,preferred_label,34310349
phosphatidylinositol kinaseakt signaling pathway,semantic_types,phosphatidylinositol kinaseakt signaling pathway,semantic_types,34310349
rapamycin,synonyms,rapamycin,synonyms,34310349
sirolimus,synonyms,sirolimus,synonyms,34310349
cancer cell line breast prostate cancer,semantic_types,cancer cell line breast prostate cancer,semantic_types,34310349
taxanes,preferred_label,taxanes,preferred_label,34310349
Monoclonal antibody,class_id,Monoclonal antibody,class_id,34310275
Breast cancer,class_id,Breast cancer,class_id,34310275
Programmed death-ligand 1 (PDL1),class_id,Programmed death-ligand 1 (PDL1),class_id,34310275
Programmed death1 (PD1),class_id,Programmed death1 (PD1),class_id,34310275
arsenical drug,drug,arsenical drug,drug,34309925
acute promyelocytic leukemia,disease,acute promyelocytic leukemia,disease,34309925
solid tumor,disease,solid tumor,disease,34309925
biocompatible pegylated arsenene nanodots,drug,biocompatible pegylated arsenene nanodots,drug,34309925
asndspeg,drug,asndspeg,drug,34309925
oxidative stress,biological process,oxidative stress,biological process,34309925
valence change of arsenic,biological process,valence change of arsenic,biological process,34309925
superoxide dismutase activity,biological process,superoxide dismutase activity,biological process,34309925
reactive oxygen species production,biological process,reactive oxygen species production,biological process,34309925
mitochondrial damage,biological process,mitochondrial damage,biological process,34309925
cell cycle arrest,biological process,cell cycle arrest,biological process,34309925
DNA damage,biological process,DNA damage,biological process,34309925
elemene,drug,elemene,drug,34309925
photothermal property,biological process,photothermal property,biological process,34309925
head and neck cancer,class_id,head and neck cancer,class_id,34308772
chemotherapy,class_id,chemotherapy,class_id,34308772
cisplatin,class_id,cisplatin,class_id,34308772
neoadjuvant chemotherapy,class_id,neoadjuvant chemotherapy,class_id,34308772
immune checkpoint inhibitor,class_id,immune checkpoint inhibitor,class_id,34308772
metastatic head and neck cancer,class_id,metastatic head and neck cancer,class_id,34308772
bevacizumab,drug,bevacizumab,drug,34308512
platinum-resistant recurrent ovarian cancer,disease,platinum-resistant recurrent ovarian cancer,disease,34308512
Japan,location,Japan,location,34308512
paclitaxel,drug,paclitaxel,drug,34308512
liposomal doxorubicin,drug,liposomal doxorubicin,drug,34308512
irinotecan,drug,irinotecan,drug,34308512
neutropenia,adverse event,neutropenia,adverse event,34308512
hypertension,adverse event,hypertension,adverse event,34308512
proteinuria,adverse event,proteinuria,adverse event,34308512
lobaplatin,drug,lobaplatin,drug,34306603
cisplatin,drug,cisplatin,drug,34306603
hypopharyngeal cancer,disease,hypopharyngeal cancer,disease,34306603
docetaxel,drug,docetaxel,drug,34306603
intensity-modulated radiotherapy,treatment,intensity-modulated radiotherapy,treatment,34306603
glucose,substance,glucose,substance,34306603
blood routine,test,blood routine,test,34306603
liver function test,test,liver function test,test,34306603
kidney function test,test,kidney function test,test,34306603
in vitro cell culture,procedure,in vitro cell culture,procedure,34306603
proliferation of cancer cell,process,proliferation of cancer cell,process,34306603
oncocardiology,preferred_label,oncocardiology,preferred_label,34305102
cancer,preferred_label,cancer,preferred_label,34305102
cardiovascular injury,preferred_label,cardiovascular injury,preferred_label,34305102
cardiac injury,preferred_label,cardiac injury,preferred_label,34305102
adverse reaction,preferred_label,adverse reaction,preferred_label,34305102
cardiovascular event,preferred_label,cardiovascular event,preferred_label,34305102
cancer treatment,preferred_label,cancer treatment,preferred_label,34305102
chemotherapy,preferred_label,chemotherapy,preferred_label,34305102
radiotherapy,preferred_label,radiotherapy,preferred_label,34305102
targeted therapy,preferred_label,targeted therapy,preferred_label,34305102
immunotherapy,preferred_label,immunotherapy,preferred_label,34305102
cardiovascular toxicity,preferred_label,cardiovascular toxicity,preferred_label,34305102
heart failure,preferred_label,heart failure,preferred_label,34305102
hypertension,preferred_label,hypertension,preferred_label,34305102
coronary heart disease,preferred_label,coronary heart disease,preferred_label,34305102
arrhythmia,preferred_label,arrhythmia,preferred_label,34305102
thromboembolism,preferred_label,thromboembolism,preferred_label,34305102
mechanism,preferred_label,mechanism,preferred_label,34305102
quality of life,preferred_label,quality of life,preferred_label,34305102
study,preferred_label,study,preferred_label,34305102
survivor,preferred_label,survivor,preferred_label,34305102
prevention,preferred_label,prevention,preferred_label,34305102
diagnosis,preferred_label,diagnosis,preferred_label,34305102
treatment,preferred_label,treatment,preferred_label,34305102
cvds,preferred_label,cvds,preferred_label,34305102
sarcoma patient,class_id,sarcoma patient,class_id,34304283
DDI,preferred_label,DDI,preferred_label,34304283
antitumor treatment,preferred_label,antitumor treatment,preferred_label,34304283
pharmacist,preferred_label,pharmacist,preferred_label,34304283
chemotherapy,synonyms,chemotherapy,synonyms,34304283
tyrosine kinase inhibitor,synonyms,tyrosine kinase inhibitor,synonyms,34304283
medication reconciliation,preferred_label,medication reconciliation,preferred_label,34304283
complementary medicine,preferred_label,complementary medicine,preferred_label,34304283
proton pump inhibitor,preferred_label,proton pump inhibitor,preferred_label,34304283
antidepressant,preferred_label,antidepressant,preferred_label,34304283
acquired resistance to tki,preferred_label,acquired resistance to tki,preferred_label,34303276
egfr mutated lung cancer,preferred_label,egfr mutated lung cancer,preferred_label,34303276
combination approach with vegf inhibitor check point inhibitor immunotherapy and platinumbased chemotherapy,preferred_label,combination approach with vegf inhibitor check point inhibitor immunotherapy and platinumbased chemotherapy,preferred_label,34303276
modified regimen,preferred_label,modified regimen,preferred_label,34303276
egfr mutated cohort,preferred_label,egfr mutated cohort,preferred_label,34303276
openlabelled single arm phase ii study,preferred_label,openlabelled single arm phase ii study,preferred_label,34303276
patient with egfr mutated nsclc,preferred_label,patient with egfr mutated nsclc,preferred_label,34303276
combination atezolizumab 1200 mg bevacizumab mgkg pemetrexed 500 mgm2 and carboplatin auc 5,preferred_label,combination atezolizumab 1200 mg bevacizumab mgkg pemetrexed 500 mgm2 and carboplatin auc 5,preferred_label,34303276
forty patient,preferred_label,forty patient,preferred_label,34303276
median age,preferred_label,median age,preferred_label,34303276
progressed on osimertinib,preferred_label,progressed on osimertinib,preferred_label,34303276
radiological progression on osimertinib,preferred_label,radiological progression on osimertinib,preferred_label,34303276
treatment related grade 3 or above adverse event ae,preferred_label,treatment related grade 3 or above adverse event ae,preferred_label,34303276
immunerelated ae,preferred_label,immunerelated ae,preferred_label,34303276
quality of life measure of function and symptom,preferred_label,quality of life measure of function and symptom,preferred_label,34303276
posttrial rechallenge with egfr tki containing regimen,preferred_label,posttrial rechallenge with egfr tki containing regimen,preferred_label,34303276
pfs of month,preferred_label,pfs of month,preferred_label,34303276
combination approach of atezolizumab bevacizumab pemetrexed and carboplatin,preferred_label,combination approach of atezolizumab bevacizumab pemetrexed and carboplatin,preferred_label,34303276
metastatic egfr mutated nsclc after tki failure,preferred_label,metastatic egfr mutated nsclc after tki failure,preferred_label,34303276
taxane based regimen of impower150,preferred_label,taxane based regimen of impower150,preferred_label,34303276
toxicity profile,preferred_label,toxicity profile,preferred_label,34303276
trastuzumabpertuzumab,preferred_label,trastuzumabpertuzumab,preferred_label,34302589
eribulin mesylate,preferred_label,eribulin mesylate,preferred_label,34302589
metastatic breast cancer,semantic_types,metastatic breast cancer,semantic_types,34302589
HP,preferred_label,HP,preferred_label,34302589
pertuzumab,preferred_label,pertuzumab,preferred_label,34302589
tumor DNA,preferred_label,tumor DNA,preferred_label,34302589
germline DNA,preferred_label,germline DNA,preferred_label,34302589
TP53,preferred_label,TP53,preferred_label,34302589
ceralasertib,preferred_label,ceralasertib,preferred_label,34301752
carboplatin,preferred_label,carboplatin,preferred_label,34301752
anemia,preferred_label,anemia,preferred_label,34301752
thrombocytopenia,preferred_label,thrombocytopenia,preferred_label,34301752
neutropenia,preferred_label,neutropenia,preferred_label,34301752
prad,preferred_label,prad,preferred_label,34301752
ataxia telangiectasia mutated,preferred_label,ataxia telangiectasia mutated,preferred_label,34301752
slfn11,preferred_label,slfn11,preferred_label,34301752
partial response,preferred_label,partial response,preferred_label,34301752
stable disease,preferred_label,stable disease,preferred_label,34301752
egfrmutated metastatic nonsmall cell lung cancer,class_id,egfrmutated metastatic nonsmall cell lung cancer,class_id,34301751
egfr tyrosine kinase inhibitor,class_id,egfr tyrosine kinase inhibitor,class_id,34301751
ex21l858r mutation,class_id,ex21l858r mutation,class_id,34301751
ex19del mutation,class_id,ex19del mutation,class_id,34301751
relay study,class_id,relay study,class_id,34301751
ramucirumab,class_id,ramucirumab,class_id,34301751
erlotinib,class_id,erlotinib,class_id,34301751
placebo,class_id,placebo,class_id,34301751
tp53 comutation,class_id,tp53 comutation,class_id,34301751
egfr t790m mutation,class_id,egfr t790m mutation,class_id,34301751
alrn6924,preferred_label,alrn6924,preferred_label,34301750
p53,preferred_label,p53,preferred_label,34301750
mdm2,preferred_label,mdm2,preferred_label,34301750
mdmx,preferred_label,mdmx,preferred_label,34301750
solid tumor,preferred_label,solid tumor,preferred_label,34301750
lymphoma,preferred_label,lymphoma,preferred_label,34301750
mic,preferred_label,mic,preferred_label,34301750
gastrointestinal side effect,preferred_label,gastrointestinal side effect,preferred_label,34301750
fatigue,preferred_label,fatigue,preferred_label,34301750
anemia,preferred_label,anemia,preferred_label,34301750
headache,preferred_label,headache,preferred_label,34301750
hypotension,preferred_label,hypotension,preferred_label,34301750
alkaline phosphatase elevation,preferred_label,alkaline phosphatase elevation,preferred_label,34301750
neutropenia,preferred_label,neutropenia,preferred_label,34301750
thrombocytopenia,preferred_label,thrombocytopenia,preferred_label,34301750
infusion-related reaction,preferred_label,infusion-related reaction,preferred_label,34301750
complete response,preferred_label,complete response,preferred_label,34301750
partial response,preferred_label,partial response,preferred_label,34301750
stable disease,preferred_label,stable disease,preferred_label,34301750
recommended phase 2 dose,preferred_label,recommended phase 2 dose,preferred_label,34301750
antitumor activity,preferred_label,antitumor activity,preferred_label,34301750
locally advanced vulvar cancer,preferred_label,locally advanced vulvar cancer,preferred_label,34301412
chemoradiation,preferred_label,chemoradiation,preferred_label,34301412
surgery,preferred_label,surgery,preferred_label,34301412
patient,preferred_label,patient,preferred_label,34301412
radiotherapy,preferred_label,radiotherapy,preferred_label,34301412
chemotherapy,preferred_label,chemotherapy,preferred_label,34301412
capecitabine,preferred_label,capecitabine,preferred_label,34301412
toxicity,preferred_label,toxicity,preferred_label,34301412
survival,preferred_label,survival,preferred_label,34301412
bevacizumab,drug,bevacizumab,drug,34299401
vascular endothelial growth factor,protein,vascular endothelial growth factor,protein,34299401
angiogenesis,process,angiogenesis,process,34299401
pathologic angiogenesis,process,pathologic angiogenesis,process,34299401
ophthalmic disorder,disease,ophthalmic disorder,disease,34299401
cancer,disease,cancer,disease,34299401
controlled release system,drug delivery system,controlled release system,drug delivery system,34299401
organic nanoparticles,nanoparticles,organic nanoparticles,nanoparticles,34299401
physicochemical characterization,process,physicochemical characterization,process,34299401
in vitro evaluation,process,in vitro evaluation,process,34299401
in vivo evaluation,process,in vivo evaluation,process,34299401
nanocarriers,drug delivery system,nanocarriers,drug delivery system,34299401
degradation,process,degradation,process,34299401
bioactivity maintenance,process,bioactivity maintenance,process,34299401
cisplatin,drug,cisplatin,drug,34299130
cudrania tricuspidata fruit-derived polysaccharide (CTPS),drug,cudrania tricuspidata fruit-derived polysaccharide (CTPS),drug,34299130
macrophage lung cancer cell line,cell line,macrophage lung cancer cell line,cell line,34299130
mouse model,animal model,mouse model,animal model,34299130
A549 lung cancer cell,cell line,A549 lung cancer cell,cell line,34299130
H460 lung cancer cell,cell line,H460 lung cancer cell,cell line,34299130
RAW cell,cell line,RAW cell,cell line,34299130
bone marrow-derived macrophage primary cell,cell,bone marrow-derived macrophage primary cell,cell,34299130
metastatic colony,biological structure,metastatic colony,biological structure,34299130
splenic T cell,cell type,splenic T cell,cell type,34299130
reactive oxygen species,molecule,reactive oxygen species,molecule,34299130
mitochondrial transmembrane potential,cellular component,mitochondrial transmembrane potential,cellular component,34299130
BAX protein,protein,BAX protein,protein,34299130
cytochrome c,protein,cytochrome c,protein,34299130
PARP cleavage,biological process,PARP cleavage,biological process,34299130
caspase,protein,caspase,protein,34299130
BCL2 protein,protein,BCL2 protein,protein,34299130
chemotherapeutic drug,drug,chemotherapeutic drug,drug,34299130
doxorubicin,drug,doxorubicin,drug,34299059
vitamin D,drug,vitamin D,drug,34299059
triple negative breast cancer,disease,triple negative breast cancer,disease,34299059
mouse,organism,mouse,organism,34299059
cardiac tissue,tissue,cardiac tissue,tissue,34299059
reactive oxygen species,chemical,reactive oxygen species,chemical,34299059
hydroxynonenal,chemical,hydroxynonenal,chemical,34299059
NADPH quinone oxidoreductase,protein,NADPH quinone oxidoreductase,protein,34299059
c-Myc,protein,c-Myc,protein,34299059
dynamin-related protein 1,protein,dynamin-related protein 1,protein,34299059
Chemotherapy,treated with drug,Chemotherapy,treated with drug,34298975
Cancer Cell,class_id,Cancer Cell,class_id,34298975
Secondary Site,location_of,Secondary Site,location_of,34298975
ATF3 Gene,class_id,ATF3 Gene,class_id,34298975
Mouse Breast Cancer Model,class_id,Mouse Breast Cancer Model,class_id,34298975
Lung,location_of,Lung,location_of,34298975
Cyclophosphamide,treated with drug,Cyclophosphamide,treated with drug,34298975
Macrophage,class_id,Macrophage,class_id,34298975
Cell Retention,realized in,Cell Retention,realized in,34298975
Extravasation,realized in,Extravasation,realized in,34298975
Proliferation,realized in,Proliferation,realized in,34298975
Colonization,realized in,Colonization,realized in,34298975
fisetin,drug,fisetin,drug,34298098
letrozole,drug,letrozole,drug,34298098
metformin,drug,metformin,drug,34298098
polycystic ovary syndrome (PCOS),disease,polycystic ovary syndrome (PCOS),disease,34298098
rat model,animal model,rat model,animal model,34298098
Wistar rat,animal model,Wistar rat,animal model,34298098
glucose,biochemical parameter,glucose,biochemical parameter,34298098
lipid profile,biochemical parameter,lipid profile,biochemical parameter,34298098
insulin,hormone,insulin,hormone,34298098
testosterone,hormone,testosterone,hormone,34298098
estradiol,hormone,estradiol,hormone,34298098
progesterone,hormone,progesterone,hormone,34298098
cytochrome p450 17a1 (CYP17A1),gene,cytochrome p450 17a1 (CYP17A1),gene,34298098
sirtuin1 (SIRT1),gene,sirtuin1 (SIRT1),gene,34298098
5' adenosine monophosphate-activated protein kinase (AMPK),gene,5' adenosine monophosphate-activated protein kinase (AMPK),gene,34298098
antioxidant enzymes,biochemical parameter,antioxidant enzymes,biochemical parameter,34298098
catalase (CAT),enzyme,catalase (CAT),enzyme,34298098
superoxide dismutase (SOD),enzyme,superoxide dismutase (SOD),enzyme,34298098
glutathione peroxidase (GPx),enzyme,glutathione peroxidase (GPx),enzyme,34298098
multiple myeloma,class_id,multiple myeloma,class_id,34297605
cyclophosphamide,preferred_label,cyclophosphamide,preferred_label,34297605
thalidomide,preferred_label,thalidomide,preferred_label,34297605
dexamethasone,preferred_label,dexamethasone,preferred_label,34297605
neutropenia,preferred_label,neutropenia,preferred_label,34297605
stem cell transplantation,preferred_label,stem cell transplantation,preferred_label,34297605
autologous transplantation,preferred_label,autologous transplantation,preferred_label,34297605
tumor microvasculature,preferred_label,tumor microvasculature,preferred_label,34297268
antiangiogenic agent,preferred_label,antiangiogenic agent,preferred_label,34297268
radiofrequency ablation rfa,preferred_label,radiofrequency ablation rfa,preferred_label,34297268
hepatocellular carcinoma hcc,preferred_label,hepatocellular carcinoma hcc,preferred_label,34297268
sorafenib,preferred_label,sorafenib,preferred_label,34297268
placebo,preferred_label,placebo,preferred_label,34297268
phase ii trial,preferred_label,phase ii trial,preferred_label,34297268
ablation zone,preferred_label,ablation zone,preferred_label,34297268
thermal parameter,preferred_label,thermal parameter,preferred_label,34297268
blood flow,preferred_label,blood flow,preferred_label,34297268
MRI,preferred_label,MRI,preferred_label,34297268
acute myeloid leukemia,class_id,acute myeloid leukemia,class_id,34297206
antecedent hematological disease,class_id,antecedent hematological disease,class_id,34297206
saml,synonyms,saml,synonyms,34297206
treatmentrelated aml,class_id,treatmentrelated aml,class_id,34297206
allohsct,class_id,allohsct,class_id,34297206
complete remission,class_id,complete remission,class_id,34297206
liposomal cytarabine and daunorubicin,class_id,liposomal cytarabine and daunorubicin,class_id,34297206
cpx351,class_id,cpx351,class_id,34297206
myeloidrelated change,class_id,myeloidrelated change,class_id,34297206
intermediatedosed cytarabine,class_id,intermediatedosed cytarabine,class_id,34297206
idarac,class_id,idarac,class_id,34297206
idarubicin,class_id,idarubicin,class_id,34297206
mitoxantrone,class_id,mitoxantrone,class_id,34297206
relapsefree survival,class_id,relapsefree survival,class_id,34297206
eventfree survival,class_id,eventfree survival,class_id,34297206
overall survival,class_id,overall survival,class_id,34297206
axicabtagene ciloleucel axicel,preferred_label,axicabtagene ciloleucel axicel,preferred_label,34296427
large B-cell lymphoma,semantic_types,large B-cell lymphoma,semantic_types,34296427
chimaeric antigen receptor,semantic_types,chimaeric antigen receptor,semantic_types,34296427
cytokine release syndrome,semantic_types,cytokine release syndrome,semantic_types,34296427
neurologic event,semantic_types,neurologic event,semantic_types,34296427
prophylactic corticosteroid,preferred_label,prophylactic corticosteroid,preferred_label,34296427
tocilizumab,preferred_label,tocilizumab,preferred_label,34296427
dexamethasone,preferred_label,dexamethasone,preferred_label,34296427
parp inhibitor,drug,parp inhibitor,drug,34293664
brca mutation,disease,brca mutation,disease,34293664
platinumsensitive recurrent ovarian cancer,disease,platinumsensitive recurrent ovarian cancer,disease,34293664
prognostic nomogram,tool,prognostic nomogram,tool,34293664
ca125,biomarker,ca125,biomarker,34293664
maintenance olaparib,drug,maintenance olaparib,drug,34293664
locally advanced nonanaplastic thyroid cancer,class_id,locally advanced nonanaplastic thyroid cancer,class_id,34293201
intensity-modulated radiation therapy (IMRT),class_id,intensity-modulated radiation therapy (IMRT),class_id,34293201
concurrent chemotherapy with IMRT (CCIMRT),class_id,concurrent chemotherapy with IMRT (CCIMRT),class_id,34293201
doxorubicin,class_id,doxorubicin,class_id,34293201
locoregional progression-free survival (PFS),class_id,locoregional progression-free survival (PFS),class_id,34293201
overall survival (OS),class_id,overall survival (OS),class_id,34293201
acute toxicity,class_id,acute toxicity,class_id,34293201
late toxicity,class_id,late toxicity,class_id,34293201
functional outcome,class_id,functional outcome,class_id,34293201
quality of life,class_id,quality of life,class_id,34293201
palbociclib,drug,palbociclib,drug,34292933
ribociclib,drug,ribociclib,drug,34292933
estrogen receptor,class_id,estrogen receptor,class_id,34292933
progesterone receptor,class_id,progesterone receptor,class_id,34292933
human epidermal growth factor receptor 2 (HER2),class_id,human epidermal growth factor receptor 2 (HER2),class_id,34292933
metastatic breast cancer,class_id,metastatic breast cancer,class_id,34292933
fulvestrant,drug,fulvestrant,drug,34292933
aromatase inhibitor,drug,aromatase inhibitor,drug,34292933
neutropenia,class_id,neutropenia,class_id,34292933
febrile neutropenia,class_id,febrile neutropenia,class_id,34292933
dose reduction,class_id,dose reduction,class_id,34292933
performance status,class_id,performance status,class_id,34292933
nanoplatform,class_id,nanoplatform,class_id,34291912
phototherapy,class_id,phototherapy,class_id,34291912
catalytic nanomaterial,class_id,catalytic nanomaterial,class_id,34291912
anisotropic truncated octahedral au,class_id,anisotropic truncated octahedral au,class_id,34291912
noble metal pt,class_id,noble metal pt,class_id,34291912
photothermal therapy,class_id,photothermal therapy,class_id,34291912
oxygen production,class_id,oxygen production,class_id,34291912
tumor hypoxia,class_id,tumor hypoxia,class_id,34291912
osteosarcoma cell,class_id,osteosarcoma cell,class_id,34291912
hyaluronic acid,class_id,hyaluronic acid,class_id,34291912
napabucasin,preferred_label,napabucasin,preferred_label,34291369
nadphquinone oxidoreductase 1,preferred_label,nadphquinone oxidoreductase 1,preferred_label,34291369
reactive oxygen specie,preferred_label,reactive oxygen specie,preferred_label,34291369
oncogenic cellular pathway,preferred_label,oncogenic cellular pathway,preferred_label,34291369
stat,preferred_label,stat,preferred_label,34291369
cancer cell death,preferred_label,cancer cell death,preferred_label,34291369
phase i study,preferred_label,phase i study,preferred_label,34291369
safety,preferred_label,safety,preferred_label,34291369
tolerability,preferred_label,tolerability,preferred_label,34291369
pharmacokinetics,preferred_label,pharmacokinetics,preferred_label,34291369
fluorouracil,preferred_label,fluorouracil,preferred_label,34291369
leucovorin,preferred_label,leucovorin,preferred_label,34291369
irinotecan,preferred_label,irinotecan,preferred_label,34291369
folfiri chemotherapy,preferred_label,folfiri chemotherapy,preferred_label,34291369
bevacizumab,preferred_label,bevacizumab,preferred_label,34291369
japanese patient,preferred_label,japanese patient,preferred_label,34291369
metastatic colorectal cancer,preferred_label,metastatic colorectal cancer,preferred_label,34291369
crc patient,preferred_label,crc patient,preferred_label,34291369
unresectable stage iv crc,preferred_label,unresectable stage iv crc,preferred_label,34291369
diarrhoea,preferred_label,diarrhoea,preferred_label,34291369
decreased appetite,preferred_label,decreased appetite,preferred_label,34291369
neutrophil count decreased,preferred_label,neutrophil count decreased,preferred_label,34291369
stable disease,preferred_label,stable disease,preferred_label,34291369
cdtargeted chimeric antigen receptor car t cell therapy,preferred_label,cdtargeted chimeric antigen receptor car t cell therapy,preferred_label,34290380
ibrutinib,preferred_label,ibrutinib,preferred_label,34290380
immune checkpoint inhibitor,preferred_label,immune checkpoint inhibitor,preferred_label,34290380
lymphoid bcell malignancy,preferred_label,lymphoid bcell malignancy,preferred_label,34290380
fluorouracil,drug,fluorouracil,drug,34290264
cholangiocarcinoma,disease,cholangiocarcinoma,disease,34290264
natural product,substance,natural product,substance,34290264
Thai noni juice,substance,Thai noni juice,substance,34290264
p53 protein,protein,p53 protein,protein,34290264
bax protein,protein,bax protein,protein,34290264
nude mouse xenograft,model,nude mouse xenograft,model,34290264
squamous cell carcinoma of the vulva,class_id,squamous cell carcinoma of the vulva,class_id,34289750
neoadjuvant chemotherapy,preferred_label,neoadjuvant chemotherapy,preferred_label,34289750
platinum,preferred_label,platinum,preferred_label,34289750
paclitaxel,preferred_label,paclitaxel,preferred_label,34289750
ifosfamide,preferred_label,ifosfamide,preferred_label,34289750
surgery,preferred_label,surgery,preferred_label,34289750
locally advanced vulvar cancer,class_id,locally advanced vulvar cancer,class_id,34289750
mastectomy,preferred_label,mastectomy,preferred_label,34289686
breast cancer,preferred_label,breast cancer,preferred_label,34289686
tumor hypoxia,preferred_label,tumor hypoxia,preferred_label,34289686
BCT,preferred_label,BCT,preferred_label,34289686
radical precursor AIPH,preferred_label,radical precursor AIPH,preferred_label,34289686
iron oxide nanoparticles,preferred_label,iron oxide nanoparticles,preferred_label,34289686
alginate hydrogel,preferred_label,alginate hydrogel,preferred_label,34289686
physiological calcium,preferred_label,physiological calcium,preferred_label,34289686
magnetic hyperthermia,preferred_label,magnetic hyperthermia,preferred_label,34289686
diffuse large B-cell lymphoma,class_id,diffuse large B-cell lymphoma,class_id,34289656
older adult,class_id,older adult,class_id,34289656
rituximabprednisone prephase treatment,class_id,rituximabprednisone prephase treatment,class_id,34289656
vulnerable patient,class_id,vulnerable patient,class_id,34289656
geriatric impairment,class_id,geriatric impairment,class_id,34289656
functional limitation,class_id,functional limitation,class_id,34289656
multimorbidity,class_id,multimorbidity,class_id,34289656
cognitive deficit,class_id,cognitive deficit,class_id,34289656
prospective pilot study,class_id,prospective pilot study,class_id,34289656
newly diagnosed DLBCL,class_id,newly diagnosed DLBCL,class_id,34289656
age 70,class_id,age 70,class_id,34289656
Karnofsky Performance Scale,class_id,Karnofsky Performance Scale,class_id,34289656
rituximab,class_id,rituximab,class_id,34289656
prednisone,class_id,prednisone,class_id,34289656
chemoimmunotherapy,class_id,chemoimmunotherapy,class_id,34289656
anthracycline-based chemoimmunotherapy,class_id,anthracycline-based chemoimmunotherapy,class_id,34289656
early cycle death,class_id,early cycle death,class_id,34289656
non-hematologic toxicity,class_id,non-hematologic toxicity,class_id,34289656
hematologic toxicity,class_id,hematologic toxicity,class_id,34289656
progression-free survival,class_id,progression-free survival,class_id,34289656
overall survival,class_id,overall survival,class_id,34289656
senescence-associated proinflammatory cytokine milieu,class_id,senescence-associated proinflammatory cytokine milieu,class_id,34289656
bct100,drug,bct100,drug,34287772
arginine,substance,arginine,substance,34287772
malignant melanoma,disease,malignant melanoma,disease,34287772
prostate cancer,disease,prostate cancer,disease,34287772
Elderly Patients,patient subset,Elderly Patients,patient subset,34287771
Phase 1 Clinical Trials,clinical trial,Phase 1 Clinical Trials,clinical trial,34287771
Immunotherapy Drug,novel agent,Immunotherapy Drug,novel agent,34287771
Targeted Agent,novel agent,Targeted Agent,novel agent,34287771
Chemotherapy,novel agent,Chemotherapy,novel agent,34287771
Younger Patients,patient subgroup,Younger Patients,patient subgroup,34287771
Objective Response,clinical outcome,Objective Response,clinical outcome,34287771
Survival,clinical outcome,Survival,clinical outcome,34287771
Toxicity,adverse event,Toxicity,adverse event,34287771
Hematological Toxicity,adverse event,Hematological Toxicity,adverse event,34287771
Non-Hematological Toxicity,adverse event,Non-Hematological Toxicity,adverse event,34287771
Antitumor Activity,clinical outcome,Antitumor Activity,clinical outcome,34287771
Early-Phase Trials,clinical trial,Early-Phase Trials,clinical trial,34287771
mitochondria,class_id,mitochondria,class_id,34286585
nanoneedle,class_id,nanoneedle,class_id,34286585
photosensitizers,class_id,photosensitizers,class_id,34286585
Fe,class_id,Fe,class_id,34286585
Bi2S3,class_id,Bi2S3,class_id,34286585
tumor,class_id,tumor,class_id,34286585
pharmacist consultation,preferred_label,pharmacist consultation,preferred_label,34286354
oncology clinical trial,preferred_label,oncology clinical trial,preferred_label,34286354
patient,preferred_label,patient,preferred_label,34286354
cotreatments,preferred_label,cotreatments,preferred_label,34286354
drug-drug interaction,preferred_label,drug-drug interaction,preferred_label,34286354
best possible medication history (BPMH),preferred_label,best possible medication history (BPMH),preferred_label,34286354
hospital pharmacist,preferred_label,hospital pharmacist,preferred_label,34286354
therapeutic drug monitoring,preferred_label,therapeutic drug monitoring,preferred_label,34286354
oral targeted therapy,preferred_label,oral targeted therapy,preferred_label,34286354
prospective clinical trial,preferred_label,prospective clinical trial,preferred_label,34286354
metastatic breast cancer cohort,preferred_label,metastatic breast cancer cohort,preferred_label,34286354
palbociclib,preferred_label,palbociclib,preferred_label,34286354
pharmacokinetics-toxicity correlation study,preferred_label,pharmacokinetics-toxicity correlation study,preferred_label,34286354
blood sample,preferred_label,blood sample,preferred_label,34286354
geometric median,preferred_label,geometric median,preferred_label,34286354
community pharmacy,preferred_label,community pharmacy,preferred_label,34286354
clinicaltrials.gov identifier NCT,preferred_label,clinicaltrials.gov identifier NCT,preferred_label,34286354
relapse,preferred_label,relapse,preferred_label,34284701
treatment failure,preferred_label,treatment failure,preferred_label,34284701
allogeneic blood or marrow transplantation,preferred_label,allogeneic blood or marrow transplantation,preferred_label,34284701
posttransplant maintenance therapy,preferred_label,posttransplant maintenance therapy,preferred_label,34284701
phase ii trial,preferred_label,phase ii trial,preferred_label,34284701
azacitidine,preferred_label,azacitidine,preferred_label,34284701
gmcsf,preferred_label,gmcsf,preferred_label,34284701
nonrelapsed posttransplant patient,preferred_label,nonrelapsed posttransplant patient,preferred_label,34284701
nonmyeloablative,preferred_label,nonmyeloablative,preferred_label,34284701
myeloablative,preferred_label,myeloablative,preferred_label,34284701
allobmt,preferred_label,allobmt,preferred_label,34284701
aml,preferred_label,aml,preferred_label,34284701
md,preferred_label,md,preferred_label,34284701
therapyrelated myeloid neoplasm,preferred_label,therapyrelated myeloid neoplasm,preferred_label,34284701
hlahaploidentical donor,preferred_label,hlahaploidentical donor,preferred_label,34284701
hematologic toxicity,preferred_label,hematologic toxicity,preferred_label,34284701
gvhd,preferred_label,gvhd,preferred_label,34284701
relapsefree survival,preferred_label,relapsefree survival,preferred_label,34284701
overall survival,preferred_label,overall survival,preferred_label,34284701
late onset neutropenia,class_id,late onset neutropenia,class_id,34284690
rituximab,preferred_label,rituximab,preferred_label,34284690
obinutuzumab,preferred_label,obinutuzumab,preferred_label,34284690
lymphoproliferative neoplasm,preferred_label,lymphoproliferative neoplasm,preferred_label,34284690
febrile neutropenia,preferred_label,febrile neutropenia,preferred_label,34284690
CLL,preferred_label,CLL,preferred_label,34284690
posttransplantation lymphoproliferative disease,preferred_label,posttransplantation lymphoproliferative disease,preferred_label,34284690
egfrtyrosine kinase inhibitor tkis,drug,egfrtyrosine kinase inhibitor tkis,drug,34281470
egfrmutant advanced nsclc patient,disease,egfrmutant advanced nsclc patient,disease,34281470
resistance mechanism,biological process,resistance mechanism,biological process,34281470
combination of tkis with antiangiogenic agent,treatment strategy,combination of tkis with antiangiogenic agent,treatment strategy,34281470
ramucirumab,drug,ramucirumab,drug,34281470
erlotinib,drug,erlotinib,drug,34281470
egfrvegf pathway,biological pathway,egfrvegf pathway,biological pathway,34281470
placebocontrolled phase 3 trial,clinical trial,placebocontrolled phase 3 trial,clinical trial,34281470
clinical relevance,concept,clinical relevance,concept,34281470
egfr and vegfrtargeting therapy,treatment approach,egfr and vegfrtargeting therapy,treatment approach,34281470
pfs benefit,clinical outcome,pfs benefit,clinical outcome,34281470
toxicity profile,side effect,toxicity profile,side effect,34281470
bimonthly infusion,treatment schedule,bimonthly infusion,treatment schedule,34281470
osimertinib,drug,osimertinib,drug,34281470
heterogeneous efficacy,clinical outcome variability,heterogeneous efficacy,clinical outcome variability,34281470
osimertinibbased combination,treatment approach,osimertinibbased combination,treatment approach,34281470
ongoing trial,clinical trial,ongoing trial,clinical trial,34281470
carboplatin,drug,carboplatin,drug,34280922
glomerular filtration rate,preferred_label,glomerular filtration rate,preferred_label,34280922
serum creatinine,preferred_label,serum creatinine,preferred_label,34280922
hematologic toxicity,adverse event,hematologic toxicity,adverse event,34280922
lung cancer,disease,lung cancer,disease,34280922
thrombocytopenia,adverse event,thrombocytopenia,adverse event,34280922
anemia,adverse event,anemia,adverse event,34280922
progression-free survival,adverse event outcome,progression-free survival,adverse event outcome,34280922
overall survival,adverse event outcome,overall survival,adverse event outcome,34280922
immune checkpoint inhibitor,preferred_label,immune checkpoint inhibitor,preferred_label,34278695
cancer,preferred_label,cancer,preferred_label,34278695
autoimmune toxicity,preferred_label,autoimmune toxicity,preferred_label,34278695
endocrine toxicity,preferred_label,endocrine toxicity,preferred_label,34278695
physician,preferred_label,physician,preferred_label,34278695
endocrinologist,preferred_label,endocrinologist,preferred_label,34278695
oncologist,preferred_label,oncologist,preferred_label,34278695
reaction,preferred_label,reaction,preferred_label,34278695
epidemiology,preferred_label,epidemiology,preferred_label,34278695
pathophysiology,preferred_label,pathophysiology,preferred_label,34278695
clinical presentation,preferred_label,clinical presentation,preferred_label,34278695
management,preferred_label,management,preferred_label,34278695
immune checkpoint inhibitor,class_id,immune checkpoint inhibitor,class_id,34275517
cancer patient,class_id,cancer patient,class_id,34275517
drug resistance,class_id,drug resistance,class_id,34275517
combination therapy,class_id,combination therapy,class_id,34275517
adverse event,class_id,adverse event,class_id,34275517
programmed cell death protein ligand 1 (PDPDL1) inhibitor,class_id,programmed cell death protein ligand 1 (PDPDL1) inhibitor,class_id,34275517
ibrutinib,preferred_label,ibrutinib,preferred_label,34275396
acalabrutinib,preferred_label,acalabrutinib,preferred_label,34275396
chronic lymphocytic leukemia,preferred_label,chronic lymphocytic leukemia,preferred_label,34275396
btk,preferred_label,btk,preferred_label,34275396
cd20 antibody,preferred_label,cd20 antibody,preferred_label,34275396
venetoclax,preferred_label,venetoclax,preferred_label,34275396
immune related adverse event,semantic_types,immune related adverse event,semantic_types,34274878
cardiotoxic side effect,semantic_types,cardiotoxic side effect,semantic_types,34274878
immune checkpoint inhibitor,semantic_types,immune checkpoint inhibitor,semantic_types,34274878
chimeric antigen receptor tcell therapy,semantic_types,chimeric antigen receptor tcell therapy,semantic_types,34274878
glucocorticoid,semantic_types,glucocorticoid,semantic_types,34274878
tocilizumab,semantic_types,tocilizumab,semantic_types,34274878
aloe vera l burm f,preferred_label,aloe vera l burm f,preferred_label,34274443
constipation,semantic_types,constipation,semantic_types,34274443
antitumor,semantic_types,antitumor,semantic_types,34274443
antiinflammatory,semantic_types,antiinflammatory,semantic_types,34274443
immune regulatory effect,semantic_types,immune regulatory effect,semantic_types,34274443
aloe vera barbadensis extract,preferred_label,aloe vera barbadensis extract,preferred_label,34274443
rat,preferred_label,rat,preferred_label,34274443
cell line,preferred_label,cell line,preferred_label,34274443
cancer cell,preferred_label,cancer cell,preferred_label,34274443
noncancer cell,preferred_label,noncancer cell,preferred_label,34274443
malic acid,preferred_label,malic acid,preferred_label,34274443
adenosine triphosphate,preferred_label,adenosine triphosphate,preferred_label,34274443
reactive oxygen specie,preferred_label,reactive oxygen specie,preferred_label,34274443
mitochondrial metabolism,preferred_label,mitochondrial metabolism,preferred_label,34274443
malignant cancer,preferred_label,malignant cancer,preferred_label,34274443
antineoplastic antimetabolite,preferred_label,antineoplastic antimetabolite,preferred_label,34273448
gut microbiota,preferred_label,gut microbiota,preferred_label,34273448
lenvatinib,drug,lenvatinib,drug,34272090
paclitaxel,drug,paclitaxel,drug,34272090
endometrial cancer,disease,endometrial cancer,disease,34272090
ovarian cancer,disease,ovarian cancer,disease,34272090
anemia,adverse event,anemia,adverse event,34272090
neutropenia,adverse event,neutropenia,adverse event,34272090
lymphopenia,adverse event,lymphopenia,adverse event,34272090
mucositis,adverse event,mucositis,adverse event,34272090
nausea,adverse event,nausea,adverse event,34272090
diarrhea,adverse event,diarrhea,adverse event,34272090
anorexia,adverse event,anorexia,adverse event,34272090
hypertension,adverse event,hypertension,adverse event,34272090
fatigue,adverse event,fatigue,adverse event,34272090
proteinuria,adverse event,proteinuria,adverse event,34272090
epistaxis,adverse event,epistaxis,adverse event,34272090
hoarseness,adverse event,hoarseness,adverse event,34272090
patient,patient,patient,patient,34272090
response,response,response,response,34272090
progression free survival,outcome,progression free survival,outcome,34272090
atezolizumab,drug,atezolizumab,drug,34272041
nabpaclitaxel,drug,nabpaclitaxel,drug,34272041
breast cancer,disease,breast cancer,disease,34272041
programmed deathligand 1,protein,programmed deathligand 1,protein,34272041
medulloblastoma,class_id,medulloblastoma,class_id,34271103
nucleosome remodeling factor,preferred_label,nucleosome remodeling factor,preferred_label,34271103
chromatin transcription complex,preferred_label,chromatin transcription complex,preferred_label,34271103
DNA repair enzyme APE1,preferred_label,DNA repair enzyme APE1,preferred_label,34271103
CBL0137,preferred_label,CBL0137,preferred_label,34271103
cisplatin,preferred_label,cisplatin,preferred_label,34271103
radiation,preferred_label,radiation,preferred_label,34271103
tnbc cell,class_id,tnbc cell,class_id,34270809
olaparib,preferred_label,olaparib,preferred_label,34270809
radiotherapy,preferred_label,radiotherapy,preferred_label,34270809
radioparp trial,preferred_label,radioparp trial,preferred_label,34270809
breast radiotherapy,preferred_label,breast radiotherapy,preferred_label,34270809
tnbc patient,preferred_label,tnbc patient,preferred_label,34270809
adverse event,preferred_label,adverse event,preferred_label,34270809
breast pain,preferred_label,breast pain,preferred_label,34270809
fibrosis,preferred_label,fibrosis,preferred_label,34270809
deformity,preferred_label,deformity,preferred_label,34270809
chemotherapy,may_treat,chemotherapy,may_treat,34270794
side effects,adverse event occurs in,side effects,adverse event occurs in,34270794
treatment discontinuation,adverse event outcome,treatment discontinuation,adverse event outcome,34270794
biomarkers,may_prevent,biomarkers,may_prevent,34270794
genomewide association study,example of usage,genomewide association study,example of usage,34270794
gene analysis,realizes,gene analysis,realizes,34270794
neutropenia,adverse event occurs in,neutropenia,adverse event occurs in,34270794
vomiting,adverse event occurs in,vomiting,adverse event occurs in,34270794
diarrhoea,adverse event occurs in,diarrhoea,adverse event occurs in,34270794
handfoot syndrome,adverse event occurs in,handfoot syndrome,adverse event occurs in,34270794
lethargy,adverse event occurs in,lethargy,adverse event occurs in,34270794
nausea,adverse event occurs in,nausea,adverse event occurs in,34270794
portal vein tumor thrombus,class_id,portal vein tumor thrombus,class_id,34269290
hepatocellular carcinoma,class_id,hepatocellular carcinoma,class_id,34269290
anlotinib,class_id,anlotinib,class_id,34269290
tumor angiogenesis,class_id,tumor angiogenesis,class_id,34269290
transarterial chemoembolization,class_id,transarterial chemoembolization,class_id,34269290
radiofrequency ablation,class_id,radiofrequency ablation,class_id,34269290
adverse event,class_id,adverse event,class_id,34269290
pharyngalgia,class_id,pharyngalgia,class_id,34269290
fatigue,class_id,fatigue,class_id,34269290
handfoot skin reaction,class_id,handfoot skin reaction,class_id,34269290
imc001,drug,imc001,drug,34268711
igg1 monoclonal antibody,drug,igg1 monoclonal antibody,drug,34268711
pdl1 programmed deathligand 1,protein,pdl1 programmed deathligand 1,protein,34268711
solid tumor,disease,solid tumor,disease,34268711
rectal cancer,disease,rectal cancer,disease,34268711
acalabrutinib,drug,acalabrutinib,drug,34268530
chronic lymphocytic leukemia,disease,chronic lymphocytic leukemia,disease,34268530
ibrutinib,drug,ibrutinib,drug,34268530
ascend trial,clinical trial,ascend trial,clinical trial,34268530
elevate-tn trial,clinical trial,elevate-tn trial,clinical trial,34268530
atrial fibrillation,adverse event,atrial fibrillation,adverse event,34268530
obinutuzumab,drug,obinutuzumab,drug,34268530
lowrisk gestational trophoblastic neoplasia,class_id,lowrisk gestational trophoblastic neoplasia,class_id,34266689
methotrexate,preferred_label,methotrexate,preferred_label,34266689
folinic acid,preferred_label,folinic acid,preferred_label,34266689
rio de janeiro federal university,preferred_label,rio de janeiro federal university,preferred_label,34266689
Immunerelated adverse event (IRAE),semantic_types,Immunerelated adverse event (IRAE),semantic_types,34265432
Steroid,preferred_label,Steroid,preferred_label,34265432
Immunosuppressant,preferred_label,Immunosuppressant,preferred_label,34265432
Lung cancer,preferred_label,Lung cancer,preferred_label,34265432
Tumor necrosis factor inhibitor,preferred_label,Tumor necrosis factor inhibitor,preferred_label,34265432
Mycophenolate mofetil,preferred_label,Mycophenolate mofetil,preferred_label,34265432
Colitis,preferred_label,Colitis,preferred_label,34265432
Pneumonitis,preferred_label,Pneumonitis,preferred_label,34265432
Hepatitis,preferred_label,Hepatitis,preferred_label,34265432
Neuromuscular,preferred_label,Neuromuscular,preferred_label,34265432
immune checkpoint inhibitor,preferred_label,immune checkpoint inhibitor,preferred_label,34265157
immune-related adverse event,preferred_label,immune-related adverse event,preferred_label,34265157
oral manifestation,preferred_label,oral manifestation,preferred_label,34265157
mucosal toxicity,preferred_label,mucosal toxicity,preferred_label,34265157
salivary gland toxicity,preferred_label,salivary gland toxicity,preferred_label,34265157
cortiosteroid,preferred_label,cortiosteroid,preferred_label,34265157
oncologist,preferred_label,oncologist,preferred_label,34265157
specialist,preferred_label,specialist,preferred_label,34265157
ipatasertib,drug,ipatasertib,drug,34264439
paclitaxel,drug,paclitaxel,drug,34264439
triple-negative breast cancer,disease,triple-negative breast cancer,disease,34264439
PIK3CA/AKT/PTEN-altered tumor,class_id,PIK3CA/AKT/PTEN-altered tumor,class_id,34264439
next-generation sequencing assay,class_id,next-generation sequencing assay,class_id,34264439
ly3076226,drug,ly3076226,drug,34264412
human fgfr3,protein,human fgfr3,protein,34264412
maytansine derivative dm4,compound,maytansine derivative dm4,compound,34264412
cancer,disease,cancer,disease,34264412
urothelial carcinoma,disease,urothelial carcinoma,disease,34264412
nivolumab plus ipilimumab,preferred_label,nivolumab plus ipilimumab,preferred_label,34264316
platinum-based chemotherapy,preferred_label,platinum-based chemotherapy,preferred_label,34264316
docetaxel,preferred_label,docetaxel,preferred_label,34264316
ipilimumab,preferred_label,ipilimumab,preferred_label,34264316
nivolumab,preferred_label,nivolumab,preferred_label,34264316
nsclc,preferred_label,nsclc,preferred_label,34264316
lung cancer master protocol lungmap s1400i phase,preferred_label,lung cancer master protocol lungmap s1400i phase,preferred_label,34264316
clinical trial network,preferred_label,clinical trial network,preferred_label,34264316
Zubrod score,preferred_label,Zubrod score,preferred_label,34264316
platinum-based chemotherapy,preferred_label,platinum-based chemotherapy,preferred_label,34264316
disease progression,preferred_label,disease progression,preferred_label,34264316
progression-free survival,preferred_label,progression-free survival,preferred_label,34264316
response rate,preferred_label,response rate,preferred_label,34264316
adverse event,preferred_label,adverse event,preferred_label,34264316
treatment-related adverse event,preferred_label,treatment-related adverse event,preferred_label,34264316
discontinuation,preferred_label,discontinuation,preferred_label,34264316
immune checkpoint inhibitor-naive sqnsclc,preferred_label,immune checkpoint inhibitor-naive sqnsclc,preferred_label,34264316
Esophageal cancer,class_id,Esophageal cancer,class_id,34263677
Platinum and fluoropyrimidine combination,class_id,Platinum and fluoropyrimidine combination,class_id,34263677
Taxane or irinotecan,class_id,Taxane or irinotecan,class_id,34263677
Immune checkpoint inhibitors (ICIs),class_id,Immune checkpoint inhibitors (ICIs),class_id,34263677
Pembrolizumab,class_id,Pembrolizumab,class_id,34263677
Nivolumab,class_id,Nivolumab,class_id,34263677
Cytotoxic agents,class_id,Cytotoxic agents,class_id,34263677
Neutropenia and neuropathy,class_id,Neutropenia and neuropathy,class_id,34263677
Neutropenia and diarrhea,class_id,Neutropenia and diarrhea,class_id,34263677
destinybreast01 study,class_id,destinybreast01 study,class_id,34263665
trastuzumab deruxtecan,preferred_label,trastuzumab deruxtecan,preferred_label,34263665
herpositive breast cancer,preferred_label,herpositive breast cancer,preferred_label,34263665
metastatic breast cancer,preferred_label,metastatic breast cancer,preferred_label,34263665
trastuzumab emtansine,preferred_label,trastuzumab emtansine,preferred_label,34263665
adverse event,preferred_label,adverse event,preferred_label,34263665
nausea,preferred_label,nausea,preferred_label,34263665
lung toxicity,preferred_label,lung toxicity,preferred_label,34263665
chemoradiotherapy,preferred_label,chemoradiotherapy,preferred_label,34263358
docetaxel,preferred_label,docetaxel,preferred_label,34263358
cisplatin,preferred_label,cisplatin,preferred_label,34263358
fluorouracil,preferred_label,fluorouracil,preferred_label,34263358
external auditory canal cancer,preferred_label,external auditory canal cancer,preferred_label,34263358
oncological outcome,preferred_label,oncological outcome,preferred_label,34263358
functional outcome,preferred_label,functional outcome,preferred_label,34263358
phase I trial,preferred_label,phase I trial,preferred_label,34263358
maximum tolerated dose,preferred_label,maximum tolerated dose,preferred_label,34263358
recommended dose,preferred_label,recommended dose,preferred_label,34263358
febrile neutropenia,preferred_label,febrile neutropenia,preferred_label,34263358
radiotherapy,preferred_label,radiotherapy,preferred_label,34263358
melphalan,drug,melphalan,drug,34262262
lpam,drug,lpam,drug,34262262
autologous stem cell transplantation,treatment,autologous stem cell transplantation,treatment,34262262
quadruplet regimen,treatment,quadruplet regimen,treatment,34262262
daratumumab,drug,daratumumab,drug,34262262
bortezomib,drug,bortezomib,drug,34262262
prednisone,drug,prednisone,drug,34262262
melflufen,drug,melflufen,drug,34262262
aminopeptidase,enzyme,aminopeptidase,enzyme,34262262
dexamethasone,drug,dexamethasone,drug,34262262
pembrolizumab,drug,pembrolizumab,drug,34261922
melanoma,disease,melanoma,disease,34261922
hypophysitis,adverse event,hypophysitis,adverse event,34261922
corticosteroid,drug,corticosteroid,drug,34261922
hormonal replacement therapy,treatment,hormonal replacement therapy,treatment,34261922
thyrotropin,hormone,thyrotropin,hormone,34261922
corticotropin hormone,hormone,corticotropin hormone,hormone,34261922
advanced nonclear cell renal cell carcinoma,class_id,advanced nonclear cell renal cell carcinoma,class_id,34261919
immunotherapy,class_id,immunotherapy,class_id,34261919
adverse event,class_id,adverse event,class_id,34261919
metastatic mucinous tubular and spindle cell carcinoma,class_id,metastatic mucinous tubular and spindle cell carcinoma,class_id,34261919
posterior reversible encephalopathy syndrome,class_id,posterior reversible encephalopathy syndrome,class_id,34261919
sunitinib,class_id,sunitinib,class_id,34261919
antivascular endothelial growth factor receptor therapy,class_id,antivascular endothelial growth factor receptor therapy,class_id,34261919
MRI,class_id,MRI,class_id,34261919
long-term response to immunotherapy,class_id,long-term response to immunotherapy,class_id,34261919
Chemoimmunotherapy,treated with drug,Chemoimmunotherapy,treated with drug,34261336
Extensive-stage small cell lung cancer (ESSCLC),has disease,Extensive-stage small cell lung cancer (ESSCLC),has disease,34261336
Chemotherapy,may_treat,Chemotherapy,may_treat,34261336
Immunotherapy,may_treat,Immunotherapy,may_treat,34261336
Cisplatin-based chemotherapy,may_treat,Cisplatin-based chemotherapy,may_treat,34261336
Brain metastasis,has disease,Brain metastasis,has disease,34261336
Lung cancer,has disease,Lung cancer,has disease,34261336
panchvalkala,preferred_label,panchvalkala,preferred_label,34260879
endometriosis,has disease,endometriosis,has disease,34260879
leucorrhea,has disease,leucorrhea,has disease,34260879
vaginal ailment,has disease,vaginal ailment,has disease,34260879
ficus glomerata,preferred_label,ficus glomerata,preferred_label,34260879
ficus virens,preferred_label,ficus virens,preferred_label,34260879
ficus religiosa,preferred_label,ficus religiosa,preferred_label,34260879
ficus benghalensis,preferred_label,ficus benghalensis,preferred_label,34260879
thespesia populnea,preferred_label,thespesia populnea,preferred_label,34260879
cervical cancer,has disease,cervical cancer,has disease,34260879
siha,preferred_label,siha,preferred_label,34260879
hela,preferred_label,hela,preferred_label,34260879
caspase,preferred_label,caspase,preferred_label,34260879
prb,preferred_label,prb,preferred_label,34260879
e6,preferred_label,e6,preferred_label,34260879
e7,preferred_label,e7,preferred_label,34260879
p53,preferred_label,p53,preferred_label,34260879
cisplatin,preferred_label,cisplatin,preferred_label,34260879
il2,preferred_label,il2,preferred_label,34260879
il10,preferred_label,il10,preferred_label,34260879
Locally advanced nonsmall cell lung cancer (LANSCLC),class_id,Locally advanced nonsmall cell lung cancer (LANSCLC),class_id,34260719
Intensity modulated radiotherapy (IMRT),class_id,Intensity modulated radiotherapy (IMRT),class_id,34260719
Involved field radiotherapy (IFRT),class_id,Involved field radiotherapy (IFRT),class_id,34260719
Platinum-based chemotherapy,class_id,Platinum-based chemotherapy,class_id,34260719
Squamous cell carcinoma,class_id,Squamous cell carcinoma,class_id,34260719
Adenocarcinoma,class_id,Adenocarcinoma,class_id,34260719
Patient,class_id,Patient,class_id,34260719
Regional lymph node,class_id,Regional lymph node,class_id,34260719
high-dose chemotherapy,preferred_label,high-dose chemotherapy,preferred_label,34260067
peripheral blood stem cell transplantation,preferred_label,peripheral blood stem cell transplantation,preferred_label,34260067
metastatic germ cell tumor,preferred_label,metastatic germ cell tumor,preferred_label,34260067
age,preferred_label,age,preferred_label,34260067
toxicity,preferred_label,toxicity,preferred_label,34260067
outcome,preferred_label,outcome,preferred_label,34260067
patient,preferred_label,patient,preferred_label,34260067
progression-free survival,preferred_label,progression-free survival,preferred_label,34260067
overall survival,preferred_label,overall survival,preferred_label,34260067
treatment-related mortality,preferred_label,treatment-related mortality,preferred_label,34260067
complication,preferred_label,complication,preferred_label,34260067
histology,preferred_label,histology,preferred_label,34260067
cycle,preferred_label,cycle,preferred_label,34260067
predictor,preferred_label,predictor,preferred_label,34260067
Eastern Cooperative Oncology Group performance status,preferred_label,Eastern Cooperative Oncology Group performance status,preferred_label,34260067
platinum refractory disease,preferred_label,platinum refractory disease,preferred_label,34260067
hyperpolarized 129xe hpxe MRI,preferred_label,hyperpolarized 129xe hpxe MRI,preferred_label,34257627
pulmonary function,preferred_label,pulmonary function,preferred_label,34257627
lung cancer model,preferred_label,lung cancer model,preferred_label,34257627
mouse model of lung cancer,preferred_label,mouse model of lung cancer,preferred_label,34257627
lc wa,synonyms,lc wa,synonyms,34257627
ethyl pyruvate,preferred_label,ethyl pyruvate,preferred_label,34257627
adenoma,preferred_label,adenoma,preferred_label,34257627
hpxe MRI metric,preferred_label,hpxe MRI metric,preferred_label,34257627
precancerous lesion microenvironment,preferred_label,precancerous lesion microenvironment,preferred_label,34257627
therapeutic efficacy in cancer,preferred_label,therapeutic efficacy in cancer,preferred_label,34257627
fludarabine cyclophosphamide and rituximab combination,drug,fludarabine cyclophosphamide and rituximab combination,drug,34257611
cytopenia,adverse event,cytopenia,adverse event,34257611
patient,patient,patient,patient,34257611
ibrutinib,drug,ibrutinib,drug,34257611
aurora kinase a,class_id,aurora kinase a,class_id,34256279
alisertib,class_id,alisertib,class_id,34256279
paclitaxel,class_id,paclitaxel,class_id,34256279
neuroendocrine tumour,class_id,neuroendocrine tumour,class_id,34256279
small-cell lung cancer,class_id,small-cell lung cancer,class_id,34256279
pancreatic ductal adenocarcinoma,class_id,pancreatic ductal adenocarcinoma,class_id,34256279
favipiravir,drug,favipiravir,drug,34255596
sarscov2 infection,disease,sarscov2 infection,disease,34255596
chemotherapeutic agent,drug,chemotherapeutic agent,drug,34255596
metastatic osteosarcoma,disease,metastatic osteosarcoma,disease,34255596
methotrexate,drug,methotrexate,drug,34255596
hepatotoxicity,adverse event,hepatotoxicity,adverse event,34255596
toxic hepatitis,adverse event,toxic hepatitis,adverse event,34255596
methylprednisolone,drug,methylprednisolone,drug,34255596
aldehyde oxidase,enzyme,aldehyde oxidase,enzyme,34255596
bartogenic acid,class_id,bartogenic acid,class_id,34255109
oleanolic acid,class_id,oleanolic acid,class_id,34255109
ursolic acid,class_id,ursolic acid,class_id,34255109
skov3 ovarian cancer,class_id,skov3 ovarian cancer,class_id,34255109
paclitaxel,class_id,paclitaxel,class_id,34255109
scid mouse,class_id,scid mouse,class_id,34255109
nfb,class_id,nfb,class_id,34255109
artemisinin compound,drug,artemisinin compound,drug,34254767
nanoprodrug,drug,nanoprodrug,drug,34254767
tumor,disease,tumor,disease,34254767
tumor microenvironment,location,tumor microenvironment,location,34254767
glutathione concentration,chemical,glutathione concentration,chemical,34254767
methotrexate pathway gene,semantic_types,methotrexate pathway gene,semantic_types,34254644
highdose methotrexaterelated hepatotoxicity,semantic_types,highdose methotrexaterelated hepatotoxicity,semantic_types,34254644
Chinese patient with primary central nervous system lymphoma,semantic_types,Chinese patient with primary central nervous system lymphoma,semantic_types,34254644
30 candidate snp,semantic_types,30 candidate snp,semantic_types,34254644
20 methotrexate pathway gene,semantic_types,20 methotrexate pathway gene,semantic_types,34254644
plink,semantic_types,plink,semantic_types,34254644
logistic regression,semantic_types,logistic regression,semantic_types,34254644
tyms 6 bp di ii rs151264360,semantic_types,tyms 6 bp di ii rs151264360,semantic_types,34254644
mthfd1 1958 ga aa rs2236225,semantic_types,mthfd1 1958 ga aa rs2236225,semantic_types,34254644
ccnd1 870 ga gg rs9344,semantic_types,ccnd1 870 ga gg rs9344,semantic_types,34254644
abcc2 intron 29 ga gg rs3740065,semantic_types,abcc2 intron 29 ga gg rs3740065,semantic_types,34254644
pi3kaktmtor inhibitor,drug,pi3kaktmtor inhibitor,drug,34253390
ovarian cancer,disease,ovarian cancer,disease,34253390
pi3kaktmtor biomarkers,biomarker,pi3kaktmtor biomarkers,biomarker,34253390
pten protein expression,biomarker,pten protein expression,biomarker,34253390
multiple myeloma,class_id,multiple myeloma,class_id,34253136
immunotherapy,class_id,immunotherapy,class_id,34253136
pdl1 axis,class_id,pdl1 axis,class_id,34253136
checkpoint inhibitor,class_id,checkpoint inhibitor,class_id,34253136
immunomodulatory drug,class_id,immunomodulatory drug,class_id,34253136
proteasome inhibitor,class_id,proteasome inhibitor,class_id,34253136
monoclonal antibody,class_id,monoclonal antibody,class_id,34253136
antipd1,class_id,antipd1,class_id,34253136
tcell engager,class_id,tcell engager,class_id,34253136
cart cell,class_id,cart cell,class_id,34253136
romidepsin,preferred_label,romidepsin,preferred_label,34251048
lenalidomide,preferred_label,lenalidomide,preferred_label,34251048
carfilzomib,preferred_label,carfilzomib,preferred_label,34251048
lymphoma,preferred_label,lymphoma,preferred_label,34251048
phase i study,preferred_label,phase i study,preferred_label,34251048
t-cell lymphoma,preferred_label,t-cell lymphoma,preferred_label,34251048
b-cell lymphoma,preferred_label,b-cell lymphoma,preferred_label,34251048
Hodgkin lymphoma,preferred_label,Hodgkin lymphoma,preferred_label,34251048
neutropenia,preferred_label,neutropenia,preferred_label,34251048
thrombocytopenia,preferred_label,thrombocytopenia,preferred_label,34251048
electrolyte abnormality,preferred_label,electrolyte abnormality,preferred_label,34251048
progression free survival,preferred_label,progression free survival,preferred_label,34251048
allogeneic transplant,preferred_label,allogeneic transplant,preferred_label,34251048
lenvatinib,drug associated with AE in patient with hcc,lenvatinib,drug associated with AE in patient with hcc,34250737
hepatocellular carcinoma,disease,hepatocellular carcinoma,disease,34250737
Arterial hypertension,adverse event,Arterial hypertension,adverse event,34250737
Decreased appetite,adverse event,Decreased appetite,adverse event,34250737
Handfoot skin reaction,adverse event,Handfoot skin reaction,adverse event,34250737
overall survival,adverse event outcome,overall survival,adverse event outcome,34250737
progression-free survival,adverse event outcome,progression-free survival,adverse event outcome,34250737
seribantumab,preferred_label,seribantumab,preferred_label,34250553
human epidermal growth factor receptor 3,preferred_label,human epidermal growth factor receptor 3,preferred_label,34250553
tumor cell,preferred_label,tumor cell,preferred_label,34250553
phase 1 study,preferred_label,phase 1 study,preferred_label,34250553
patient,preferred_label,patient,preferred_label,34250553
solid tumor,preferred_label,solid tumor,preferred_label,34250553
dose cohort,preferred_label,dose cohort,preferred_label,34250553
monoclonal antibody,preferred_label,monoclonal antibody,preferred_label,34250553
objective response rate,preferred_label,objective response rate,preferred_label,34250553
safety,preferred_label,safety,preferred_label,34250553
doselimiting toxicity,preferred_label,doselimiting toxicity,preferred_label,34250553
pharmacokinetics,preferred_label,pharmacokinetics,preferred_label,34250553
patient enrollment,preferred_label,patient enrollment,preferred_label,34250553
steady state concentration,preferred_label,steady state concentration,preferred_label,34250553
immune checkpoint inhibitor,drug,immune checkpoint inhibitor,drug,34247513
cancer,disease,cancer,disease,34247513
adverse event,adverse event,adverse event,adverse event,34247513
nervous system,anatomy,nervous system,anatomy,34247513
immunerelated autonomic neuropathy,adverse event,immunerelated autonomic neuropathy,adverse event,34247513
intestinal pseudoobstruction,adverse event,intestinal pseudoobstruction,adverse event,34247513
enteric plexus neuropathy,adverse event,enteric plexus neuropathy,adverse event,34247513
pd-l1 blockade,drug,pd-l1 blockade,drug,34247513
small cell lung cancer,disease,small cell lung cancer,disease,34247513
enteric nerve damage,adverse event,enteric nerve damage,adverse event,34247513
chemotherapy drug,drug,chemotherapy drug,drug,34245737
cancer cell,cell type,cancer cell,cell type,34245737
nanocarrier,nanoparticle,nanocarrier,nanoparticle,34245737
cd73,molecule,cd73,molecule,34245737
doxorubicin,drug,doxorubicin,drug,34245737
tumor microenvironment,biological environment,tumor microenvironment,biological environment,34245737
tumorbearing mouse,animal model,tumorbearing mouse,animal model,34245737
testicular germ cell tumor,class_id,testicular germ cell tumor,class_id,34245663
cisplatin,preferred_label,cisplatin,preferred_label,34245663
chemotherapy,preferred_label,chemotherapy,preferred_label,34245663
cardiovascular disease,preferred_label,cardiovascular disease,preferred_label,34245663
metabolic disease,preferred_label,metabolic disease,preferred_label,34245663
secondary cancer,preferred_label,secondary cancer,preferred_label,34245663
nephrotoxicity,preferred_label,nephrotoxicity,preferred_label,34245663
neurotoxicity,preferred_label,neurotoxicity,preferred_label,34245663
exercise,preferred_label,exercise,preferred_label,34245663
colorectal cancer,disease,colorectal cancer,disease,34245224
obesity,disease,obesity,disease,34245224
phytochemical garcinol,drug,phytochemical garcinol,drug,34245224
polyisoprenylated benzophenone derivative,chemical compound,polyisoprenylated benzophenone derivative,chemical compound,34245224
garcinia plant,plant,garcinia plant,plant,34245224
high-fat diet,diet,high-fat diet,diet,34245224
colitis-associated colon cancer,disease,colitis-associated colon cancer,disease,34245224
AOM (azoxymethane)/DSS (dextran sodium sulfate),chemical compound,AOM (azoxymethane)/DSS (dextran sodium sulfate),chemical compound,34245224
microbiota,biological entity,microbiota,biological entity,34245224
genus alistipes,microorganism,genus alistipes,microorganism,34245224
genus romboutsia,microorganism,genus romboutsia,microorganism,34245224
genus ruminococcus,microorganism,genus ruminococcus,microorganism,34245224
Thyroid immune-related adverse event (Thyroid IRAE),adverse event outcome,Thyroid immune-related adverse event (Thyroid IRAE),adverse event outcome,34244291
Immune checkpoint inhibitor (CPI) therapy,may_treat,Immune checkpoint inhibitor (CPI) therapy,may_treat,34244291
Genetic risk for hypothyroidism,genetic risk factor,Genetic risk for hypothyroidism,genetic risk factor,34244291
Antipd1 therapy,may_treat,Antipd1 therapy,may_treat,34244291
methotrexate,drug,methotrexate,drug,34244200
antineoplastic agent,drug,antineoplastic agent,drug,34244200
immunosuppressive agent,drug,immunosuppressive agent,drug,34244200
young adult,age group,young adult,age group,34244200
cancer and leukaemia group b 10403 treatment protocol,treatment protocol,cancer and leukaemia group b 10403 treatment protocol,treatment protocol,34244200
bcell acute lymphoblastic leukaemia,disease,bcell acute lymphoblastic leukaemia,disease,34244200
pancytopaenia,adverse event,pancytopaenia,adverse event,34244200
dermatologic toxicity,adverse event,dermatologic toxicity,adverse event,34244200
methotrexate toxicity,adverse event,methotrexate toxicity,adverse event,34244200
leucovorin therapy,treatment,leucovorin therapy,treatment,34244200
pembrolizumab,drug,pembrolizumab,drug,34244116
axitinib,drug,axitinib,drug,34244116
sunitinib,drug,sunitinib,drug,34244116
renal cell carcinoma,disease,renal cell carcinoma,disease,34244116
hepatic adverse event,adverse event,hepatic adverse event,adverse event,34244116
alanine aminotransferase,enzyme,alanine aminotransferase,enzyme,34244116
corticosteroid,drug,corticosteroid,drug,34244116
topoisomerase1 inhibitor,class_id,topoisomerase1 inhibitor,class_id,34243976
crlx101,preferred_label,crlx101,preferred_label,34243976
camptothecin,synonyms,camptothecin,synonyms,34243976
nanoparticles,preferred_label,nanoparticles,preferred_label,34243976
cancer cell,preferred_label,cancer cell,preferred_label,34243976
bevacizumab,preferred_label,bevacizumab,preferred_label,34243976
ovarian cancer,preferred_label,ovarian cancer,preferred_label,34243976
platinum refractory,preferred_label,platinum refractory,preferred_label,34243976
nausea,preferred_label,nausea,preferred_label,34243976
fatigue,preferred_label,fatigue,preferred_label,34243976
anemia,preferred_label,anemia,preferred_label,34243976
hypertension,preferred_label,hypertension,preferred_label,34243976
bladder toxicity,preferred_label,bladder toxicity,preferred_label,34243976
peptide receptor radionuclide therapy,preferred_label,peptide receptor radionuclide therapy,preferred_label,34242948
patient,preferred_label,patient,preferred_label,34242948
unresectable or metastasized somatostatin receptor type 2 sstr2expressing gastroenteropancreatic neuroendocrine tumour,preferred_label,unresectable or metastasized somatostatin receptor type 2 sstr2expressing gastroenteropancreatic neuroendocrine tumour,preferred_label,34242948
177luludotatate,preferred_label,177luludotatate,preferred_label,34242948
kidney,preferred_label,kidney,preferred_label,34242948
radiation nephropathy,preferred_label,radiation nephropathy,preferred_label,34242948
hematologic toxicity,preferred_label,hematologic toxicity,preferred_label,34242948
metastatic castrationresistant prostate cancer,class_id,metastatic castrationresistant prostate cancer,class_id,34242474
docetaxel,class_id,docetaxel,class_id,34242474
cabazitaxel,class_id,cabazitaxel,class_id,34242474
haematological toxicity,class_id,haematological toxicity,class_id,34242474
patient,class_id,patient,class_id,34242474
sepsis,class_id,sepsis,class_id,34242474
proteolysis targeting chimera protacs,preferred_label,proteolysis targeting chimera protacs,preferred_label,34240523
drug development,preferred_label,drug development,preferred_label,34240523
heterobifunctional protac molecule,preferred_label,heterobifunctional protac molecule,preferred_label,34240523
membrane permeability,preferred_label,membrane permeability,preferred_label,34240523
in vivo efficacy,preferred_label,in vivo efficacy,preferred_label,34240523
aptamerprotac conjugation approach,preferred_label,aptamerprotac conjugation approach,preferred_label,34240523
tumorspecific targeting ability,preferred_label,tumorspecific targeting ability,preferred_label,34240523
in vivo antitumor potency,preferred_label,in vivo antitumor potency,preferred_label,34240523
conventional protacs,preferred_label,conventional protacs,preferred_label,34240523
proof of concept,preferred_label,proof of concept,preferred_label,34240523
bettargeting protac,preferred_label,bettargeting protac,preferred_label,34240523
nucleic acid aptamer as1411,preferred_label,nucleic acid aptamer as1411,preferred_label,34240523
cleavable linker,preferred_label,cleavable linker,preferred_label,34240523
mcf7 xenograft model,preferred_label,mcf7 xenograft model,preferred_label,34240523
bet degradation,preferred_label,bet degradation,preferred_label,34240523
antitumor potency,preferred_label,antitumor potency,preferred_label,34240523
toxicity,preferred_label,toxicity,preferred_label,34240523
apc strategy,preferred_label,apc strategy,preferred_label,34240523
tumorspecific targeting protacs,preferred_label,tumorspecific targeting protacs,preferred_label,34240523
protacbased drug,preferred_label,protacbased drug,preferred_label,34240523
locally recurrent pancreatic cancer,preferred_label,locally recurrent pancreatic cancer,preferred_label,34237249
stereotactic body radiotherapy,preferred_label,stereotactic body radiotherapy,preferred_label,34237249
pembrolizumab,preferred_label,pembrolizumab,preferred_label,34237249
trametinib,preferred_label,trametinib,preferred_label,34237249
pancreatic ductal adenocarcinoma,preferred_label,pancreatic ductal adenocarcinoma,preferred_label,34237249
mfolfirinox,preferred_label,mfolfirinox,preferred_label,34237249
fluorouracil,preferred_label,fluorouracil,preferred_label,34237249
gemcitabine,preferred_label,gemcitabine,preferred_label,34237249
overall survival,preferred_label,overall survival,preferred_label,34237249
adverse effect,preferred_label,adverse effect,preferred_label,34237249
hepatocellular carcinoma,class_id,hepatocellular carcinoma,class_id,34237154
transarterial chemoembolization,class_id,transarterial chemoembolization,class_id,34237154
lenvatinib,class_id,lenvatinib,class_id,34237154
portal vein tumor thrombus,class_id,portal vein tumor thrombus,class_id,34237154
sorafenib,class_id,sorafenib,class_id,34237154
patient,class_id,patient,class_id,34237154
primary cns lymphoma,class_id,primary cns lymphoma,class_id,34236556
cytarabine,preferred_label,cytarabine,preferred_label,34236556
highdose methotrexate,preferred_label,highdose methotrexate,preferred_label,34236556
chemotherapy,synonyms,chemotherapy,synonyms,34236556
toxicity,semantic_types,toxicity,semantic_types,34236556
wholebrain radiotherapy,preferred_label,wholebrain radiotherapy,preferred_label,34236556
sarscov2 vaccine,drug,sarscov2 vaccine,drug,34236381
cancer patient,patient,cancer patient,patient,34236381
bnt162b2 vaccine,drug,bnt162b2 vaccine,drug,34236381
Israel,location,Israel,location,34236381
Rambam Health Care Campus,location,Rambam Health Care Campus,location,34236381
oncology division,medical center division,oncology division,medical center division,34236381
blood cell count,medical test,blood cell count,medical test,34236381
liver enzyme level,medical test,liver enzyme level,medical test,34236381
imaging study,medical test,imaging study,medical test,34236381
leukopenia,medical condition,leukopenia,medical condition,34236381
COVID-19 infection,disease,COVID-19 infection,disease,34236381
folic acid,preferred_label,folic acid,preferred_label,34235555
methotrexate,preferred_label,methotrexate,preferred_label,34235555
acute lymphoblastic leukemia,preferred_label,acute lymphoblastic leukemia,preferred_label,34235555
toxicity,preferred_label,toxicity,preferred_label,34235555
hospitalization,preferred_label,hospitalization,preferred_label,34235555
epithelial mesenchymal transition,preferred_label,epithelial mesenchymal transition,preferred_label,34233590
inflammation,preferred_label,inflammation,preferred_label,34233590
trichloroethylene,preferred_label,trichloroethylene,preferred_label,34233590
curcumin,preferred_label,curcumin,preferred_label,34233590
hepatocellular carcinoma,preferred_label,hepatocellular carcinoma,preferred_label,34233590
IL-6R,preferred_label,IL-6R,preferred_label,34233590
STAT3,preferred_label,STAT3,preferred_label,34233590
snail,preferred_label,snail,preferred_label,34233590
survivin,preferred_label,survivin,preferred_label,34233590
cyclin D1,preferred_label,cyclin D1,preferred_label,34233590
metastatic urothelial carcinoma,class_id,metastatic urothelial carcinoma,class_id,34232950
chemotherapy,class_id,chemotherapy,class_id,34232950
checkpoint inhibitor,class_id,checkpoint inhibitor,class_id,34232950
cpi,synonyms,cpi,synonyms,34232950
carboplatin,class_id,carboplatin,class_id,34232950
paclitaxel,class_id,paclitaxel,class_id,34232950
pembrolizumab,class_id,pembrolizumab,class_id,34232950
clinical characteristic response,class_id,clinical characteristic response,class_id,34232950
progression-free survival,class_id,progression-free survival,class_id,34232950
safety/tolerance,class_id,safety/tolerance,class_id,34232950
Pulmonary toxicity,semantic_types,Pulmonary toxicity,semantic_types,34232946
Neoadjuvant chemotherapy treatment,semantic_types,Neoadjuvant chemotherapy treatment,semantic_types,34232946
Doxorubicin,rxnorm_cui,Doxorubicin,rxnorm_cui,34232946
Cyclophosphamide,rxnorm_cui,Cyclophosphamide,rxnorm_cui,34232946
Triple-negative breast cancer,semantic_types,Triple-negative breast cancer,semantic_types,34232946
Granulocyte colony-stimulating factor (GCSF),rxnorm_cui,Granulocyte colony-stimulating factor (GCSF),rxnorm_cui,34232946
Acute respiratory distress syndrome,semantic_types,Acute respiratory distress syndrome,semantic_types,34232946
camrelizumab,drug,camrelizumab,drug,34232941
apatinib,drug,apatinib,drug,34232941
liver cancer,disease,liver cancer,disease,34232941
peripheral blood parameter,biomarker,peripheral blood parameter,biomarker,34232941
tumor response rate,clinical outcome,tumor response rate,clinical outcome,34232941
blood routine test,medical test,blood routine test,medical test,34232941
disease progression,clinical outcome,disease progression,clinical outcome,34232941
adverse event,clinical outcome,adverse event,clinical outcome,34232941
lymphocyte to monocyte ratio,biomarker,lymphocyte to monocyte ratio,biomarker,34232941
prognostic nutritional index,biomarker,prognostic nutritional index,biomarker,34232941
immunotherapy,treatment,immunotherapy,treatment,34232941
targeted therapy,treatment,targeted therapy,treatment,34232941
neuroendocrine carcinoma,class_id,neuroendocrine carcinoma,class_id,34231124
irinotecan,preferred_label,irinotecan,preferred_label,34231124
extrapulmonary NEC patient,class_id,extrapulmonary NEC patient,class_id,34231124
platinum plus etoposide regimen,preferred_label,platinum plus etoposide regimen,preferred_label,34231124
FOLFIRI,preferred_label,FOLFIRI,preferred_label,34231124
XELIRI,preferred_label,XELIRI,preferred_label,34231124
neutropenia,preferred_label,neutropenia,preferred_label,34231124
anemia,preferred_label,anemia,preferred_label,34231124
nausea,preferred_label,nausea,preferred_label,34231124
osteosarcoma,class_id,osteosarcoma,class_id,34229968
polychemotherapy,preferred_label,polychemotherapy,preferred_label,34229968
nephrotoxic drug,preferred_label,nephrotoxic drug,preferred_label,34229968
ifosfamide,preferred_label,ifosfamide,preferred_label,34229968
methotrexate,preferred_label,methotrexate,preferred_label,34229968
cisplatinum,preferred_label,cisplatinum,preferred_label,34229968
chronic kidney disease,preferred_label,chronic kidney disease,preferred_label,34229968
dialysis,preferred_label,dialysis,preferred_label,34229968
pediatric patient,preferred_label,pediatric patient,preferred_label,34229968
tubulopathy,preferred_label,tubulopathy,preferred_label,34229968
renal transplantation,preferred_label,renal transplantation,preferred_label,34229968
chondroblastic osteosarcoma,preferred_label,chondroblastic osteosarcoma,preferred_label,34229968
renal toxicity,preferred_label,renal toxicity,preferred_label,34229968
specific risk factor,preferred_label,specific risk factor,preferred_label,34229968
cancer,class_id,cancer,class_id,34229596
genetic disorder,class_id,genetic disorder,class_id,34229596
metabolic disorder,class_id,metabolic disorder,class_id,34229596
tumor cell metabolism,class_id,tumor cell metabolism,class_id,34229596
cancer therapy,class_id,cancer therapy,class_id,34229596
patient compliance,class_id,patient compliance,class_id,34229596
toxicity to normal tissue,class_id,toxicity to normal tissue,class_id,34229596
multidrug resistance development,class_id,multidrug resistance development,class_id,34229596
genetic epigenetic and transcriptional change,class_id,genetic epigenetic and transcriptional change,class_id,34229596
thiazolidinone nucleus,class_id,thiazolidinone nucleus,class_id,34229596
biotargets,class_id,biotargets,class_id,34229596
breast cancer,class_id,breast cancer,class_id,34229596
prostate cancer,class_id,prostate cancer,class_id,34229596
lung cancer,class_id,lung cancer,class_id,34229596
colorectal cancer,class_id,colorectal cancer,class_id,34229596
colon cancer,class_id,colon cancer,class_id,34229596
renal cell adenocarcinoma,class_id,renal cell adenocarcinoma,class_id,34229596
glioma,class_id,glioma,class_id,34229596
nanocarrier system,class_id,nanocarrier system,class_id,34229596
anticancer efficiency,class_id,anticancer efficiency,class_id,34229596
adverse effect,class_id,adverse effect,class_id,34229596
drug resistance development,class_id,drug resistance development,class_id,34229596
personalized pharmacotherapy,class_id,personalized pharmacotherapy,class_id,34229596
literature survey,class_id,literature survey,class_id,34229596
thiazolidinone derivative,class_id,thiazolidinone derivative,class_id,34229596
Unresectable Stage III Squamous Cell Lung Cancer,class_id,Unresectable Stage III Squamous Cell Lung Cancer,class_id,34229051
Nimotuzumab,preferred_label,Nimotuzumab,preferred_label,34229051
Chemoradiation Therapy,preferred_label,Chemoradiation Therapy,preferred_label,34229051
Docetaxel,preferred_label,Docetaxel,preferred_label,34229051
Cisplatin,preferred_label,Cisplatin,preferred_label,34229051
Brain Metastasis,preferred_label,Brain Metastasis,preferred_label,34229051
Pneumonitis,preferred_label,Pneumonitis,preferred_label,34229051
Esophagitis,preferred_label,Esophagitis,preferred_label,34229051
danafarber cancer institute,class_id,danafarber cancer institute,class_id,34228505
acute lymphoblastic leukemia,class_id,acute lymphoblastic leukemia,class_id,34228505
calaspargase pegol,preferred_label,calaspargase pegol,preferred_label,34228505
pegaspargase,preferred_label,pegaspargase,preferred_label,34228505
lymphoblastic lymphoma,class_id,lymphoblastic lymphoma,class_id,34228505
nonfluorescent peptide,class_id,nonfluorescent peptide,class_id,34227796
fluorescent peptide nanoparticles,class_id,fluorescent peptide nanoparticles,class_id,34227796
drug delivery,preferred_label,drug delivery,preferred_label,34227796
imaging,preferred_label,imaging,preferred_label,34227796
tracking therapeutic agent,preferred_label,tracking therapeutic agent,preferred_label,34227796
pharmacologically inactive peptide,class_id,pharmacologically inactive peptide,class_id,34227796
tumor-targeting peptide,class_id,tumor-targeting peptide,class_id,34227796
antitumor dipeptide carnosine,class_id,antitumor dipeptide carnosine,class_id,34227796
fluorescent carnosine nanoparticles,class_id,fluorescent carnosine nanoparticles,class_id,34227796
zinc ion,class_id,zinc ion,class_id,34227796
visible and near-infrared range,preferred_label,visible and near-infrared range,preferred_label,34227796
fibroblast cell,class_id,fibroblast cell,class_id,34227796
major organ,class_id,major organ,class_id,34227796
adjuvant concurrent chemoradiotherapy,preferred_label,adjuvant concurrent chemoradiotherapy,preferred_label,34226296
fluorouracil,preferred_label,fluorouracil,preferred_label,34226296
gastric cancer,preferred_label,gastric cancer,preferred_label,34226296
patient,preferred_label,patient,preferred_label,34226296
d2 lymph node dissection,preferred_label,d2 lymph node dissection,preferred_label,34226296
radiotherapy,preferred_label,radiotherapy,preferred_label,34226296
age,preferred_label,age,preferred_label,34226296
Pulmonary toxicity induced by radiation therapy,class_id,Pulmonary toxicity induced by radiation therapy,class_id,34226162
Breast cancer treatment,class_id,Breast cancer treatment,class_id,34226162
targeted agent,drug,targeted agent,drug,34226158
gastrointestinal cancer,disease,gastrointestinal cancer,disease,34226158
older patient,patient,older patient,patient,34226158
toxicity profile,adverse event outcome,toxicity profile,adverse event outcome,34226158
efficacy,adverse event outcome,efficacy,adverse event outcome,34226158
safety,adverse event outcome,safety,adverse event outcome,34226158
colorectal cancer,disease,colorectal cancer,disease,34226158
geriatric oncology,medical specialty,geriatric oncology,medical specialty,34226158
pertuzumab,drug,pertuzumab,drug,34224826
trastuzumab,drug,trastuzumab,drug,34224826
docetaxel,drug,docetaxel,drug,34224826
breast cancer,disease,breast cancer,disease,34224826
her2positive,semantic type,her2positive,semantic_types,34224826
locally recurrent/metastatic,semantic type,locally recurrent/metastatic,semantic_types,34224826
phase iii clinical evaluation,class_id,phase iii clinical evaluation,class_id,34224826
cleopatra trial,class_id,cleopatra trial,class_id,34224826
pertuzumab global safety peruse study,class_id,pertuzumab global safety peruse study,class_id,34224826
breast cancer,has disease,breast cancer,has disease,34218783
aromatase enzyme,class_id,aromatase enzyme,class_id,34218783
estrogen,preferred_label,estrogen,preferred_label,34218783
androgen,preferred_label,androgen,preferred_label,34218783
aromatase inhibitor,class_id,aromatase inhibitor,class_id,34218783
interleukin il2,class_id,interleukin il2,class_id,34218217
cancer progression,preferred_label,cancer progression,preferred_label,34218217
advanced/metastatic melanoma,preferred_label,advanced/metastatic melanoma,preferred_label,34218217
renal cell carcinoma,preferred_label,renal cell carcinoma,preferred_label,34218217
high-dose il2 therapy,preferred_label,high-dose il2 therapy,preferred_label,34218217
toxicity,preferred_label,toxicity,preferred_label,34218217
endothelial cell,preferred_label,endothelial cell,preferred_label,34218217
effector t cell,preferred_label,effector t cell,preferred_label,34218217
tumor microenvironment,preferred_label,tumor microenvironment,preferred_label,34218217
cytokine therapy,preferred_label,cytokine therapy,preferred_label,34218217
engineered il2 variant,preferred_label,engineered il2 variant,preferred_label,34218217
cancer immunotherapy,preferred_label,cancer immunotherapy,preferred_label,34218217
ChitosanMagnetiteReduced Graphene Oxide Nanocomposites,class_id,ChitosanMagnetiteReduced Graphene Oxide Nanocomposites,class_id,34216673
Curcumin,preferred_label,Curcumin,preferred_label,34216673
MCF7 Breast Cancer Cell,class_id,MCF7 Breast Cancer Cell,class_id,34216673
Water-in-Oil Emulsification Procedure,class_id,Water-in-Oil Emulsification Procedure,class_id,34216673
FTIR,preferred_label,FTIR,preferred_label,34216673
XRD,preferred_label,XRD,preferred_label,34216673
Dynamic Light Scattering Analyzer,class_id,Dynamic Light Scattering Analyzer,class_id,34216673
Zeta Potential Measurement,class_id,Zeta Potential Measurement,class_id,34216673
SEM Mapping,preferred_label,SEM Mapping,preferred_label,34216673
EDX Diagram Measurement,class_id,EDX Diagram Measurement,class_id,34216673
VSM,preferred_label,VSM,preferred_label,34216673
MTT Assay,preferred_label,MTT Assay,preferred_label,34216673
Flow Cytometry,preferred_label,Flow Cytometry,preferred_label,34216673
Dialysis Method,class_id,Dialysis Method,class_id,34216673
ramucirumab,drug,ramucirumab,drug,34215931
erlotinib,drug,erlotinib,drug,34215931
osimertinib,drug,osimertinib,drug,34215931
EGFR-mutated non-small cell lung cancer,disease,EGFR-mutated non-small cell lung cancer,disease,34215931
brain metastasis,disease,brain metastasis,disease,34215931
asymptomatic brain metastasis,disease,asymptomatic brain metastasis,disease,34215931
hypertension,adverse event,hypertension,adverse event,34215931
central nervous system hemorrhage,adverse event,central nervous system hemorrhage,adverse event,34215931
immunotherapy,preferred_label,immunotherapy,preferred_label,34215680
cancer treatment,preferred_label,cancer treatment,preferred_label,34215680
toxicity,preferred_label,toxicity,preferred_label,34215680
adverse event,preferred_label,adverse event,preferred_label,34215680
antitumor reaction,preferred_label,antitumor reaction,preferred_label,34215680
anticd40 treatment,preferred_label,anticd40 treatment,preferred_label,34215680
mouse model,preferred_label,mouse model,preferred_label,34215680
liver macrophage,preferred_label,liver macrophage,preferred_label,34215680
local immunerelated adverse event,preferred_label,local immunerelated adverse event,preferred_label,34215680
tissueresident kupffer cell,preferred_label,tissueresident kupffer cell,preferred_label,34215680
lymphocytederived ifn,preferred_label,lymphocytederived ifn,preferred_label,34215680
il,preferred_label,il,preferred_label,34215680
dendritic cell,preferred_label,dendritic cell,preferred_label,34215680
tumor control,preferred_label,tumor control,preferred_label,34215680
il12,preferred_label,il12,preferred_label,34215680
neutrophil response,preferred_label,neutrophil response,preferred_label,34215680
inflammatory pathway,preferred_label,inflammatory pathway,preferred_label,34215680
antipd1 immunotherapy,preferred_label,antipd1 immunotherapy,preferred_label,34215680
antictla4 immunotherapy,preferred_label,antictla4 immunotherapy,preferred_label,34215680
macrophage,preferred_label,macrophage,preferred_label,34215680
neutrophil,preferred_label,neutrophil,preferred_label,34215680
inflammation,preferred_label,inflammation,preferred_label,34215680
antitumor immunity,preferred_label,antitumor immunity,preferred_label,34215680
glioblastoma,class_id,glioblastoma,class_id,34214730
temozolomide,preferred_label,temozolomide,preferred_label,34214730
tumor treating field,preferred_label,tumor treating field,preferred_label,34214730
chemoradiotherapy,preferred_label,chemoradiotherapy,preferred_label,34214730
apoptosis,preferred_label,apoptosis,preferred_label,34214730
immune pathway,preferred_label,immune pathway,preferred_label,34214730
adverse event,preferred_label,adverse event,preferred_label,34214730
Bevacizumab,drug,Bevacizumab,drug,34214711
Neurofibromatosis type related vestibular schwannomas (NFVS),disease,Neurofibromatosis type related vestibular schwannomas (NFVS),disease,34214711
Hypertension,adverse event,Hypertension,adverse event,34214711
Proteinuria,adverse event,Proteinuria,adverse event,34214711
Menstrual disorder,adverse event,Menstrual disorder,adverse event,34214711
Hemorrhage,adverse event,Hemorrhage,adverse event,34214711
High-dose regimen,treatment,High-dose regimen,treatment,34214711
Age,patient characteristic,Age,patient characteristic,34214711
colorectal cancer,class_id,colorectal cancer,class_id,34213984
chemotherapy,class_id,chemotherapy,class_id,34213984
adjuvant chemotherapy,class_id,adjuvant chemotherapy,class_id,34213984
gastrointestinal toxicity,class_id,gastrointestinal toxicity,class_id,34213984
fluorouracil (FU),class_id,fluorouracil (FU),class_id,34213984
mucositis,class_id,mucositis,class_id,34213984
silk fibroin nanoparticles,class_id,silk fibroin nanoparticles,class_id,34213984
tumor cells,class_id,tumor cells,class_id,34213984
mouse model,class_id,mouse model,class_id,34213984
large cell lymphoma,class_id,large cell lymphoma,class_id,34213084
lasparaginase,preferred_label,lasparaginase,preferred_label,34213084
dog,class_id,dog,class_id,34213084
gastrointestinal gi,semantic_types,gastrointestinal gi,semantic_types,34213084
ultrasonographic finding,preferred_label,ultrasonographic finding,preferred_label,34213084
clinical sign,preferred_label,clinical sign,preferred_label,34213084
pembrolizumab,drug,pembrolizumab,drug,34210681
ipilimumab,drug,ipilimumab,drug,34210681
melanoma,disease,melanoma,disease,34210681
cohort b,class_id,cohort b,class_id,34210681
phase 1 keynote029 study,class_id,phase 1 keynote029 study,class_id,34210681
patient,class_id,patient,class_id,34210681
stage iiiiv melanoma,class_id,stage iiiiv melanoma,class_id,34210681
treatmentnaive,preferred_label,treatmentnaive,preferred_label,34210681
unresectable,preferred_label,unresectable,preferred_label,34210681
grade treatmentrelated adverse event,semantic_types,grade treatmentrelated adverse event,semantic_types,34210681
objective response rate,semantic_types,objective response rate,semantic_types,34210681
recist v,class_id,recist v,class_id,34210681
autoimmune myocarditis,synonyms,autoimmune myocarditis,synonyms,34210681
immunemediated aes,synonyms,immunemediated aes,synonyms,34210681
infusion reaction,synonyms,infusion reaction,synonyms,34210681
antitumor activity,semantic_types,antitumor activity,semantic_types,34210681
immune-based treatment,preferred_label,immune-based treatment,preferred_label,34201529
iatrogenic immunotoxicities,preferred_label,iatrogenic immunotoxicities,preferred_label,34201529
immune-related adverse event iraes,preferred_label,immune-related adverse event iraes,preferred_label,34201529
neurological iraes,preferred_label,neurological iraes,preferred_label,34201529
immune checkpoint inhibitor ici,preferred_label,immune checkpoint inhibitor ici,preferred_label,34201529
chimeric antigen receptor car t cell immunotherapy,preferred_label,chimeric antigen receptor car t cell immunotherapy,preferred_label,34201529
mechanism,preferred_label,mechanism,preferred_label,34201529
higher risk for iraes,preferred_label,higher risk for iraes,preferred_label,34201529
safety parameter for resuming cancer immunotherapy,preferred_label,safety parameter for resuming cancer immunotherapy,preferred_label,34201529
tumor heterogeneity,preferred_label,tumor heterogeneity,preferred_label,34197599
hypoxic region,preferred_label,hypoxic region,preferred_label,34197599
apobec activity,preferred_label,apobec activity,preferred_label,34197599
mutation,preferred_label,mutation,preferred_label,34197599
genomic instability,preferred_label,genomic instability,preferred_label,34197599
entinostat,drug,entinostat,drug,34196874
exemestane,drug,exemestane,drug,34196874
breast cancer,disease,breast cancer,disease,34196874
hormone receptor positive,semantic type,hormone receptor positive,semantic_types,34196874
HER2 negative,semantic type,HER2 negative,semantic_types,34196874
neutropenia,adverse event,neutropenia,adverse event,34196874
thrombocytopenia,adverse event,thrombocytopenia,adverse event,34196874
anemia,adverse event,anemia,adverse event,34196874
fatigue,adverse event,fatigue,adverse event,34196874
tafasitamab mor208,preferred_label,tafasitamab mor208,preferred_label,34196165
lenalidomide,preferred_label,lenalidomide,preferred_label,34196165
diffuse large b-cell lymphoma,preferred_label,diffuse large b-cell lymphoma,preferred_label,34196165
autologous stem cell transplantation,preferred_label,autologous stem cell transplantation,preferred_label,34196165
patient,preferred_label,patient,preferred_label,34196165
cycle,preferred_label,cycle,preferred_label,34196165
complete response,preferred_label,complete response,preferred_label,34196165
partial response,preferred_label,partial response,preferred_label,34196165
toxicity,preferred_label,toxicity,preferred_label,34196165
nivolumab,drug,nivolumab,drug,34196124
advanced nsclc,disease,advanced nsclc,disease,34196124
patient,class_id,patient,class_id,34196124
performance status,class_id,performance status,class_id,34196124
chemotherapy,class_id,chemotherapy,class_id,34196124
brain metastasis,class_id,brain metastasis,class_id,34196124
overall survival,class_id,overall survival,class_id,34196124
adverse event,class_id,adverse event,class_id,34196124
toxicity,class_id,toxicity,class_id,34196124
immunotherapy,class_id,immunotherapy,class_id,34196124
lung cancer,disease,lung cancer,disease,34196124
cisplatin,drug,cisplatin,drug,34194837
thrombin,protein,thrombin,protein,34194837
dabigatran,drug,dabigatran,drug,34194837
kidney,organ,kidney,organ,34194837
apoptosis marker,biomarker,apoptosis marker,biomarker,34194837
oxidative stress,biological process,oxidative stress,biological process,34194837
histopathological evaluation,procedure,histopathological evaluation,procedure,34194837
tissue factor,protein,tissue factor,protein,34194837
protease-activated receptor2,protein,protease-activated receptor2,protein,34194837
fibrin,protein,fibrin,protein,34194837
p53 protein,protein,p53 protein,protein,34194837
cleaved caspase,protein,cleaved caspase,protein,34194837
erk,protein,erk,protein,34194837
caspase3,protein,caspase3,protein,34194837
rituximab,drug,rituximab,drug,34193755
elderly patient,patient,elderly patient,patient,34193755
chemotherapy regimen,treatment,chemotherapy regimen,treatment,34193755
indolent b-cell lymphoma,disease,indolent b-cell lymphoma,disease,34193755
rthpcop therapy,treatment,rthpcop therapy,treatment,34193755
chimeric antigen receptor t cell therapy,preferred_label,chimeric antigen receptor t cell therapy,preferred_label,34191515
cytokine release syndrome,preferred_label,cytokine release syndrome,preferred_label,34191515
safety switch for cart cell,preferred_label,safety switch for cart cell,preferred_label,34191515
genetic engineering,preferred_label,genetic engineering,preferred_label,34191515
chemical technology,preferred_label,chemical technology,preferred_label,34191515
smallmoleculebased safety switch,preferred_label,smallmoleculebased safety switch,preferred_label,34191515
fitc folate rimiducid rapamycin proteolysistargeting chimera protac compound,preferred_label,fitc folate rimiducid rapamycin proteolysistargeting chimera protac compound,preferred_label,34191515
dasatinib,preferred_label,dasatinib,preferred_label,34191515
cart cell,preferred_label,cart cell,preferred_label,34191515
cancer immunotherapy,preferred_label,cancer immunotherapy,preferred_label,34191515
gabapentin,drug,gabapentin,drug,34191128
pregabalin,drug,pregabalin,drug,34191128
melphalan,drug,melphalan,drug,34191128
peripheral neuropathy,disease,peripheral neuropathy,disease,34191128
multiple myeloma,disease,multiple myeloma,disease,34191128
autologous hematopoietic cell transplant,procedure,autologous hematopoietic cell transplant,procedure,34191128
lamino acid transporter 1,protein,lamino acid transporter 1,protein,34191128
lamino acid transporter 2,protein,lamino acid transporter 2,protein,34191128
mucosal injury,adverse event,mucosal injury,adverse event,34191128
mucositis,adverse event,mucositis,adverse event,34191128
nausea,adverse event,nausea,adverse event,34191128
vomiting,adverse event,vomiting,adverse event,34191128
diarrhea,adverse event,diarrhea,adverse event,34191128
opioid requirement,adverse event,opioid requirement,adverse event,34191128
neutrophil engraftment,procedure,neutrophil engraftment,procedure,34191128
platelet engraftment,procedure,platelet engraftment,procedure,34191128
treatment-related mortality,adverse event outcome,treatment-related mortality,adverse event outcome,34191128
progression-free survival,outcome,progression-free survival,outcome,34191128
overall survival,outcome,overall survival,outcome,34191128
endometrial carcinoma,class_id,endometrial carcinoma,class_id,34190370
lenvatinib plus pembrolizumab,class_id,lenvatinib plus pembrolizumab,class_id,34190370
hypothyroidism,class_id,hypothyroidism,class_id,34190370
hypertension,class_id,hypertension,class_id,34190370
fatigue,class_id,fatigue,class_id,34190370
nausea/vomiting,class_id,nausea/vomiting,class_id,34190370
diarrhea,class_id,diarrhea,class_id,34190370
decreased appetite/weight loss,class_id,decreased appetite/weight loss,class_id,34190370
palmar-plantar erythrodysesthesia syndrome,class_id,palmar-plantar erythrodysesthesia syndrome,class_id,34190370
musculoskeletal pain,class_id,musculoskeletal pain,class_id,34190370
stomatitis,class_id,stomatitis,class_id,34190370
proteinuria,class_id,proteinuria,class_id,34190370
COVID-19,class_id,COVID-19,class_id,34189948
vaccination,class_id,vaccination,class_id,34189948
cancer patient,class_id,cancer patient,class_id,34189948
immunosuppression,class_id,immunosuppression,class_id,34189948
immune checkpoint inhibitor (ICI),class_id,immune checkpoint inhibitor (ICI),class_id,34189948
Trabectedin,drug,Trabectedin,drug,34189636
Pegylated liposomal doxorubicin,drug,Pegylated liposomal doxorubicin,drug,34189636
Ovarian cancer,disease,Ovarian cancer,disease,34189636
Japanese patients,patient,Japanese patients,patient,34189636
radium223,preferred_label,radium223,preferred_label,34187853
metastatic castrationresistant prostate cancer,preferred_label,metastatic castrationresistant prostate cancer,preferred_label,34187853
external beam radiotherapy,preferred_label,external beam radiotherapy,preferred_label,34187853
prostate,preferred_label,prostate,preferred_label,34187853
hormonesensitive prostate cancer,preferred_label,hormonesensitive prostate cancer,preferred_label,34187853
combination radium223 pelvic ebrt,preferred_label,combination radium223 pelvic ebrt,preferred_label,34187853
bone metastatic mhspc,preferred_label,bone metastatic mhspc,preferred_label,34187853
androgen deprivation therapy,preferred_label,androgen deprivation therapy,preferred_label,34187853
docetaxel,preferred_label,docetaxel,preferred_label,34187853
clinical trial,preferred_label,clinical trial,preferred_label,34187853
neoadjuvant androgen deprivation therapy,preferred_label,neoadjuvant androgen deprivation therapy,preferred_label,34187853
radiotherapy,preferred_label,radiotherapy,preferred_label,34187853
pelvic lymph node,preferred_label,pelvic lymph node,preferred_label,34187853
toxicity,preferred_label,toxicity,preferred_label,34187853
efficacy,preferred_label,efficacy,preferred_label,34187853
progressionfree survival,preferred_label,progressionfree survival,preferred_label,34187853
trial,preferred_label,trial,preferred_label,34187853
CARG toxicity score,preferred_label,CARG toxicity score,preferred_label,34187825
geriatric patient,semantic_types,geriatric patient,semantic_types,34187825
chemotherapy,preferred_label,chemotherapy,preferred_label,34187825
curative intent chemotherapy,preferred_label,curative intent chemotherapy,preferred_label,34187825
Tata Memorial Hospital,preferred_label,Tata Memorial Hospital,preferred_label,34187825
gastrointestinal cancer,preferred_label,gastrointestinal cancer,preferred_label,34187825
breast cancer,preferred_label,breast cancer,preferred_label,34187825
gynaecological cancer,preferred_label,gynaecological cancer,preferred_label,34187825
grade toxicity,preferred_label,grade toxicity,preferred_label,34187825
Eastern Cooperative Oncology Group (ECOG) performance status,preferred_label,Eastern Cooperative Oncology Group (ECOG) performance status,preferred_label,34187825
age-adjusted Charlson Comorbidity Index,preferred_label,age-adjusted Charlson Comorbidity Index,preferred_label,34187825
geriatric oncology patient,semantic_types,geriatric oncology patient,semantic_types,34187825
elderly patient,semantic_types,elderly patient,semantic_types,34187825
bevacizumab,drug,bevacizumab,drug,34186494
brain radiation necrosis,disease,brain radiation necrosis,disease,34186494
stereotactic radiosurgery,procedure,stereotactic radiosurgery,procedure,34186494
nonsmall cell lung cancer,disease,nonsmall cell lung cancer,disease,34186494
immune checkpoint inhibitor,drug,immune checkpoint inhibitor,drug,34186494
immunotherapy,preferred_label,immunotherapy,preferred_label,34186441
target therapy,preferred_label,target therapy,preferred_label,34186441
patient,preferred_label,patient,preferred_label,34186441
melanoma,preferred_label,melanoma,preferred_label,34186441
BRAFV600 mutation,preferred_label,BRAFV600 mutation,preferred_label,34186441
combination of BRAF/MEK inhibitor,preferred_label,combination of BRAF/MEK inhibitor,preferred_label,34186441
immune checkpoint inhibitor,preferred_label,immune checkpoint inhibitor,preferred_label,34186441
pembrolizumab,preferred_label,pembrolizumab,preferred_label,34186441
nivolumab,preferred_label,nivolumab,preferred_label,34186441
ipilimumab,preferred_label,ipilimumab,preferred_label,34186441
atezolizumab,preferred_label,atezolizumab,preferred_label,34186441
vemurafenib,preferred_label,vemurafenib,preferred_label,34186441
cobimetinib,preferred_label,cobimetinib,preferred_label,34186441
FDA,preferred_label,FDA,preferred_label,34186441
colorectal cancer,class_id,colorectal cancer,class_id,34186049
polyursolic acid,class_id,polyursolic acid,class_id,34186049
nanoparticles,class_id,nanoparticles,class_id,34186049
mithramycin,class_id,mithramycin,class_id,34186049
ct26 colorectal cancer cell,class_id,ct26 colorectal cancer cell,class_id,34186049
ly01008,preferred_label,ly01008,preferred_label,34184418
avastin,preferred_label,avastin,preferred_label,34184418
bevacizumab,synonyms,bevacizumab,synonyms,34184418
chinese patient,semantic_types,chinese patient,semantic_types,34184418
nonsquamous nonsmall cell lung cancer,semantic_types,nonsquamous nonsmall cell lung cancer,semantic_types,34184418
paclitaxelcarboplatin,preferred_label,paclitaxelcarboplatin,preferred_label,34184418
recist version,preferred_label,recist version,preferred_label,34184418
radiological review committee,preferred_label,radiological review committee,preferred_label,34184418
gastric cancer,class_id,gastric cancer,class_id,34183522
perioperative chemotherapy,preferred_label,perioperative chemotherapy,preferred_label,34183522
cisplatin-capecitabine,preferred_label,cisplatin-capecitabine,preferred_label,34183522
preoperative chemoradiation,preferred_label,preoperative chemoradiation,preferred_label,34183522
neoadjuvant chemotherapy,preferred_label,neoadjuvant chemotherapy,preferred_label,34183522
surgical resection,preferred_label,surgical resection,preferred_label,34183522
adjuvant chemotherapy,preferred_label,adjuvant chemotherapy,preferred_label,34183522
radiotherapy,preferred_label,radiotherapy,preferred_label,34183522
disease progression,preferred_label,disease progression,preferred_label,34183522
surgery-first strategy,preferred_label,surgery-first strategy,preferred_label,34183522
highdose methotrexate,preferred_label,highdose methotrexate,preferred_label,34182493
acute leukemia malignant lymphoma,preferred_label,acute leukemia malignant lymphoma,preferred_label,34182493
osteosarcoma,preferred_label,osteosarcoma,preferred_label,34182493
glycyrrhizin,preferred_label,glycyrrhizin,preferred_label,34182493
hepatic dysfunction,preferred_label,hepatic dysfunction,preferred_label,34182493
male wistar rat,preferred_label,male wistar rat,preferred_label,34182493
plasma concentration,preferred_label,plasma concentration,preferred_label,34182493
alanine aminotransferase,preferred_label,alanine aminotransferase,preferred_label,34182493
aspartate aminotransferase,preferred_label,aspartate aminotransferase,preferred_label,34182493
total bilirubin,preferred_label,total bilirubin,preferred_label,34182493
hepatic enzyme,preferred_label,hepatic enzyme,preferred_label,34182493
hepatic toxicity,preferred_label,hepatic toxicity,preferred_label,34182493
pemetrexed,drug,pemetrexed,drug,34181276
nonsquamous nonsmall cell lung cancer,disease,nonsquamous nonsmall cell lung cancer,disease,34181276
renal impairment,disease,renal impairment,disease,34181276
hematological toxicity,adverse event,hematological toxicity,adverse event,34181276
neutropenia,adverse event,neutropenia,adverse event,34181276
glomerular filtration rate,biomarker,glomerular filtration rate,biomarker,34181276
idasanutlin,preferred_label,idasanutlin,preferred_label,34180037
p53 activation,preferred_label,p53 activation,preferred_label,34180037
tumor growth inhibition,preferred_label,tumor growth inhibition,preferred_label,34180037
maximum tolerated dose,preferred_label,maximum tolerated dose,preferred_label,34180037
safety pharmacokinetics,preferred_label,safety pharmacokinetics,preferred_label,34180037
pharmacodynamics,preferred_label,pharmacodynamics,preferred_label,34180037
food effect,preferred_label,food effect,preferred_label,34180037
clinical activity,preferred_label,clinical activity,preferred_label,34180037
patient,preferred_label,patient,preferred_label,34180037
malignancy,preferred_label,malignancy,preferred_label,34180037
phase i study,preferred_label,phase i study,preferred_label,34180037
doseescalation phase,preferred_label,doseescalation phase,preferred_label,34180037
adverse event,preferred_label,adverse event,preferred_label,34180037
diarrhea,preferred_label,diarrhea,preferred_label,34180037
nausea/vomiting,preferred_label,nausea/vomiting,preferred_label,34180037
decreased appetite,preferred_label,decreased appetite,preferred_label,34180037
thrombocytopenia,preferred_label,thrombocytopenia,preferred_label,34180037
doselimiting toxicity,preferred_label,doselimiting toxicity,preferred_label,34180037
myelosuppression,preferred_label,myelosuppression,preferred_label,34180037
pharmacokinetic exposure,preferred_label,pharmacokinetic exposure,preferred_label,34180037
interpatient variability,preferred_label,interpatient variability,preferred_label,34180037
cumulative idasanutlin exposure,preferred_label,cumulative idasanutlin exposure,preferred_label,34180037
food effect,preferred_label,food effect,preferred_label,34180037
mic1 level,preferred_label,mic1 level,preferred_label,34180037
best response,preferred_label,best response,preferred_label,34180037
stable disease,preferred_label,stable disease,preferred_label,34180037
sarcoma,preferred_label,sarcoma,preferred_label,34180037
vascular endothelial growth factor,class_id,vascular endothelial growth factor,class_id,34180036
hepatocyte growth factor,class_id,hepatocyte growth factor,class_id,34180036
vegfr,class_id,vegfr,class_id,34180036
hgfcmet signaling pathway,class_id,hgfcmet signaling pathway,class_id,34180036
angiogenesis,class_id,angiogenesis,class_id,34180036
vegf inhibition,class_id,vegf inhibition,class_id,34180036
phosphorylated cmet,class_id,phosphorylated cmet,class_id,34180036
chemoresistance,class_id,chemoresistance,class_id,34180036
phase 1 clinical trial,class_id,phase 1 clinical trial,class_id,34180036
solid tumor,class_id,solid tumor,class_id,34180036
pazopanib,class_id,pazopanib,class_id,34180036
arq197 tivantinib,class_id,arq197 tivantinib,class_id,34180036
dose limiting toxicity,class_id,dose limiting toxicity,class_id,34180036
maximum tolerated dose,class_id,maximum tolerated dose,class_id,34180036
hypertension,class_id,hypertension,class_id,34180036
stable disease,class_id,stable disease,class_id,34180036
circulating vegf,class_id,circulating vegf,class_id,34180036
cmet level,class_id,cmet level,class_id,34180036
biopsy,class_id,biopsy,class_id,34180036
epithelialmesenchymal transition,class_id,epithelialmesenchymal transition,class_id,34180036
adrenocortical carcinoma,class_id,adrenocortical carcinoma,class_id,34176818
mitotane,class_id,mitotane,class_id,34176818
Asian population,class_id,Asian population,class_id,34176818
patient,class_id,patient,class_id,34176818
cytotoxic chemotherapy,class_id,cytotoxic chemotherapy,class_id,34176818
clinical trial,class_id,clinical trial,class_id,34176818
kavain,class_id,kavain,class_id,34176449
piper methysticum,class_id,piper methysticum,class_id,34176449
anticonvulsive,semantic_types,anticonvulsive,semantic_types,34176449
analgesic,semantic_types,analgesic,semantic_types,34176449
anxiolytic,semantic_types,anxiolytic,semantic_types,34176449
antiepileptic,semantic_types,antiepileptic,semantic_types,34176449
antithrombotic,semantic_types,antithrombotic,semantic_types,34176449
antiinflammatory,semantic_types,antiinflammatory,semantic_types,34176449
antioxidant,semantic_types,antioxidant,semantic_types,34176449
doxorubicin,class_id,doxorubicin,class_id,34176449
somatic mutation and recombination test,class_id,somatic mutation and recombination test,class_id,34176449
epithelial tumor test,class_id,epithelial tumor test,class_id,34176449
drosophila melanogaster,class_id,drosophila melanogaster,class_id,34176449
metastatic triple-negative breast cancer,class_id,metastatic triple-negative breast cancer,class_id,34176192
sacituzumab govitecan,class_id,sacituzumab govitecan,class_id,34176192
antibody-drug conjugate,class_id,antibody-drug conjugate,class_id,34176192
irinotecan,class_id,irinotecan,class_id,34176192
sn-38,class_id,sn-38,class_id,34176192
monoclonal antibody,class_id,monoclonal antibody,class_id,34176192
trophoblast cell surface antigen,class_id,trophoblast cell surface antigen,class_id,34176192
Chemotherapy,may_treat,Chemotherapy,may_treat,34176021
Peripheral Neuropathy,drug AE occurs in,Peripheral Neuropathy,drug AE occurs in,34176021
Oxaliplatin,drug associated with AE,Oxaliplatin,drug associated with AE,34176021
Colon Cancer,has disease,Colon Cancer,has disease,34176021
mifap protocol,preferred_label,mifap protocol,preferred_label,34176014
dexabeam,preferred_label,dexabeam,preferred_label,34176014
hodgkin lymphoma,preferred_label,hodgkin lymphoma,preferred_label,34176014
nonhodgkins lymphoma,preferred_label,nonhodgkins lymphoma,preferred_label,34176014
patient,preferred_label,patient,preferred_label,34176014
salvage chemotherapy,preferred_label,salvage chemotherapy,preferred_label,34176014
highdose therapy,preferred_label,highdose therapy,preferred_label,34176014
hematopoietic cell transplantation,preferred_label,hematopoietic cell transplantation,preferred_label,34176014
toxicity,preferred_label,toxicity,preferred_label,34176014
immunotherapy,preferred_label,immunotherapy,preferred_label,34176014
diffuse large B-cell lymphoma,class_id,diffuse large B-cell lymphoma,class_id,34175369
"R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)",drug,"R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)",drug,34175369
pharmacological treatment,class_id,pharmacological treatment,class_id,34175369
international prognostic index (IPI),class_id,international prognostic index (IPI),class_id,34175369
molecular biomarkers,class_id,molecular biomarkers,class_id,34175369
single nucleotide polymorphism (SNP),class_id,single nucleotide polymorphism (SNP),class_id,34175369
candidate gene,class_id,candidate gene,class_id,34175369
genomewide association study (GWAS),class_id,genomewide association study (GWAS),class_id,34175369
Neck dissection,procedure,Neck dissection,procedure,34175226
Chemoradiotherapy,treatment,Chemoradiotherapy,treatment,34175226
Intensity-modulated conformal radiotherapy (IMRT),treatment,Intensity-modulated conformal radiotherapy (IMRT),treatment,34175226
Nasopharyngeal squamous cell carcinoma,disease,Nasopharyngeal squamous cell carcinoma,disease,34175226
Induction chemotherapy,treatment,Induction chemotherapy,treatment,34175226
Cisplatin-based chemoradiotherapy,treatment,Cisplatin-based chemoradiotherapy,treatment,34175226
Lymph node failure,outcome,Lymph node failure,outcome,34175226
Xerostomia,adverse event,Xerostomia,adverse event,34175226
ibrutinib,preferred_label,ibrutinib,preferred_label,34174986
acalabrutinib,preferred_label,acalabrutinib,preferred_label,34174986
chronic lymphocytic leukemia,preferred_label,chronic lymphocytic leukemia,preferred_label,34174986
adverse event,preferred_label,adverse event,preferred_label,34174986
venetoclax,preferred_label,venetoclax,preferred_label,34174986
phosphatidylinositol kinase inhibitor,preferred_label,phosphatidylinositol kinase inhibitor,preferred_label,34174986
cellular therapy,preferred_label,cellular therapy,preferred_label,34174986
clinical trial,preferred_label,clinical trial,preferred_label,34174986
cd137 bb,preferred_label,cd137 bb,preferred_label,34172583
cytotoxic t lymphocyte,preferred_label,cytotoxic t lymphocyte,preferred_label,34172583
cd137 agonist antibody,preferred_label,cd137 agonist antibody,preferred_label,34172583
liver inflammation,preferred_label,liver inflammation,preferred_label,34172583
urelumab,preferred_label,urelumab,preferred_label,34172583
antihuman cd137 agonist monoclonal antibody,preferred_label,antihuman cd137 agonist monoclonal antibody,preferred_label,34172583
proteaseactivated prodrug,preferred_label,proteaseactivated prodrug,preferred_label,34172583
antimouse cd137 agonist antibody,preferred_label,antimouse cd137 agonist antibody,preferred_label,34172583
1d8 1d8 probody therapeutic pbtx,preferred_label,1d8 1d8 probody therapeutic pbtx,preferred_label,34172583
tumor microenvironment,preferred_label,tumor microenvironment,preferred_label,34172583
pd1 blockade,preferred_label,pd1 blockade,preferred_label,34172583
adoptive tcell therapy,preferred_label,adoptive tcell therapy,preferred_label,34172583
tumordraining lymph node,preferred_label,tumordraining lymph node,preferred_label,34172583
regional lymphadenectomy,preferred_label,regional lymphadenectomy,preferred_label,34172583
s1p receptordependent recirculation,preferred_label,s1p receptordependent recirculation,preferred_label,34172583
neoadjuvant therapy,preferred_label,neoadjuvant therapy,preferred_label,34172583
spontaneous metastasis,preferred_label,spontaneous metastasis,preferred_label,34172583
immune checkpoint inhibitor,preferred_label,immune checkpoint inhibitor,preferred_label,34172516
cancer,preferred_label,cancer,preferred_label,34172516
immunotherapy,preferred_label,immunotherapy,preferred_label,34172516
toxicity,preferred_label,toxicity,preferred_label,34172516
immunerelated adverse event,preferred_label,immunerelated adverse event,preferred_label,34172516
guideline,preferred_label,guideline,preferred_label,34172516
society for immunotherapy of cancer,preferred_label,society for immunotherapy of cancer,preferred_label,34172516
expert panel,preferred_label,expert panel,preferred_label,34172516
clinical practice guideline,preferred_label,clinical practice guideline,preferred_label,34172516
recommendation,preferred_label,recommendation,preferred_label,34172516
medical professional,preferred_label,medical professional,preferred_label,34172516
patient,preferred_label,patient,preferred_label,34172516
Trastuzumab,drug,Trastuzumab,drug,34171733
Gastroesophageal adenocarcinoma,disease,Gastroesophageal adenocarcinoma,disease,34171733
HER2,gene,HER2,gene,34171733
Chemotherapy,treatment,Chemotherapy,treatment,34171733
Checkpoint inhibitor,drug,Checkpoint inhibitor,drug,34171733
childhood acute lymphocytic leukaemia,class_id,childhood acute lymphocytic leukaemia,class_id,34171282
severe toxicity-free survival (STFS),preferred_label,severe toxicity-free survival (STFS),preferred_label,34171282
physician-prioritized toxicity,preferred_label,physician-prioritized toxicity,preferred_label,34171282
cancer outcome reporting,preferred_label,cancer outcome reporting,preferred_label,34171282
curcumin,preferred_label,curcumin,preferred_label,34169637
rhizome of curcuma,preferred_label,rhizome of curcuma,preferred_label,34169637
antitumour effect,preferred_label,antitumour effect,preferred_label,34169637
psychological stress-induced tumour proliferation,preferred_label,psychological stress-induced tumour proliferation,preferred_label,34169637
xenograft,preferred_label,xenograft,preferred_label,34169637
matrix metalloproteinase mmp,preferred_label,matrix metalloproteinase mmp,preferred_label,34169637
cd147,preferred_label,cd147,preferred_label,34169637
norepinephrine,preferred_label,norepinephrine,preferred_label,34169637
glioma cell,preferred_label,glioma cell,preferred_label,34169637
mitogen-activated protein kinase mapk signalling pathway,preferred_label,mitogen-activated protein kinase mapk signalling pathway,preferred_label,34169637
extracellular signal-regulated kinase erk phosphorylation,preferred_label,extracellular signal-regulated kinase erk phosphorylation,preferred_label,34169637
cyclin dcdk,preferred_label,cyclin dcdk,preferred_label,34169637
antiapoptotic protein bclbclxl,preferred_label,antiapoptotic protein bclbclxl,preferred_label,34169637
cell cycle change,preferred_label,cell cycle change,preferred_label,34169637
apoptosis,preferred_label,apoptosis,preferred_label,34169637
progression of glioma induced by adverse psychological stress,preferred_label,progression of glioma induced by adverse psychological stress,preferred_label,34169637
stat3,class_id,stat3,class_id,34169393
iljakstats100as100a9 signaling cascade,class_id,iljakstats100as100a9 signaling cascade,class_id,34169393
ruxolitinib,class_id,ruxolitinib,class_id,34169393
jak1,class_id,jak1,class_id,34169393
jak,class_id,jak,class_id,34169393
trastuzumab,class_id,trastuzumab,class_id,34169393
metastatic her breast cancer,class_id,metastatic her breast cancer,class_id,34169393
herdirected therapy,class_id,herdirected therapy,class_id,34169393
dose limiting toxicity,class_id,dose limiting toxicity,class_id,34169393
progression free survival,class_id,progression free survival,class_id,34169393
adverse event,class_id,adverse event,class_id,34169393
hematologic,class_id,hematologic,class_id,34169393
metastatic renal cell carcinoma,class_id,metastatic renal cell carcinoma,class_id,34167420
immune checkpoint inhibitor,class_id,immune checkpoint inhibitor,class_id,34167420
tyrosine kinase inhibitor,class_id,tyrosine kinase inhibitor,class_id,34167420
gastrointestinal adverse event,class_id,gastrointestinal adverse event,class_id,34167420
diarrhea,class_id,diarrhea,class_id,34167420
decreased appetite,class_id,decreased appetite,class_id,34167420
nausea,class_id,nausea,class_id,34167420
sunitinib,class_id,sunitinib,class_id,34167420
peripheral tcell lymphoma,class_id,peripheral tcell lymphoma,class_id,34167407
phosphatidylinositol kinase pi3k inhibitor duvelisib,class_id,phosphatidylinositol kinase pi3k inhibitor duvelisib,class_id,34167407
ptcl,synonyms,ptcl,synonyms,34167407
tcell malignancy,semantic_types,tcell malignancy,semantic_types,34167407
patient,class_id,patient,class_id,34167407
relapsedrefractory rr disease,synonyms,relapsedrefractory rr disease,synonyms,34167407
median overall survival,preferred_label,median overall survival,preferred_label,34167407
treatment,class_id,treatment,class_id,34167407
complete response,preferred_label,complete response,preferred_label,34167407
human leukocyte antigen fully matched unrelated donor allotransplantation,preferred_label,human leukocyte antigen fully matched unrelated donor allotransplantation,preferred_label,34167407
acute myeloid leukemia,class_id,acute myeloid leukemia,class_id,34166980
map4k1,preferred_label,map4k1,preferred_label,34166980
kinase,semantic_types,kinase,semantic_types,34166980
biomarkers,preferred_label,biomarkers,preferred_label,34166980
immune regulation,preferred_label,immune regulation,preferred_label,34166980
cancer progression,preferred_label,cancer progression,preferred_label,34166980
cell line,preferred_label,cell line,preferred_label,34166980
cell culture,preferred_label,cell culture,preferred_label,34166980
transfection,preferred_label,transfection,preferred_label,34166980
cell proliferation,preferred_label,cell proliferation,preferred_label,34166980
apoptosis,preferred_label,apoptosis,preferred_label,34166980
cell cycle assay,preferred_label,cell cycle assay,preferred_label,34166980
rna-seq profiling,preferred_label,rna-seq profiling,preferred_label,34166980
homoharringtonine,preferred_label,homoharringtonine,preferred_label,34166980
differential analysis,preferred_label,differential analysis,preferred_label,34166980
quantitative rt-pcr,preferred_label,quantitative rt-pcr,preferred_label,34166980
western blotting analysis,preferred_label,western blotting analysis,preferred_label,34166980
dna damage repair pathway,preferred_label,dna damage repair pathway,preferred_label,34166980
therapy,preferred_label,therapy,preferred_label,34166980
hepatic arterial infusion chemotherapy,treated with drug,hepatic arterial infusion chemotherapy,treated with drug,34166806
fluorouracil leucovorin and oxaliplatin,drug associated with AE,fluorouracil leucovorin and oxaliplatin,drug associated with AE,34166806
transarterial chemoembolization,treated with drug,transarterial chemoembolization,treated with drug,34166806
hepatocellular carcinoma,has disease,hepatocellular carcinoma,has disease,34166806
hematotoxicity,preferred_label,hematotoxicity,preferred_label,34166502
chimeric antigen receptor car tcellrelated adverse event,synonyms,chimeric antigen receptor car tcellrelated adverse event,synonyms,34166502
neutropenia,preferred_label,neutropenia,preferred_label,34166502
thrombocytopenia,preferred_label,thrombocytopenia,preferred_label,34166502
hyperferritinemia,preferred_label,hyperferritinemia,preferred_label,34166502
cytokinerelease syndrome,preferred_label,cytokinerelease syndrome,preferred_label,34166502
immune effector cellassociated neurotoxicity syndrome,preferred_label,immune effector cellassociated neurotoxicity syndrome,preferred_label,34166502
carhematotox model,preferred_label,carhematotox model,preferred_label,34166502
platelet count,preferred_label,platelet count,preferred_label,34166502
hemoglobin,preferred_label,hemoglobin,preferred_label,34166502
creactive protein,preferred_label,creactive protein,preferred_label,34166502
ferritin,preferred_label,ferritin,preferred_label,34166502
bone marrow reserve,preferred_label,bone marrow reserve,preferred_label,34166502
inflammation,preferred_label,inflammation,preferred_label,34166502
car tcell therapy,preferred_label,car tcell therapy,preferred_label,34166502
cytopenia,preferred_label,cytopenia,preferred_label,34166502
nivolumab,drug,nivolumab,drug,34166302
ipilimumab,drug,ipilimumab,drug,34166302
melanoma,disease,melanoma,disease,34166302
achalasia,disease,achalasia,disease,34166302
autonomic neuropathy,disease,autonomic neuropathy,disease,34166302
trastuzumab emtansine tdm1,preferred_label,trastuzumab emtansine tdm1,preferred_label,34165503
breast cancer,semantic_types,breast cancer,semantic_types,34165503
neoadjuvant therapy,preferred_label,neoadjuvant therapy,preferred_label,34165503
docetaxel,preferred_label,docetaxel,preferred_label,34165503
trastuzumab,preferred_label,trastuzumab,preferred_label,34165503
pertuzumab,preferred_label,pertuzumab,preferred_label,34165503
erbb2,preferred_label,erbb2,preferred_label,34165503
her2positive,synonyms,her2positive,synonyms,34165503
phase 2 trial,preferred_label,phase 2 trial,preferred_label,34165503
Sweden,preferred_label,Sweden,preferred_label,34165503
fluorodeoxyglucose,preferred_label,fluorodeoxyglucose,preferred_label,34165503
positron emission tomography,preferred_label,positron emission tomography,preferred_label,34165503
tivantinib,drug,tivantinib,drug,34164713
bevacizumab,drug,bevacizumab,drug,34164713
cmet,protein,cmet,protein,34164713
vegfa,protein,vegfa,protein,34164713
solid tumor,disease,solid tumor,disease,34164713
hypertension,adverse event,hypertension,adverse event,34164713
lymphopenia,adverse event,lymphopenia,adverse event,34164713
electrolyte disturbance,adverse event,electrolyte disturbance,adverse event,34164713
bfgf,cytokine,bfgf,cytokine,34164713
phosphomet,biomarker,phosphomet,biomarker,34164713
tubulin,protein,tubulin,protein,34164713
immune checkpoint inhibitor,class_id,immune checkpoint inhibitor,class_id,34162429
monoclonal antibody,class_id,monoclonal antibody,class_id,34162429
t cell-mediated immune response,class_id,t cell-mediated immune response,class_id,34162429
intestinal microbiome,class_id,intestinal microbiome,class_id,34162429
antibiotics,class_id,antibiotics,class_id,34162429
fecal microbiota transplantation,class_id,fecal microbiota transplantation,class_id,34162429
therapy response,class_id,therapy response,class_id,34162429
tumor microenvironment,class_id,tumor microenvironment,class_id,34162429
intestinal microbial metabolites,class_id,intestinal microbial metabolites,class_id,34162429
toxicity,class_id,toxicity,class_id,34162429
colitis,class_id,colitis,class_id,34162429
antitumor response,class_id,antitumor response,class_id,34162429
adaptive immune cells,class_id,adaptive immune cells,class_id,34162429
microbiome-based biomarkers,class_id,microbiome-based biomarkers,class_id,34162429
cancer immunotherapy,class_id,cancer immunotherapy,class_id,34162429
Steven Johnson Syndrome,class_id,Steven Johnson Syndrome,class_id,34162250
Capecitabine,class_id,Capecitabine,class_id,34162250
Gemcitabine,class_id,Gemcitabine,class_id,34162250
Carboplatin,class_id,Carboplatin,class_id,34162250
Mucositis,class_id,Mucositis,class_id,34162250
Hyperpigmentation,class_id,Hyperpigmentation,class_id,34162250
Itching,class_id,Itching,class_id,34162250
Scrotal mucosal peeling,class_id,Scrotal mucosal peeling,class_id,34162250
Hypersensitivity reaction,class_id,Hypersensitivity reaction,class_id,34162250
nitric oxide,preferred_label,nitric oxide,preferred_label,34162207
albumincoated polylacticcoglycolic acid plgaconjugated linear polyethylenimine diazeniumdiolate lpno nanoparticles,preferred_label,albumincoated polylacticcoglycolic acid plgaconjugated linear polyethylenimine diazeniumdiolate lpno nanoparticles,preferred_label,34162207
melanoma,preferred_label,melanoma,preferred_label,34162207
b16f10 murine melanoma cell,preferred_label,b16f10 murine melanoma cell,preferred_label,34162207
b16ftumorbearing mouse,preferred_label,b16ftumorbearing mouse,preferred_label,34162207
Classical Hodgkin Lymphoma,semantic_types,Classical Hodgkin Lymphoma,semantic_types,34162178
Brentuximab Vedotin,drug associated with AE,Brentuximab Vedotin,drug associated with AE,34162178
Doxorubicin,drug associated with AE,Doxorubicin,drug associated with AE,34162178
Vinblastine,drug associated with AE,Vinblastine,drug associated with AE,34162178
Dacarbazine,drug associated with AE,Dacarbazine,drug associated with AE,34162178
Echelon1 Study,class_id,Echelon1 Study,class_id,34162178
Peripheral Neuropathy,semantic_types,Peripheral Neuropathy,semantic_types,34162178
Febrile Neutropenia,semantic_types,Febrile Neutropenia,semantic_types,34162178
Pulmonary Toxicity,semantic_types,Pulmonary Toxicity,semantic_types,34162178
renal toxicity,preferred_label,renal toxicity,preferred_label,34160983
antineoplasic agent,preferred_label,antineoplasic agent,preferred_label,34160983
oncologist,preferred_label,oncologist,preferred_label,34160983
nephrologists,preferred_label,nephrologists,preferred_label,34160983
therapeutic class,preferred_label,therapeutic class,preferred_label,34160983
patient comorbidities,preferred_label,patient comorbidities,preferred_label,34160983
nephrotoxicity,preferred_label,nephrotoxicity,preferred_label,34160983
acute kidney injury,preferred_label,acute kidney injury,preferred_label,34160983
chronic kidney disease,preferred_label,chronic kidney disease,preferred_label,34160983
urinary abnormality,preferred_label,urinary abnormality,preferred_label,34160983
proteinuria,preferred_label,proteinuria,preferred_label,34160983
vital prognosis,preferred_label,vital prognosis,preferred_label,34160983
medication,preferred_label,medication,preferred_label,34160983
cancer-specific mortality,preferred_label,cancer-specific mortality,preferred_label,34160983
prevention,preferred_label,prevention,preferred_label,34160983
rapid diagnosis,preferred_label,rapid diagnosis,preferred_label,34160983
cancer patient,preferred_label,cancer patient,preferred_label,34160983
talazoparib,drug,talazoparib,drug,34160752
polyadpribose polymerase enzyme inhibitor,drug,polyadpribose polymerase enzyme inhibitor,drug,34160752
Japanese patient,patient,Japanese patient,patient,34160752
solid tumor,disease,solid tumor,disease,34160752
mutation in DNA damage repair-related gene,gene mutation,mutation in DNA damage repair-related gene,gene mutation,34160752
anemia,adverse event,anemia,adverse event,34160752
stomatitis,adverse event,stomatitis,adverse event,34160752
maculopapular rash,adverse event,maculopapular rash,adverse event,34160752
platelet count decreased,adverse event,platelet count decreased,adverse event,34160752
neutrophil count decreased,adverse event,neutrophil count decreased,adverse event,34160752
alanine aminotransferase increased,adverse event,alanine aminotransferase increased,adverse event,34160752
brain metastasis,disease,brain metastasis,disease,34160752
white blood cell count decreased,adverse event,white blood cell count decreased,adverse event,34160752
tazemetostat,drug,tazemetostat,drug,34159682
histone methyltransferase enzyme enhancer of zest homolog 2 ezh2,gene/protein,histone methyltransferase enzyme enhancer of zest homolog 2 ezh2,gene/protein,34159682
Japanese patient with relapsed or refractory rr B-cell non-Hodgkin lymphoma,patient,Japanese patient with relapsed or refractory rr B-cell non-Hodgkin lymphoma,patient,34159682
follicular lymphoma fl,disease,follicular lymphoma fl,disease,34159682
diffuse large B-cell lymphoma,disease,diffuse large B-cell lymphoma,disease,34159682
lymphopenia,adverse event,lymphopenia,adverse event,34159682
hypertriglyceridemia,adverse event,hypertriglyceridemia,adverse event,34159682
pneumonia aspiration,adverse event,pneumonia aspiration,adverse event,34159682
immune checkpoint inhibitor,drug,immune checkpoint inhibitor,drug,34157863
metastatic melanoma,disease,metastatic melanoma,disease,34157863
clinical benefit,outcome,clinical benefit,outcome,34157863
disease resistance,outcome,disease resistance,outcome,34157863
immune-related adverse event,adverse event,immune-related adverse event,adverse event,34157863
sargramostim,drug,sargramostim,drug,34157863
gmcsf,protein,gmcsf,protein,34157863
solid tumor,disease,solid tumor,disease,34157863
innate immune response,biological process,innate immune response,biological process,34157863
adaptive immune response,biological process,adaptive immune response,biological process,34157863
mechanism of action,process,mechanism of action,process,34157863
synergy,interaction,synergy,interaction,34157863
efficacy,outcome,efficacy,outcome,34157863
treatment-related toxicity,adverse event,treatment-related toxicity,adverse event,34157863
side effects,adverse event,side effects,adverse event,34157863
healthy cells,cell,healthy cells,cell,34157863
protein,biological molecule,protein,biological molecule,34157863
cancer,disease,cancer,disease,34157863
natural defense,biological process,natural defense,biological process,34157863
boosted immune system,biological process,boosted immune system,biological process,34157863
lung cancer,class_id,lung cancer,class_id,34157804
molecular targeted drug,class_id,molecular targeted drug,class_id,34157804
chemotherapy,class_id,chemotherapy,class_id,34157804
precision medicine,class_id,precision medicine,class_id,34157804
department of thoracic surgery,class_id,department of thoracic surgery,class_id,34157804
adverse reaction,class_id,adverse reaction,class_id,34157804
comprehensive therapy,class_id,comprehensive therapy,class_id,34157804
antiangiogenic agent,class_id,antiangiogenic agent,class_id,34157804
local radiotherapy,class_id,local radiotherapy,class_id,34157804
nonsmall cell lung cancer,class_id,nonsmall cell lung cancer,class_id,34157804
epidermal growth factor receptor (EGFR),class_id,epidermal growth factor receptor (EGFR),class_id,34157804
genetic test,class_id,genetic test,class_id,34157804
circulating tumor DNA test,class_id,circulating tumor DNA test,class_id,34157804
palbociclib,drug,palbociclib,drug,34157782
hematologic toxicity,adverse event,hematologic toxicity,adverse event,34157782
African American women,population,African American women,population,34157782
neutropenia,adverse event,neutropenia,adverse event,34157782
breast cancer,disease,breast cancer,disease,34157782
endocrine therapy,treatment,endocrine therapy,treatment,34157782
Duffy polymorphism,genetic factor,Duffy polymorphism,genetic factor,34157782
chronic myeloid leukemia,class_id,chronic myeloid leukemia,class_id,34156283
bcrabl fusion gene,class_id,bcrabl fusion gene,class_id,34156283
reactive oxygen species,class_id,reactive oxygen species,class_id,34156283
DNA double-strand break,class_id,DNA double-strand break,class_id,34156283
alternative end-joining pathway,class_id,alternative end-joining pathway,class_id,34156283
flap endonuclease 1 (FEN1),class_id,flap endonuclease 1 (FEN1),class_id,34156283
DNA ligase1,class_id,DNA ligase1,class_id,34156283
proliferating cell nuclear antigen,class_id,proliferating cell nuclear antigen,class_id,34156283
imatinib,class_id,imatinib,class_id,34156283
Programmed Cell Death Ligand1,class_id,Programmed Cell Death Ligand1,class_id,34153830
Programmed Cell Death1,class_id,Programmed Cell Death1,class_id,34153830
Metastatic Renal Cell Carcinoma,class_id,Metastatic Renal Cell Carcinoma,class_id,34153830
Antipd1,class_id,Antipd1,class_id,34153830
Antipdl1,class_id,Antipdl1,class_id,34153830
Sunitinib,class_id,Sunitinib,class_id,34153830
Pembrolizumab,class_id,Pembrolizumab,class_id,34153830
Lenvatinib,class_id,Lenvatinib,class_id,34153830
Epidermal growth factor receptor (EGFR),class_id,Epidermal growth factor receptor (EGFR),class_id,34153652
Gefitinib,preferred_label,Gefitinib,preferred_label,34153652
Chemoradiotherapy (CRT),preferred_label,Chemoradiotherapy (CRT),preferred_label,34153652
Cisplatin,preferred_label,Cisplatin,preferred_label,34153652
Docetaxel,preferred_label,Docetaxel,preferred_label,34153652
Adenocarcinoma,preferred_label,Adenocarcinoma,preferred_label,34153652
Hepatic toxicity,preferred_label,Hepatic toxicity,preferred_label,34153652
Neutropenia,preferred_label,Neutropenia,preferred_label,34153652
Febrile neutropenia,preferred_label,Febrile neutropenia,preferred_label,34153652
Radiation pneumonitis,preferred_label,Radiation pneumonitis,preferred_label,34153652
Treatment-related death,preferred_label,Treatment-related death,preferred_label,34153652
lateonset adverse event,adverse event,lateonset adverse event,adverse event,34153388
antiprogrammed cell death 1 antipd1 antibody,drug,antiprogrammed cell death 1 antipd1 antibody,drug,34153388
melanoma patient,patient,melanoma patient,patient,34153388
melbase,biobank,melbase,biobank,34153388
nivolumab,drug,nivolumab,drug,34153388
pembrolizumab,drug,pembrolizumab,drug,34153388
gastric cancer patient,class_id,gastric cancer patient,class_id,34149004
fluorouracil,rxnorm_cui,fluorouracil,rxnorm_cui,34149004
cisplatin,rxnorm_cui,cisplatin,rxnorm_cui,34149004
epirubicin,rxnorm_cui,epirubicin,rxnorm_cui,34149004
candidate gene,class_id,candidate gene,class_id,34149004
single nucleotide polymorphism,class_id,single nucleotide polymorphism,class_id,34149004
gstp1 rs1695,class_id,gstp1 rs1695,class_id,34149004
ercc1 rs11615,class_id,ercc1 rs11615,class_id,34149004
rs3212986 xrcc1,class_id,rs3212986 xrcc1,class_id,34149004
ugt2b7 rs7439366,class_id,ugt2b7 rs7439366,class_id,34149004
tyms rs34743033,class_id,tyms rs34743033,class_id,34149004
logistic regression,class_id,logistic regression,class_id,34149004
log rank test,class_id,log rank test,class_id,34149004
neutropenia,class_id,neutropenia,class_id,34149004
leukopenia,class_id,leukopenia,class_id,34149004
progression-free survival,class_id,progression-free survival,class_id,34149004
non-hispanic white patient,class_id,non-hispanic white patient,class_id,34149004
amarogentin,preferred_label,amarogentin,preferred_label,34148876
chirata,preferred_label,chirata,preferred_label,34148876
limd,preferred_label,limd,preferred_label,34148876
p16,preferred_label,p16,preferred_label,34148876
rbsp3,preferred_label,rbsp3,preferred_label,34148876
dnmt1,preferred_label,dnmt1,preferred_label,34148876
hdac,preferred_label,hdac,preferred_label,34148876
azadeoxycytidine,preferred_label,azadeoxycytidine,preferred_label,34148876
hepg2 cell line,preferred_label,hepg2 cell line,preferred_label,34148876
quercetin,preferred_label,quercetin,preferred_label,34147524
chitosan,preferred_label,chitosan,preferred_label,34147524
copper oxide nanoparticle,preferred_label,copper oxide nanoparticle,preferred_label,34147524
antiproliferating agent,preferred_label,antiproliferating agent,preferred_label,34147524
dmbainduced mammary carcinoma,preferred_label,dmbainduced mammary carcinoma,preferred_label,34147524
female rat,preferred_label,female rat,preferred_label,34147524
human cell line,preferred_label,human cell line,preferred_label,34147524
breast tumor,preferred_label,breast tumor,preferred_label,34147524
apoptosis,preferred_label,apoptosis,preferred_label,34147524
p53 gene,preferred_label,p53 gene,preferred_label,34147524
cell-cycle,preferred_label,cell-cycle,preferred_label,34147524
cytochrome c,preferred_label,cytochrome c,preferred_label,34147524
caspase3,preferred_label,caspase3,preferred_label,34147524
pcna gene,preferred_label,pcna gene,preferred_label,34147524
mammary carcinoma cell,preferred_label,mammary carcinoma cell,preferred_label,34147524
chemotherapeutic agent,preferred_label,chemotherapeutic agent,preferred_label,34147524
breast cancer,preferred_label,breast cancer,preferred_label,34147524
toxicity,preferred_label,toxicity,preferred_label,34147524
vital organ,preferred_label,vital organ,preferred_label,34147524
cdk inhibitor,preferred_label,cdk inhibitor,preferred_label,34145976
hormone receptorpositive and hernegative metastatic breast cancer,preferred_label,hormone receptorpositive and hernegative metastatic breast cancer,preferred_label,34145976
endocrine therapy,preferred_label,endocrine therapy,preferred_label,34145976
postmenopausal woman,preferred_label,postmenopausal woman,preferred_label,34145976
radiotherapy,preferred_label,radiotherapy,preferred_label,34145976
palbociclib,preferred_label,palbociclib,preferred_label,34145976
soft tissue skin and gastrointestinal toxicity,preferred_label,soft tissue skin and gastrointestinal toxicity,preferred_label,34145976
osteonecrosis,preferred_label,osteonecrosis,preferred_label,34145469
mercaptopurine,preferred_label,mercaptopurine,preferred_label,34145469
methotrexate,preferred_label,methotrexate,preferred_label,34145469
acute lymphoblastic leukemia,preferred_label,acute lymphoblastic leukemia,preferred_label,34145469
patient,preferred_label,patient,preferred_label,34145469
nopho all2008 protocol,preferred_label,nopho all2008 protocol,preferred_label,34145469
mtx6mp metabolite,preferred_label,mtx6mp metabolite,preferred_label,34145469
symptomatic osteonecrosis,preferred_label,symptomatic osteonecrosis,preferred_label,34145469
erythrocyte level of thioguanine,preferred_label,erythrocyte level of thioguanine,preferred_label,34145469
nucleotide p methylated 6mp metabolite,preferred_label,nucleotide p methylated 6mp metabolite,preferred_label,34145469
mtx polyglutamates,preferred_label,mtx polyglutamates,preferred_label,34145469
dnatg p,preferred_label,dnatg p,preferred_label,34145469
cox model,preferred_label,cox model,preferred_label,34145469
jcog1113,class_id,jcog1113,class_id,34145336
gemcitabine,preferred_label,gemcitabine,preferred_label,34145336
s1,synonyms,s1,synonyms,34145336
cisplatin,preferred_label,cisplatin,preferred_label,34145336
renal function,semantic_types,renal function,semantic_types,34145336
creatinine clearance,preferred_label,creatinine clearance,preferred_label,34145336
patient,preferred_label,patient,preferred_label,34145336
biliary tract cancer,preferred_label,biliary tract cancer,preferred_label,34145336
adverse reaction,preferred_label,adverse reaction,preferred_label,34145336
cytoreductive surgery,procedure,cytoreductive surgery,procedure,34145180
hyperthermic intraperitoneal chemotherapy,treatment,hyperthermic intraperitoneal chemotherapy,treatment,34145180
mitomycin C,drug,mitomycin C,drug,34145180
neutropenia,adverse event,neutropenia,adverse event,34145180
pancytopenia,adverse event,pancytopenia,adverse event,34145180
splenectomy,procedure,splenectomy,procedure,34145180
apalutamide,drug,apalutamide,drug,34144936
prostate cancer,disease,prostate cancer,disease,34144936
interstitial lung disease,disease,interstitial lung disease,disease,34144936
androgen receptor,protein,androgen receptor,protein,34144936
respiratory failure,symptom,respiratory failure,symptom,34144936
corticosteroid,drug,corticosteroid,drug,34144936
hepatocellular carcinoma,class_id,hepatocellular carcinoma,class_id,34143971
hepatitis b virus infection,class_id,hepatitis b virus infection,class_id,34143971
sintilimab,preferred_label,sintilimab,preferred_label,34143971
bevacizumab biosimilar,preferred_label,bevacizumab biosimilar,preferred_label,34143971
sorafenib,preferred_label,sorafenib,preferred_label,34143971
unresectable hbvassociated hepatocellular carcinoma,preferred_label,unresectable hbvassociated hepatocellular carcinoma,preferred_label,34143971
metastatic renal cell carcinoma,class_id,metastatic renal cell carcinoma,class_id,34143969
pembrolizumab,preferred_label,pembrolizumab,preferred_label,34143969
lenvatinib,preferred_label,lenvatinib,preferred_label,34143969
immune checkpoint inhibitor,synonyms,immune checkpoint inhibitor,synonyms,34143969
solid tumor,semantic_types,solid tumor,semantic_types,34143969
hypertension,preferred_label,hypertension,preferred_label,34143969
upper gastrointestinal haemorrhage,preferred_label,upper gastrointestinal haemorrhage,preferred_label,34143969
sudden death,preferred_label,sudden death,preferred_label,34143969
pneumonia,preferred_label,pneumonia,preferred_label,34143969
osimertinib,drug,osimertinib,drug,34140482
dacomitinib,drug,dacomitinib,drug,34140482
egfr,class_id,egfr,class_id,34140482
nonsmall cell lung cancer,class_id,nonsmall cell lung cancer,class_id,34140482
tumor heterogeneity,class_id,tumor heterogeneity,class_id,34140482
intersubject pharmacokinetic variability,class_id,intersubject pharmacokinetic variability,class_id,34140482
onalespib,preferred_label,onalespib,preferred_label,34140248
heat shock protein 90 inhibitor,semantic_types,heat shock protein 90 inhibitor,semantic_types,34140248
hsp90i,synonyms,hsp90i,synonyms,34140248
egfrmutant nonsmall cell lung cancer,semantic_types,egfrmutant nonsmall cell lung cancer,semantic_types,34140248
erlotinib,preferred_label,erlotinib,preferred_label,34140248
epidermal growth factor receptor exon 20 insertion,semantic_types,epidermal growth factor receptor exon 20 insertion,semantic_types,34140248
nextgeneration sequencing,preferred_label,nextgeneration sequencing,preferred_label,34140248
plasma circulating tumor dna,semantic_types,plasma circulating tumor dna,semantic_types,34140248
diarrhea,preferred_label,diarrhea,preferred_label,34140248
nivolumab,drug,nivolumab,drug,34139272
bevacizumab,drug,bevacizumab,drug,34139272
chemotherapy,treatment,chemotherapy,treatment,34139272
carboplatin,drug,carboplatin,drug,34139272
paclitaxel,drug,paclitaxel,drug,34139272
nsclc,disease,nsclc,disease,34139272
egfr,gene,egfr,gene,34139272
alk,gene,alk,gene,34139272
ros1,gene,ros1,gene,34139272
progression-free survival,outcome,progression-free survival,outcome,34139272
treatment-related adverse event,adverse event,treatment-related adverse event,adverse event,34139272
death,outcome,death,outcome,34139272
sotorasib,class_id,sotorasib,class_id,34137282
kras pg12c mutation,class_id,kras pg12c mutation,class_id,34137282
genotoxicity assay,class_id,genotoxicity assay,class_id,34137282
phototoxicity assay,class_id,phototoxicity assay,class_id,34137282
renal toxicity,class_id,renal toxicity,class_id,34137282
hepatocellular hypertrophy,class_id,hepatocellular hypertrophy,class_id,34137282
teratogenic,class_id,teratogenic,class_id,34137282
blocker,class_id,blocker,class_id,34136985
adrenergic receptor,class_id,adrenergic receptor,class_id,34136985
cardiovascular problem,class_id,cardiovascular problem,class_id,34136985
apoptosis-related disease,class_id,apoptosis-related disease,class_id,34136985
esmolol,class_id,esmolol,class_id,34136985
ICI,class_id,ICI,class_id,34136985
nadolol,class_id,nadolol,class_id,34136985
lung cell,class_id,lung cell,class_id,34136985
MTT test,class_id,MTT test,class_id,34136985
annexin V-FITC/PI assay,class_id,annexin V-FITC/PI assay,class_id,34136985
JC-1 staining,class_id,JC-1 staining,class_id,34136985
caspase-4,class_id,caspase-4,class_id,34136985
Bcl-2,class_id,Bcl-2,class_id,34136985
Bax,class_id,Bax,class_id,34136985
JNK level,class_id,JNK level,class_id,34136985
reactive oxygen species (ROS),class_id,reactive oxygen species (ROS),class_id,34136985
mitochondrial stress,class_id,mitochondrial stress,class_id,34136985
endoplasmic reticulum stress,class_id,endoplasmic reticulum stress,class_id,34136985
arsenic trioxide,drug,arsenic trioxide,drug,34134554
all-trans retinoic acid,drug,all-trans retinoic acid,drug,34134554
acute promyelocytic leukemia,disease,acute promyelocytic leukemia,disease,34134554
hepatotoxicity,adverse event,hepatotoxicity,adverse event,34134554
qtc prolongation,adverse event,qtc prolongation,adverse event,34134554
neurotoxicity,adverse event,neurotoxicity,adverse event,34134554
cardiac toxicity,adverse event,cardiac toxicity,adverse event,34134554
parpi,preferred_label,parpi,preferred_label,34134553
ovarian cancer,preferred_label,ovarian cancer,preferred_label,34134553
cancer,preferred_label,cancer,preferred_label,34134553
toxicity,preferred_label,toxicity,preferred_label,34134553
patient,preferred_label,patient,preferred_label,34134553
gynecologic malignancy,preferred_label,gynecologic malignancy,preferred_label,34134553
olaparib,preferred_label,olaparib,preferred_label,34134553
niraparib,preferred_label,niraparib,preferred_label,34134553
rucaparib,preferred_label,rucaparib,preferred_label,34134553
dose reduction,preferred_label,dose reduction,preferred_label,34134553
malignant central airway obstruction,class_id,malignant central airway obstruction,class_id,34134548
respiratory failure,class_id,respiratory failure,class_id,34134548
tumor,class_id,tumor,class_id,34134548
rigid bronchoscopy,class_id,rigid bronchoscopy,class_id,34134548
oncologic therapy,class_id,oncologic therapy,class_id,34134548
immunooncologic therapy,class_id,immunooncologic therapy,class_id,34134548
immune system,class_id,immune system,class_id,34134548
standard chemotherapy,class_id,standard chemotherapy,class_id,34134548
advanced cancer,class_id,advanced cancer,class_id,34134548
Cancer,has disease,Cancer,has disease,34134525
Cardiovascular toxicity,adverse event occurs in,Cardiovascular toxicity,adverse event occurs in,34134525
Arrhythmia,adverse event occurs in,Arrhythmia,adverse event occurs in,34134525
Atrial fibrillation,may_diagnose,Atrial fibrillation,may_diagnose,34134525
Ventricular arrhythmia,may_diagnose,Ventricular arrhythmia,may_diagnose,34134525
QT prolongation,may_diagnose,QT prolongation,may_diagnose,34134525
Bradyarrhythmias,may_diagnose,Bradyarrhythmias,may_diagnose,34134525
checkpoint blockade-based immunotherapy,preferred_label,checkpoint blockade-based immunotherapy,preferred_label,34127515
lung cancer,preferred_label,lung cancer,preferred_label,34127515
anticancer drug,preferred_label,anticancer drug,preferred_label,34127515
autoimmune condition,preferred_label,autoimmune condition,preferred_label,34127515
rheumatologist,preferred_label,rheumatologist,preferred_label,34127515
endocrinologist,preferred_label,endocrinologist,preferred_label,34127515
gastroenterologist,preferred_label,gastroenterologist,preferred_label,34127515
mechanism of action,preferred_label,mechanism of action,preferred_label,34127515
toxicity,preferred_label,toxicity,preferred_label,34127515
adverse event,preferred_label,adverse event,preferred_label,34127515
Hyaluronic acid-based multifunctional tumor theranostic nanoplatform,class_id,Hyaluronic acid-based multifunctional tumor theranostic nanoplatform,class_id,34127228
magnetic resonance imaging agent,class_id,magnetic resonance imaging agent,class_id,34127228
doxorubicin hydrochloride,class_id,doxorubicin hydrochloride,class_id,34127228
chlorin e,class_id,chlorin e,class_id,34127228
melanoma,class_id,melanoma,class_id,34127228
Traditional chemotherapy drug,drug,Traditional chemotherapy drug,drug,34127219
Lung cancer,disease,Lung cancer,disease,34127219
T7 peptide-modified nanoparticles TCMCS-BAPE-CBT,drug delivery system,T7 peptide-modified nanoparticles TCMCS-BAPE-CBT,drug delivery system,34127219
Carboxymethyl chitosan (CMCS),compound,Carboxymethyl chitosan (CMCS),compound,34127219
Transferrin receptor (TFR),protein,Transferrin receptor (TFR),protein,34127219
Docetaxel (DTX),drug,Docetaxel (DTX),drug,34127219
Curcumin (CUR),drug,Curcumin (CUR),drug,34127219
CBTDC complex,drug combination,CBTDC complex,drug combination,34127219
Immunosuppressive microenvironment,biological environment,Immunosuppressive microenvironment,biological environment,34127219
Tumor growth inhibition,biological process,Tumor growth inhibition,biological process,34127219
vincristine irinotecan and temozolomide combination,preferred_label,vincristine irinotecan and temozolomide combination,preferred_label,34126703
sarcoma,preferred_label,sarcoma,preferred_label,34126703
child and young adult,preferred_label,child and young adult,preferred_label,34126703
rhabdomyosarcoma,preferred_label,rhabdomyosarcoma,preferred_label,34126703
osteosarcoma,preferred_label,osteosarcoma,preferred_label,34126703
Ewing sarcoma,preferred_label,Ewing sarcoma,preferred_label,34126703
colon cancer,class_id,colon cancer,class_id,34126112
ruthenium-rifampicin complex,class_id,ruthenium-rifampicin complex,class_id,34126112
ht29,class_id,ht29,class_id,34126112
hct116,class_id,hct116,class_id,34126112
murine colorectal cancer model,class_id,murine colorectal cancer model,class_id,34126112
cat,class_id,cat,class_id,34126112
sod,class_id,sod,class_id,34126112
glutathione,class_id,glutathione,class_id,34126112
p53,class_id,p53,class_id,34126112
bcl2,class_id,bcl2,class_id,34126112
bax,class_id,bax,class_id,34126112
akt-mtor-vegf pathway,class_id,akt-mtor-vegf pathway,class_id,34126112
wnt-catenin trail,class_id,wnt-catenin trail,class_id,34126112
antiangiogenic pathway,class_id,antiangiogenic pathway,class_id,34126112
Gemcitabine,drug,Gemcitabine,drug,34125951
Nonmuscle Invasive Bladder Cancer,disease,Nonmuscle Invasive Bladder Cancer,disease,34125951
Saline,drug,Saline,drug,34125951
Mitomycin,drug,Mitomycin,drug,34125951
Bacillus Calmette-Gurin (BCG),drug,Bacillus Calmette-Gurin (BCG),drug,34125951
gemcitabine plus nabpaclitaxel,drug,gemcitabine plus nabpaclitaxel,drug,34125338
metastatic pancreatic cancer,disease,metastatic pancreatic cancer,disease,34125338
mpc patient,class_id,mpc patient,class_id,34125338
biliary stent placement,procedure,biliary stent placement,procedure,34125338
tumor response,outcome,tumor response,outcome,34125338
overall survival,outcome,overall survival,outcome,34125338
adverse event,outcome,adverse event,outcome,34125338
biliary obstruction,disease,biliary obstruction,disease,34125338
febrile neutropenia,adverse event,febrile neutropenia,adverse event,34125338
bleomycin,drug,bleomycin,drug,34121690
etoposide,drug,etoposide,drug,34121690
cisplatin,drug,cisplatin,drug,34121690
germcell tumor,disease,germcell tumor,disease,34121690
bleomycin-induced pulmonary toxicity,adverse event,bleomycin-induced pulmonary toxicity,adverse event,34121690
patient,class_id,patient,class_id,34121690
radiological feature,class_id,radiological feature,class_id,34121690
clinical symptom,class_id,clinical symptom,class_id,34121690
overall survival,class_id,overall survival,class_id,34121690
skeletal muscle mass,semantic_types,skeletal muscle mass,semantic_types,34121365
capecitabine,preferred_label,capecitabine,preferred_label,34121365
fluorouracil,synonyms,fluorouracil,synonyms,34121365
metabolite,semantic_types,metabolite,semantic_types,34121365
patient,semantic_types,patient,semantic_types,34121365
fluoroalanine,synonyms,fluoroalanine,synonyms,34121365
alox5,class_id,alox5,class_id,34121352
hete,class_id,hete,class_id,34121352
gastric cancer,class_id,gastric cancer,class_id,34121352
erkmediated signaling pathway,class_id,erkmediated signaling pathway,class_id,34121352
zileuton,class_id,zileuton,class_id,34121352
chemotherapy,class_id,chemotherapy,class_id,34121352
idelalisib,preferred_label,idelalisib,preferred_label,34121184
phosphatidylinositol kinase delta,semantic_types,phosphatidylinositol kinase delta,semantic_types,34121184
chronic lymphocytic leukaemia,preferred_label,chronic lymphocytic leukaemia,preferred_label,34121184
rituximab,preferred_label,rituximab,preferred_label,34121184
retroidel,preferred_label,retroidel,preferred_label,34121184
patient,preferred_label,patient,preferred_label,34121184
tumour protein p,preferred_label,tumour protein p,preferred_label,34121184
respiratory tract infection,preferred_label,respiratory tract infection,preferred_label,34121184
diarrhoea,preferred_label,diarrhoea,preferred_label,34121184
colitis,preferred_label,colitis,preferred_label,34121184
Chemotherapy-related amenorrhea,preferred_label,Chemotherapy-related amenorrhea,preferred_label,34120223
Ovarian toxicity,preferred_label,Ovarian toxicity,preferred_label,34120223
Infertility,preferred_label,Infertility,preferred_label,34120223
Premature menopause,preferred_label,Premature menopause,preferred_label,34120223
Paclitaxel,preferred_label,Paclitaxel,preferred_label,34120223
Trastuzumab,preferred_label,Trastuzumab,preferred_label,34120223
Ado-trastuzumab emtansine,preferred_label,Ado-trastuzumab emtansine,preferred_label,34120223
Breast cancer,preferred_label,Breast cancer,preferred_label,34120223
HER2,preferred_label,HER2,preferred_label,34120223
ATempt trial,preferred_label,ATempt trial,preferred_label,34120223
Gonadotropin-releasing hormone agonist,preferred_label,Gonadotropin-releasing hormone agonist,preferred_label,34120223
Hysterectomy,preferred_label,Hysterectomy,preferred_label,34120223
Oophorectomy,preferred_label,Oophorectomy,preferred_label,34120223
Amenorrhea,preferred_label,Amenorrhea,preferred_label,34120223
breast cancer,class_id,breast cancer,class_id,34119547
nanodrug therapeutic system,class_id,nanodrug therapeutic system,class_id,34119547
chitosan nanoparticles,class_id,chitosan nanoparticles,class_id,34119547
doxorubicin,class_id,doxorubicin,class_id,34119547
polyethylene glycol,class_id,polyethylene glycol,class_id,34119547
monoclonal antibody,class_id,monoclonal antibody,class_id,34119547
mammaglobin,class_id,mammaglobin,class_id,34119547
epidermal growth factor,class_id,epidermal growth factor,class_id,34119547
MCF7 cancer cell,class_id,MCF7 cancer cell,class_id,34119547
L929 normal cell,class_id,L929 normal cell,class_id,34119547
cytokine,preferred_label,cytokine,preferred_label,34119189
tumortargeted and microenvironmentresponsive nanocarriers,preferred_label,tumortargeted and microenvironmentresponsive nanocarriers,preferred_label,34119189
tocopheryl succinate,preferred_label,tocopheryl succinate,preferred_label,34119189
mesoporous silica nanoparticles,preferred_label,mesoporous silica nanoparticles,preferred_label,34119189
carboxymethyl chitin,preferred_label,carboxymethyl chitin,preferred_label,34119189
glucoseregulated protein binding peptide,preferred_label,glucoseregulated protein binding peptide,preferred_label,34119189
IL-12,preferred_label,IL-12,preferred_label,34119189
4T1 cell,preferred_label,4T1 cell,preferred_label,34119189
macrophage,preferred_label,macrophage,preferred_label,34119189
BALB/c nude mouse,preferred_label,BALB/c nude mouse,preferred_label,34119189
tumor tissue,preferred_label,tumor tissue,preferred_label,34119189
tumor-associated macrophage,preferred_label,tumor-associated macrophage,preferred_label,34119189
M1 phenotype,preferred_label,M1 phenotype,preferred_label,34119189
lrps2,polysaccharide,lrps2,polysaccharide,34119144
arabinogalactan,chemical compound,arabinogalactan,chemical compound,34119144
pectin,chemical compound,pectin,chemical compound,34119144
pancreatic cancer cell,cell line,pancreatic cancer cell,cell line,34119144
normal pancreatic hpdec7 cell,cell line,normal pancreatic hpdec7 cell,cell line,34119144
bxpc3,cell line,bxpc3,cell line,34119144
p38 mapknfb,signaling pathway,p38 mapknfb,signaling pathway,34119144
gsk3catenin signaling pathway,signaling pathway,gsk3catenin signaling pathway,signaling pathway,34119144
tabebuia pallida,preferred_label,tabebuia pallida,preferred_label,34118341
cancer,semantic_types,cancer,semantic_types,34118341
fever,semantic_types,fever,semantic_types,34118341
pain,semantic_types,pain,semantic_types,34118341
Ehrlich ascites carcinoma,preferred_label,Ehrlich ascites carcinoma,preferred_label,34118341
mouse model,semantic_types,mouse model,semantic_types,34118341
apoptosis,semantic_types,apoptosis,semantic_types,34118341
gene expression,semantic_types,gene expression,semantic_types,34118341
antioxidant enzyme,semantic_types,antioxidant enzyme,semantic_types,34118341
caspase,semantic_types,caspase,semantic_types,34118341
balance of gene expression,semantic_types,balance of gene expression,semantic_types,34118341
cell death,semantic_types,cell death,semantic_types,34118341
adriamycin,drug,adriamycin,drug,34117724
breast cancer,disease,breast cancer,disease,34117724
plac8,protein,plac8,protein,34117724
oncogene,protein,oncogene,protein,34117724
tumour suppressor,protein,tumour suppressor,protein,34117724
lc3,protein,lc3,protein,34117724
p62,protein,p62,protein,34117724
rapamycin,drug,rapamycin,drug,34117724
mcfadmr cell,cell line,mcfadmr cell,cell line,34117724
autophagy inhibitor ma,drug,autophagy inhibitor ma,drug,34117724
afatinib,drug,afatinib,drug,34115855
bevacizumab,drug,bevacizumab,drug,34115855
epidermal growth factor receptor,protein,epidermal growth factor receptor,protein,34115855
nonsmallcell lung cancer,disease,nonsmallcell lung cancer,disease,34115855
diarrhoea,adverse event,diarrhoea,adverse event,34115855
skin rash,adverse event,skin rash,adverse event,34115855
t790m,mutation,t790m,mutation,34115855
breast tumor,class_id,breast tumor,class_id,34112795
ADCs,class_id,ADCs,class_id,34112795
T-DM1,class_id,T-DM1,class_id,34112795
intratumor heterogeneity,class_id,intratumor heterogeneity,class_id,34112795
dual-drug ADC,class_id,dual-drug ADC,class_id,34112795
payload,class_id,payload,class_id,34112795
her2 heterogeneity,class_id,her2 heterogeneity,class_id,34112795
drug resistance,class_id,drug resistance,class_id,34112795
xenograft mouse model,class_id,xenograft mouse model,class_id,34112795
refractory breast cancer,class_id,refractory breast cancer,class_id,34112795
chickpea,class_id,chickpea,class_id,34111539
isoflavones,class_id,isoflavones,class_id,34111539
phytoestrogens,class_id,phytoestrogens,class_id,34111539
polycystic ovary syndrome,class_id,polycystic ovary syndrome,class_id,34111539
cicer arietinum l seed ethanol extract,class_id,cicer arietinum l seed ethanol extract,class_id,34111539
letrozole,class_id,letrozole,class_id,34111539
clomiphene citrate,class_id,clomiphene citrate,class_id,34111539
ovary,class_id,ovary,class_id,34111539
uterus,class_id,uterus,class_id,34111539
granulosa cell,class_id,granulosa cell,class_id,34111539
theca cell,class_id,theca cell,class_id,34111539
cyp11a1,class_id,cyp11a1,class_id,34111539
neuroblastoma,class_id,neuroblastoma,class_id,34111492
paclitaxel,class_id,paclitaxel,class_id,34111492
taxol,synonyms,taxol,synonyms,34111492
poly lacticcoglycolic acid,preferred_label,poly lacticcoglycolic acid,preferred_label,34111492
human neuroblastoma cell shsy5y,class_id,human neuroblastoma cell shsy5y,class_id,34111492
transition metal dichalcogenides,class_id,transition metal dichalcogenides,class_id,34110773
nanoparticles,class_id,nanoparticles,class_id,34110773
distearoylsnglycerophosphoethanolaminepolyethylene glycol,class_id,distearoylsnglycerophosphoethanolaminepolyethylene glycol,class_id,34110773
tumor,class_id,tumor,class_id,34110773
normal tissue,class_id,normal tissue,class_id,34110773
BRAFV600E mutation,class_id,BRAFV600E mutation,class_id,34109735
Langerhans cell histiocytosis (LCH),class_id,Langerhans cell histiocytosis (LCH),class_id,34109735
Vemurafenib (VMF),class_id,Vemurafenib (VMF),class_id,34109735
Cutaneous adverse event (CAE),class_id,Cutaneous adverse event (CAE),class_id,34109735
Skin tumor,class_id,Skin tumor,class_id,34109735
Squamous cell carcinoma,class_id,Squamous cell carcinoma,class_id,34109735
Melanoma,class_id,Melanoma,class_id,34109735
Child,class_id,Child,class_id,34109735
Dermatological follow-up,class_id,Dermatological follow-up,class_id,34109735
fcn437c,drug,fcn437c,drug,34109484
breast cancer,disease,breast cancer,disease,34109484
cyclin-dependent kinase 4,protein,cyclin-dependent kinase 4,protein,34109484
cyclin-dependent kinase 6,protein,cyclin-dependent kinase 6,protein,34109484
thrombocytopenia,adverse event,thrombocytopenia,adverse event,34109484
neutropenia,adverse event,neutropenia,adverse event,34109484
anemia,adverse event,anemia,adverse event,34109484
leukopenia,adverse event,leukopenia,adverse event,34109484
patient,class_id,patient,class_id,34107744
soft tissue sarcoma,class_id,soft tissue sarcoma,class_id,34107744
longterm efficacy,preferred_label,longterm efficacy,preferred_label,34107744
quality of life,preferred_label,quality of life,preferred_label,34107744
QOL,synonyms,QOL,synonyms,34107744
treatment,class_id,treatment,class_id,34107744
progression,preferred_label,progression,preferred_label,34107744
disease,class_id,disease,class_id,34107744
histology,preferred_label,histology,preferred_label,34107744
toxicity profile,preferred_label,toxicity profile,preferred_label,34107744
regimen,class_id,regimen,class_id,34107744
surgical outcome,preferred_label,surgical outcome,preferred_label,34107744
expert care,preferred_label,expert care,preferred_label,34107744
sarcoma reference center,preferred_label,sarcoma reference center,preferred_label,34107744
survival,preferred_label,survival,preferred_label,34107744
intraarterial chemotherapy,treatment,intraarterial chemotherapy,treatment,34106637
retinoblastoma,disease,retinoblastoma,disease,34106637
eye,anatomical structure,eye,anatomical structure,34106637
infant,age group,infant,age group,34106637
birth weight,attribute,birth weight,attribute,34106637
ophthalmic artery,anatomical structure,ophthalmic artery,anatomical structure,34106637
eyelid edema,adverse event,eyelid edema,adverse event,34106637
neutropenia,adverse event,neutropenia,adverse event,34106637
calcification,process,calcification,process,34106637
new drug,drug,new drug,drug,34105810
lymphoid malignancy,disease,lymphoid malignancy,disease,34105810
adverse event,adverse event,adverse event,adverse event,34105810
drug interaction,interaction,drug interaction,interaction,34105810
toxicity,adverse event outcome,toxicity,adverse event outcome,34105810
efficacy,adverse event outcome,efficacy,adverse event outcome,34105810
AML,class_id,AML,class_id,34105456
body mass index (BMI),class_id,body mass index (BMI),class_id,34105456
clinical characteristic,class_id,clinical characteristic,class_id,34105456
laboratory examination index,class_id,laboratory examination index,class_id,34105456
adult patient,class_id,adult patient,class_id,34105456
acute myeloid leukemia,class_id,acute myeloid leukemia,class_id,34105456
chemotherapy,class_id,chemotherapy,class_id,34105456
anthracyclines,class_id,anthracyclines,class_id,34105456
cytarabine,class_id,cytarabine,class_id,34105456
white blood cell (WBC),class_id,white blood cell (WBC),class_id,34105456
hemoglobin (Hb),class_id,hemoglobin (Hb),class_id,34105456
albumin,class_id,albumin,class_id,34105456
triglyceride (TG),class_id,triglyceride (TG),class_id,34105456
total cholesterol (TC),class_id,total cholesterol (TC),class_id,34105456
high-density lipoprotein (HDL),class_id,high-density lipoprotein (HDL),class_id,34105456
low-density lipoprotein (LDL),class_id,low-density lipoprotein (LDL),class_id,34105456
lactate dehydrogenase (LDH),class_id,lactate dehydrogenase (LDH),class_id,34105456
mutation,class_id,mutation,class_id,34105456
infection,class_id,infection,class_id,34105456
adverse reaction,class_id,adverse reaction,class_id,34105456
Durvalumab,drug,Durvalumab,drug,34103352
Endometrial cancer,disease,Endometrial cancer,disease,34103352
Woman,patient,Woman,patient,34103352
Mismatch repair proficient (PMMR),class_id,Mismatch repair proficient (PMMR),class_id,34103352
Mismatch repair deficient (DMMR),class_id,Mismatch repair deficient (DMMR),class_id,34103352
Chemotherapy,treatment,Chemotherapy,treatment,34103352
Immune checkpoint inhibitor,drug,Immune checkpoint inhibitor,drug,34102607
Esophagitis,disease,Esophagitis,disease,34102607
Gastrointestinal toxicity,adverse event,Gastrointestinal toxicity,adverse event,34102607
University of Texas MD Anderson Cancer Center,medical facility,University of Texas MD Anderson Cancer Center,medical facility,34102607
Proton pump inhibitor,drug,Proton pump inhibitor,drug,34102607
Steroid (Prednisone or Budesonide),drug,Steroid (Prednisone or Budesonide),drug,34102607
radiation dermatitis,preferred_label,radiation dermatitis,preferred_label,34102298
chemoradiation therapy,preferred_label,chemoradiation therapy,preferred_label,34102298
cancer,semantic_types,cancer,semantic_types,34102298
topical steroid,preferred_label,topical steroid,preferred_label,34102298
phase multiinstitutional randomized doubleblind placebocontrolled trial,preferred_label,phase multiinstitutional randomized doubleblind placebocontrolled trial,preferred_label,34102298
patient,preferred_label,patient,preferred_label,34102298
head and neck region,preferred_label,head and neck region,preferred_label,34102298
neck irradiation,preferred_label,neck irradiation,preferred_label,34102298
cisplatin,preferred_label,cisplatin,preferred_label,34102298
skin care,preferred_label,skin care,preferred_label,34102298
national cancer institute common terminology criterion,preferred_label,national cancer institute common terminology criterion,preferred_label,34102298
adverse event,preferred_label,adverse event,preferred_label,34102298
local infection,preferred_label,local infection,preferred_label,34102298
immune checkpoint inhibitor,drug,immune checkpoint inhibitor,drug,34101874
nonsmall cell lung cancer,disease,nonsmall cell lung cancer,disease,34101874
cytotoxic tlymphocyteassociated protein 4,drug,cytotoxic tlymphocyteassociated protein 4,drug,34101874
programmed cell death 1 receptor,drug,programmed cell death 1 receptor,drug,34101874
programmed cell death receptor ligand 1,drug,programmed cell death receptor ligand 1,drug,34101874
chemotherapy,drug,chemotherapy,drug,34101874
immune checkpoint inhibitor,drug,immune checkpoint inhibitor,drug,34101756
acute kidney injury,disease,acute kidney injury,disease,34101756
renal outcome,outcome,renal outcome,outcome,34101756
mortality,outcome,mortality,outcome,34101756
serum creatinine,biomarker,serum creatinine,biomarker,34101756
gynecologic malignancy,disease,gynecologic malignancy,disease,34101756
ipilimumab,drug,ipilimumab,drug,34101756
diuretic,drug,diuretic,drug,34101756
angiotensin-converting enzyme inhibitor,drug,angiotensin-converting enzyme inhibitor,drug,34101756
angiotensin-receptor blocker,drug,angiotensin-receptor blocker,drug,34101756
proton pump inhibitor,drug,proton pump inhibitor,drug,34101756
irtmpps,preferred_label,irtmpps,preferred_label,34101408
singlet oxygen,preferred_label,singlet oxygen,preferred_label,34101408
nadph,preferred_label,nadph,preferred_label,34101408
cancer cells,preferred_label,cancer cells,preferred_label,34101408
tumor,preferred_label,tumor,preferred_label,34101408
lung,preferred_label,lung,preferred_label,34101408
locally advanced head and neck carcinoma,class_id,locally advanced head and neck carcinoma,class_id,34101389
cisplatin,preferred_label,cisplatin,preferred_label,34101389
chemoradiation,preferred_label,chemoradiation,preferred_label,34101389
renal toxicity,preferred_label,renal toxicity,preferred_label,34101389
hematologic toxicity,preferred_label,hematologic toxicity,preferred_label,34101389
randomized clinical trial,preferred_label,randomized clinical trial,preferred_label,34101389
glomerular filtration rate,preferred_label,glomerular filtration rate,preferred_label,34101389
neutropenia,preferred_label,neutropenia,preferred_label,34101389
thrombocytopenia,preferred_label,thrombocytopenia,preferred_label,34101389
stereotactic radiosurgery,preferred_label,stereotactic radiosurgery,preferred_label,34100178
brain metastasis,preferred_label,brain metastasis,preferred_label,34100178
radionecrosis,preferred_label,radionecrosis,preferred_label,34100178
local progression,preferred_label,local progression,preferred_label,34100178
bevacizumab,preferred_label,bevacizumab,preferred_label,34100178
radiotherapy,preferred_label,radiotherapy,preferred_label,34100178
tumor cell,class_id,tumor cell,class_id,34099106
selfantigens,preferred_label,selfantigens,preferred_label,34099106
selftolerance,preferred_label,selftolerance,preferred_label,34099106
immunotherapy,preferred_label,immunotherapy,preferred_label,34099106
coinhibitory molecule,preferred_label,coinhibitory molecule,preferred_label,34099106
immune cell,preferred_label,immune cell,preferred_label,34099106
antitumor immunity,preferred_label,antitumor immunity,preferred_label,34099106
antibody,preferred_label,antibody,preferred_label,34099106
ctla4,preferred_label,ctla4,preferred_label,34099106
metastatic melanoma,preferred_label,metastatic melanoma,preferred_label,34099106
checkpoint blockade,preferred_label,checkpoint blockade,preferred_label,34099106
pd1,preferred_label,pd1,preferred_label,34099106
pdl,preferred_label,pdl,preferred_label,34099106
checkpoint inhibitor,preferred_label,checkpoint inhibitor,preferred_label,34099106
icis,preferred_label,icis,preferred_label,34099106
clinical benefit,preferred_label,clinical benefit,preferred_label,34099106
solid tumor,preferred_label,solid tumor,preferred_label,34099106
antigen presentation,preferred_label,antigen presentation,preferred_label,34099106
immunerelated adverse event,preferred_label,immunerelated adverse event,preferred_label,34099106
platinum compound,class_id,platinum compound,class_id,34098035
cisplatin,class_id,cisplatin,class_id,34098035
carboplatin,class_id,carboplatin,class_id,34098035
lung cancer,class_id,lung cancer,class_id,34098035
platinum resistance,class_id,platinum resistance,class_id,34098035
molecular mechanism,class_id,molecular mechanism,class_id,34098035
predictive marker,class_id,predictive marker,class_id,34098035
newer more effective agent,class_id,newer more effective agent,class_id,34098035
toxic agent,class_id,toxic agent,class_id,34098035
refractory lung cancer,class_id,refractory lung cancer,class_id,34098035
lowrisk human papillomavirus hpv associated oropharyngeal squamous cell carcinoma,class_id,lowrisk human papillomavirus hpv associated oropharyngeal squamous cell carcinoma,class_id,34098030
cisplatin,preferred_label,cisplatin,preferred_label,34098030
cetuximab,preferred_label,cetuximab,preferred_label,34098030
radiation therapy,preferred_label,radiation therapy,preferred_label,34098030
drug delivery system,class_id,drug delivery system,class_id,34097960
curcumin,class_id,curcumin,class_id,34097960
nano cellulose,class_id,nano cellulose,class_id,34097960
MDA-MB231 breast cancer cell,class_id,MDA-MB231 breast cancer cell,class_id,34097960
cancer patient,class_id,cancer patient,class_id,34097901
radiotherapy chemotherapy,class_id,radiotherapy chemotherapy,class_id,34097901
targeted cancer therapy,class_id,targeted cancer therapy,class_id,34097901
side effect,class_id,side effect,class_id,34097901
ionizing radiation,class_id,ionizing radiation,class_id,34097901
chemotherapy drug,class_id,chemotherapy drug,class_id,34097901
DNA,class_id,DNA,class_id,34097901
mitochondrion,class_id,mitochondrion,class_id,34097901
membrane,class_id,membrane,class_id,34097901
organelle,class_id,organelle,class_id,34097901
normal tissue cell,class_id,normal tissue cell,class_id,34097901
cardiomyocytes,class_id,cardiomyocytes,class_id,34097901
endothelial cell,class_id,endothelial cell,class_id,34097901
toxin,class_id,toxin,class_id,34097901
inflammatory cell,class_id,inflammatory cell,class_id,34097901
cytokine,class_id,cytokine,class_id,34097901
chemokines,class_id,chemokines,class_id,34097901
reactive oxygen species,class_id,reactive oxygen species,class_id,34097901
reactive nitrogen species,class_id,reactive nitrogen species,class_id,34097901
antioxidant defense enzyme,class_id,antioxidant defense enzyme,class_id,34097901
macromolecule,class_id,macromolecule,class_id,34097901
cytokine,class_id,cytokine,class_id,34097901
oxidative injury,class_id,oxidative injury,class_id,34097901
heart injury,class_id,heart injury,class_id,34097901
fibrosis,class_id,fibrosis,class_id,34097901
cardiomyopathy,class_id,cardiomyopathy,class_id,34097901
endothelium injury,class_id,endothelium injury,class_id,34097901
heart disease,class_id,heart disease,class_id,34097901
letrozole,drug,letrozole,drug,34096894
hormone-receptor-positive breast cancer,disease,hormone-receptor-positive breast cancer,disease,34096894
cytochrome p450 2a6 (CYP2A6),gene,cytochrome p450 2a6 (CYP2A6),gene,34096894
rs7937,genetic variant,rs7937,genetic variant,34096894
rs56113850,genetic variant,rs56113850,genetic variant,34096894
ncf4 rs1883112,class_id,ncf4 rs1883112,class_id,34096893
cbr3 rs1056892,class_id,cbr3 rs1056892,class_id,34096893
abcc1 rs3743527,class_id,abcc1 rs3743527,class_id,34096893
doxorubicin,preferred_label,doxorubicin,preferred_label,34096893
left ventricular ejection fraction,preferred_label,left ventricular ejection fraction,preferred_label,34096893
diastolic filling ratio,preferred_label,diastolic filling ratio,preferred_label,34096893
anthracycline,preferred_label,anthracycline,preferred_label,34096893
pediatric patient,preferred_label,pediatric patient,preferred_label,34096893
acute lymphoblastic leukemia,preferred_label,acute lymphoblastic leukemia,preferred_label,34096893
chemotherapeutic regimen,preferred_label,chemotherapeutic regimen,preferred_label,34096893
mexican child,preferred_label,mexican child,preferred_label,34096893
cancer chemotherapy,preferred_label,cancer chemotherapy,preferred_label,34096893
genetic polymorphism,preferred_label,genetic polymorphism,preferred_label,34096893
p53,class_id,p53,class_id,34093867
inauhzin,preferred_label,inauhzin,preferred_label,34093867
Nanoparticle,preferred_label,Nanoparticle,preferred_label,34093867
lung cancer,preferred_label,lung cancer,preferred_label,34093867
colorectal cancer,preferred_label,colorectal cancer,preferred_label,34093867
wi38 cell,preferred_label,wi38 cell,preferred_label,34093867
mouse mef cell,preferred_label,mouse mef cell,preferred_label,34093867
carmustine implant gliadel wafer,drug,carmustine implant gliadel wafer,drug,34092748
malignant glioma,disease,malignant glioma,disease,34092748
Japanese patient,patient,Japanese patient,patient,34092748
postmarketing surveillance study,study,postmarketing surveillance study,study,34092748
adverse event,event,adverse event,event,34092748
adverse drug reaction,event,adverse drug reaction,event,34092748
cerebral edema,event,cerebral edema,event,34092748
convulsion,event,convulsion,event,34092748
impaired healing,event,impaired healing,event,34092748
infection,event,infection,event,34092748
rutheniumii complex,class_id,rutheniumii complex,class_id,34090039
naphthoquinone ligand,class_id,naphthoquinone ligand,class_id,34090039
lapachol,preferred_label,lapachol,preferred_label,34090039
lawsone,preferred_label,lawsone,preferred_label,34090039
bisdiphenylphosphinomethane dppm ligand,class_id,bisdiphenylphosphinomethane dppm ligand,class_id,34090039
syngeneic murine melanoma model,class_id,syngeneic murine melanoma model,class_id,34090039
apoptotic pathway,class_id,apoptotic pathway,class_id,34090039
immunohistochemistry,class_id,immunohistochemistry,class_id,34090039
antiproliferative activity,class_id,antiproliferative activity,class_id,34090039
cleaved caspase,preferred_label,cleaved caspase,preferred_label,34090039
cisplatin,preferred_label,cisplatin,preferred_label,34090039
binding energy,class_id,binding energy,class_id,34090039
molar volume,class_id,molar volume,class_id,34090039
rituximab,drug,rituximab,drug,34088724
lenalidomide,drug,lenalidomide,drug,34088724
non-hodgkin lymphoma,disease,non-hodgkin lymphoma,disease,34088724
patient,patient,patient,patient,34088724
granb,protein,granb,protein,34088724
cd t cell,cell type,cd t cell,cell type,34088724
b cell,cell type,b cell,cell type,34088724
plasma ifn,protein,plasma ifn,protein,34088724
Platinum resistant/refractory epithelial ovarian cancer,class_id,Platinum resistant/refractory epithelial ovarian cancer,class_id,34088513
Oral metronomic therapy,class_id,Oral metronomic therapy,class_id,34088513
Etoposide,preferred_label,Etoposide,preferred_label,34088513
Cyclophosphamide,preferred_label,Cyclophosphamide,preferred_label,34088513
Pazopanib,preferred_label,Pazopanib,preferred_label,34088513
Quality of life,preferred_label,Quality of life,preferred_label,34088513
Serum VEGF,preferred_label,Serum VEGF,preferred_label,34088513
Serum PDGF,preferred_label,Serum PDGF,preferred_label,34088513
Yamabudo,class_id,Yamabudo,class_id,34087405
Dimethoxybenzoquinone,class_id,Dimethoxybenzoquinone,class_id,34087405
Fertaric acid,class_id,Fertaric acid,class_id,34087405
Caftaric acid,class_id,Caftaric acid,class_id,34087405
NNK,class_id,NNK,class_id,34087405
DNA,class_id,DNA,class_id,34087405
A549 cell line,class_id,A549 cell line,class_id,34087405
Salmonella typhimurium TA1535,class_id,Salmonella typhimurium TA1535,class_id,34087405
ERK,class_id,ERK,class_id,34087405
AKT,class_id,AKT,class_id,34087405
STAT3,class_id,STAT3,class_id,34087405
doxorubicin,drug,doxorubicin,drug,34087342
diffuse large b-cell lymphoma,disease,diffuse large b-cell lymphoma,disease,34087342
elderly population,age group,elderly population,age group,34087342
liposome encapsulated drug delivery system,drug delivery system,liposome encapsulated drug delivery system,drug delivery system,34087342
solid cancer,cancer,solid cancer,cancer,34087342
lymphoma,cancer,lymphoma,cancer,34087342
non-pegylated liposome doxorubicin (NPLD),drug,non-pegylated liposome doxorubicin (NPLD),drug,34087342
R-CHOP,drug combination,R-CHOP,drug combination,34087342
R-COMP,drug combination,R-COMP,drug combination,34087342
daratumumab,drug,daratumumab,drug,34087126
pomalidomide,drug,pomalidomide,drug,34087126
dexamethasone,drug,dexamethasone,drug,34087126
multiple myeloma,disease,multiple myeloma,disease,34087126
patient,person,patient,person,34087126
lenalidomide,drug,lenalidomide,drug,34087126
proteasome inhibitor,drug,proteasome inhibitor,drug,34087126
neutropenia,adverse event,neutropenia,adverse event,34087126
anaemia,adverse event,anaemia,adverse event,34087126
thrombocytopenia,adverse event,thrombocytopenia,adverse event,34087126
pneumonia,adverse event,pneumonia,adverse event,34087126
lower respiratory tract infection,adverse event,lower respiratory tract infection,adverse event,34087126
esophagogastric adenocarcinoma,preferred_label,esophagogastric adenocarcinoma,preferred_label,34086514
docetaxel,preferred_label,docetaxel,preferred_label,34086514
cisplatin,preferred_label,cisplatin,preferred_label,34086514
fluorouracil,preferred_label,fluorouracil,preferred_label,34086514
carboplatin,preferred_label,carboplatin,preferred_label,34086514
capecitabine,preferred_label,capecitabine,preferred_label,34086514
DCF,synonyms,DCF,synonyms,34086514
EPIRUBICIN,preferred_label,EPIRUBICIN,preferred_label,34086514
OXALIPLATIN,preferred_label,OXALIPLATIN,preferred_label,34086514
febrile neutropenia,preferred_label,febrile neutropenia,preferred_label,34086514
unresectable gallbladder cancer,class_id,unresectable gallbladder cancer,class_id,34086477
gemcitabine,preferred_label,gemcitabine,preferred_label,34086477
platinum,preferred_label,platinum,preferred_label,34086477
modified flourouracil,preferred_label,modified flourouracil,preferred_label,34086477
oxaliplatin,preferred_label,oxaliplatin,preferred_label,34086477
irinotecan,preferred_label,irinotecan,preferred_label,34086477
prospective phase ii singlearm pilot study,class_id,prospective phase ii singlearm pilot study,class_id,34086477
granulocyte colonystimulating factor,preferred_label,granulocyte colonystimulating factor,preferred_label,34086477
herpositive breast cancer,class_id,herpositive breast cancer,class_id,34086171
neoadjuvant chemotherapy,class_id,neoadjuvant chemotherapy,class_id,34086171
dual hertargeted therapy,class_id,dual hertargeted therapy,class_id,34086171
pathologic complete response,class_id,pathologic complete response,class_id,34086171
weekly paclitaxel,class_id,weekly paclitaxel,class_id,34086171
carboplatin,class_id,carboplatin,class_id,34086171
trastuzumab,class_id,trastuzumab,class_id,34086171
pertuzumab,class_id,pertuzumab,class_id,34086171
loading dose,class_id,loading dose,class_id,34086171
grade 2 diarrhea,class_id,grade 2 diarrhea,class_id,34086171
highgrade glioma,class_id,highgrade glioma,class_id,34081269
bevacizumab,preferred_label,bevacizumab,preferred_label,34081269
recurrent glioblastoma,synonyms,recurrent glioblastoma,synonyms,34081269
patient,class_id,patient,class_id,34081269
chemotherapy,preferred_label,chemotherapy,preferred_label,34081269
corticosteroid,preferred_label,corticosteroid,preferred_label,34081269
chemotherapy-induced peripheral neurotoxicity,class_id,chemotherapy-induced peripheral neurotoxicity,class_id,34078718
total neuropathy score,preferred_label,total neuropathy score,preferred_label,34078718
functional assessment of cancer treatment,preferred_label,functional assessment of cancer treatment,preferred_label,34078718
neurotoxicity,semantic_types,neurotoxicity,semantic_types,34078718
observational prospective study,preferred_label,observational prospective study,preferred_label,34078718
patient-based method,preferred_label,patient-based method,preferred_label,34078718
physician-based method,preferred_label,physician-based method,preferred_label,34078718
neuropathy,preferred_label,neuropathy,preferred_label,34078718
neurologic examination,preferred_label,neurologic examination,preferred_label,34078718
pemetrexed,drug,pemetrexed,drug,34078521
platinum,drug,platinum,drug,34078521
renin-angiotensin system,class_id,renin-angiotensin system,class_id,34078521
organic anion transporter,class_id,organic anion transporter,class_id,34078521
ra inhibitor,drug,ra inhibitor,drug,34078521
nonsmall cell lung cancer,class_id,nonsmall cell lung cancer,class_id,34078521
malignant pleural mesothelioma,class_id,malignant pleural mesothelioma,class_id,34078521
patient,class_id,patient,class_id,34078134
urothelial carcinoma of the bladder,class_id,urothelial carcinoma of the bladder,class_id,34078134
immunotherapy,class_id,immunotherapy,class_id,34078134
glioblastoma multiforme,class_id,glioblastoma multiforme,class_id,34074038
irinotecan,class_id,irinotecan,class_id,34074038
temozolomide,class_id,temozolomide,class_id,34074038
sn38,class_id,sn38,class_id,34074038
polydllactidecoglycolide microparticles,class_id,polydllactidecoglycolide microparticles,class_id,34074038
brain tissue,class_id,brain tissue,class_id,34074038
human glioblastoma cell line,class_id,human glioblastoma cell line,class_id,34074038
xenograft model,class_id,xenograft model,class_id,34074038
mouse,class_id,mouse,class_id,34074038
prostate cancer,class_id,prostate cancer,class_id,34071152
immunotoxin molecule,class_id,immunotoxin molecule,class_id,34071152
psma receptor,class_id,psma receptor,class_id,34071152
psma-positive lncap cell,class_id,psma-positive lncap cell,class_id,34071152
psma-negative cell,class_id,psma-negative cell,class_id,34071152
pseudomonas exotoxin A,class_id,pseudomonas exotoxin A,class_id,34071152
demethoxycurcumin,class_id,demethoxycurcumin,class_id,34071132
glioblastoma multiforme,class_id,glioblastoma multiforme,class_id,34071132
GBM8401 cell,class_id,GBM8401 cell,class_id,34071132
mouse model,class_id,mouse model,class_id,34071132
luciferase-expressing stable clone,class_id,luciferase-expressing stable clone,class_id,34071132
phosphate-buffered solution,class_id,phosphate-buffered solution,class_id,34071132
dimethyl sulfoxide,class_id,dimethyl sulfoxide,class_id,34071132
xenograft tumor,class_id,xenograft tumor,class_id,34071132
tumor volume,class_id,tumor volume,class_id,34071132
body weight,class_id,body weight,class_id,34071132
protein expression,class_id,protein expression,class_id,34071132
cleaved caspase-3,class_id,cleaved caspase-3,class_id,34071132
liver tissue,class_id,liver tissue,class_id,34071132
personalized therapy,may_treat,personalized therapy,may_treat,34070464
oncological scenario,occurs in,oncological scenario,occurs in,34070464
drug-drug gene interaction (DDGI),drug AE occurs in,drug-drug gene interaction (DDGI),drug AE occurs in,34070464
single nucleotide polymorphism (SNP),realizes,single nucleotide polymorphism (SNP),realizes,34070464
breast cancer,has disease,breast cancer,has disease,34070464
metastatic disease,develops from,metastatic disease,develops from,34070464
toxicity,adverse event occurs in,toxicity,adverse event occurs in,34070464
antineoplastic treatment,may_treat,antineoplastic treatment,may_treat,34070464
supportive treatment,may_prevent,supportive treatment,may_prevent,34070464
drug dosage reduction,may_prevent,drug dosage reduction,may_prevent,34070464
biochemical data,source,biochemical data,source,34070464
genomic data,source,genomic data,source,34070464
enzyme and transporter,has part,enzyme and transporter,has part,34070464
drug metabolism,may_prevent,drug metabolism,may_prevent,34070464
breast cancer treatment,may_treat,breast cancer treatment,may_treat,34070464
drugpin software,example of usage,drugpin software,example of usage,34070464
dihydropyrimidine dehydrogenase,class_id,dihydropyrimidine dehydrogenase,class_id,34069161
fluorouracil,class_id,fluorouracil,class_id,34069161
missense mutation,class_id,missense mutation,class_id,34069161
African descent,class_id,African descent,class_id,34069161
amber force field parameter,class_id,amber force field parameter,class_id,34069161
collation feature visual force field derivation toolkit,class_id,collation feature visual force field derivation toolkit,class_id,34069161
all-atom MD simulation,class_id,all-atom MD simulation,class_id,34069161
Fucoidan,drug,Fucoidan,drug,34068561
Chemotherapy drugs,drug,Chemotherapy drugs,drug,34068561
Cancer cells,cell,Cancer cells,cell,34068561
Healthy tissue,tissue,Healthy tissue,tissue,34068561
Natural killer cells,cell,Natural killer cells,cell,34068561
Macrophages,cell,Macrophages,cell,34068561
marine ecosystem,class_id,marine ecosystem,class_id,34068184
anthraquinones,class_id,anthraquinones,class_id,34068184
marine organism,class_id,marine organism,class_id,34068184
genotoxicity,class_id,genotoxicity,class_id,34068184
mutagenicity,class_id,mutagenicity,class_id,34068184
anticancer potential,class_id,anticancer potential,class_id,34068184
folfirinox,preferred_label,folfirinox,preferred_label,34067288
gemcitabine nabpaclitaxel,preferred_label,gemcitabine nabpaclitaxel,preferred_label,34067288
chemotherapy regimen,semantic_types,chemotherapy regimen,semantic_types,34067288
metastatic pancreatic cancer,semantic_types,metastatic pancreatic cancer,semantic_types,34067288
prospective trial,semantic_types,prospective trial,semantic_types,34067288
retrospective study,semantic_types,retrospective study,semantic_types,34067288
matchingadjusted indirect comparison,preferred_label,matchingadjusted indirect comparison,preferred_label,34067288
patient,semantic_types,patient,semantic_types,34067288
data,semantic_types,data,semantic_types,34067288
realworld setting,semantic_types,realworld setting,semantic_types,34067288
prodige trial,preferred_label,prodige trial,preferred_label,34067288
survival outcome,semantic_types,survival outcome,semantic_types,34067288
overall survival,semantic_types,overall survival,semantic_types,34067288
progressionfree survival,semantic_types,progressionfree survival,semantic_types,34067288
toxicity profile,semantic_types,toxicity profile,semantic_types,34067288
anemia,semantic_types,anemia,semantic_types,34067288
vomiting,semantic_types,vomiting,semantic_types,34067288
diarrhea,semantic_types,diarrhea,semantic_types,34067288
efficacy,semantic_types,efficacy,semantic_types,34067288
safety profile,semantic_types,safety profile,semantic_types,34067288
firstline therapy,semantic_types,firstline therapy,semantic_types,34067288
reliable predictive biomarkers,semantic_types,reliable predictive biomarkers,semantic_types,34067288
therapeutic strategy,semantic_types,therapeutic strategy,semantic_types,34067288
leukemia,class_id,leukemia,class_id,34066963
drug,class_id,drug,class_id,34066963
immune cell,class_id,immune cell,class_id,34066963
bone marrow,class_id,bone marrow,class_id,34066963
spleen,class_id,spleen,class_id,34066963
therapy,class_id,therapy,class_id,34066963
patient survival,class_id,patient survival,class_id,34066963
drug resistance,class_id,drug resistance,class_id,34066963
research,class_id,research,class_id,34066963
therapeutic approach,class_id,therapeutic approach,class_id,34066963
natural product,class_id,natural product,class_id,34066963
medicinal plant,class_id,medicinal plant,class_id,34066963
antileukemic drug,class_id,antileukemic drug,class_id,34066963
cytotoxicity,class_id,cytotoxicity,class_id,34066963
mechanism of action,class_id,mechanism of action,class_id,34066963
cardiac glycoside,preferred_label,cardiac glycoside,preferred_label,34064873
cgs toxin,preferred_label,cgs toxin,preferred_label,34064873
nakatpase,preferred_label,nakatpase,preferred_label,34064873
sodiumpotassium pump,preferred_label,sodiumpotassium pump,preferred_label,34064873
cancer cell,preferred_label,cancer cell,preferred_label,34064873
aplysinopsins,class_id,aplysinopsins,class_id,34063867
ee84,class_id,ee84,class_id,34063867
chronic myeloid leukemia,class_id,chronic myeloid leukemia,class_id,34063867
k562 cell,class_id,k562 cell,class_id,34063867
bh3 mimetic,class_id,bh3 mimetic,class_id,34063867
mcl1 inhibitor,class_id,mcl1 inhibitor,class_id,34063867
nanoformulations,class_id,nanoformulations,class_id,34063119
doxorubicin,class_id,doxorubicin,class_id,34063119
iron oxide particle,class_id,iron oxide particle,class_id,34063119
polymeric shell,class_id,polymeric shell,class_id,34063119
cholesterol moiety,class_id,cholesterol moiety,class_id,34063119
cell membrane,class_id,cell membrane,class_id,34063119
polycholesteryl acrylate,class_id,polycholesteryl acrylate,class_id,34063119
cancer cell,class_id,cancer cell,class_id,34063119
breast cancer cell line,class_id,breast cancer cell line,class_id,34063119
mcf7,class_id,mcf7,class_id,34063119
mdamb231,class_id,mdamb231,class_id,34063119
do,class_id,do,class_id,34063119
active compound,class_id,active compound,class_id,34063119
material,class_id,material,class_id,34063119
human red blood cell,class_id,human red blood cell,class_id,34063119
immune monocytic thp1 cell,class_id,immune monocytic thp1 cell,class_id,34063119
cardiomyocyte h9c2 cell,class_id,cardiomyocyte h9c2 cell,class_id,34063119
polymeriron oxide hybrid,class_id,polymeriron oxide hybrid,class_id,34063119
quinacrine sterilization,preferred_label,quinacrine sterilization,preferred_label,34062206
FDA approval,preferred_label,FDA approval,preferred_label,34062206
woman,preferred_label,woman,preferred_label,34062206
negative international health consequence,preferred_label,negative international health consequence,preferred_label,34062206
year rat study,preferred_label,year rat study,preferred_label,34062206
cancel et al,preferred_label,cancel et al,preferred_label,34062206
regulatory toxicology and pharmacology,preferred_label,regulatory toxicology and pharmacology,preferred_label,34062206
mtd,preferred_label,mtd,preferred_label,34062206
uterus,preferred_label,uterus,preferred_label,34062206
genotoxicity,preferred_label,genotoxicity,preferred_label,34062206
fda,preferred_label,fda,preferred_label,34062206
mcconnell et al,preferred_label,mcconnell et al,preferred_label,34062206
haseman et al,preferred_label,haseman et al,preferred_label,34062206
necrosis,preferred_label,necrosis,preferred_label,34062206
chronic inflammation,preferred_label,chronic inflammation,preferred_label,34062206
Anticancer Drug,drug,Anticancer Drug,drug,34061498
Dendritic Polyglycerol Sulfate-bearing Polycaprolactone,drug delivery system,Dendritic Polyglycerol Sulfate-bearing Polycaprolactone,drug delivery system,34061498
Sunitinib,drug,Sunitinib,drug,34061498
Tumor Environment,location,Tumor Environment,location,34061498
A431 Cell,cell line,A431 Cell,cell line,34061498
HT29 Cell,cell line,HT29 Cell,cell line,34061498
AIDS-related Kaposi sarcoma,class_id,AIDS-related Kaposi sarcoma,class_id,34060438
combination antiretroviral therapy,class_id,combination antiretroviral therapy,class_id,34060438
chemotherapy,class_id,chemotherapy,class_id,34060438
pegylated liposomal doxorubicin,class_id,pegylated liposomal doxorubicin,class_id,34060438
HIV infection,class_id,HIV infection,class_id,34060438
nanomaterials,class_id,nanomaterials,class_id,34058149
graphene oxide,class_id,graphene oxide,class_id,34058149
tubulin,class_id,tubulin,class_id,34058149
microtubule,class_id,microtubule,class_id,34058149
cellular function,class_id,cellular function,class_id,34058149
proliferation,class_id,proliferation,class_id,34058149
anticancer drug,class_id,anticancer drug,class_id,34058149
human colon cancer cell hct116,class_id,human colon cancer cell hct116,class_id,34058149
human embryonic kidney epithelial cell hek293,class_id,human embryonic kidney epithelial cell hek293,class_id,34058149
apoptosis,class_id,apoptosis,class_id,34058149
reactive oxygen species (ROS),class_id,reactive oxygen species (ROS),class_id,34058149
colorectal carcinoma cell,class_id,colorectal carcinoma cell,class_id,34058149
cancer therapeutic,class_id,cancer therapeutic,class_id,34058149
nanomedicine,class_id,nanomedicine,class_id,34058149
docetaxelcisplatinfluorouracil,drug,docetaxelcisplatinfluorouracil,drug,34057299
gastric adenocarcinoma,disease,gastric adenocarcinoma,disease,34057299
chemonave,treatment,chemonave,treatment,34057299
granulocyte colonystimulating factor,drug,granulocyte colonystimulating factor,drug,34057299
febrile neutropenia,adverse event,febrile neutropenia,adverse event,34057299
neutropenia,adverse event,neutropenia,adverse event,34057299
fatigue,adverse event,fatigue,adverse event,34057299
vomiting,adverse event,vomiting,adverse event,34057299
anorexia,adverse event,anorexia,adverse event,34057299
diarrhea,adverse event,diarrhea,adverse event,34057299
progressionfree survival,outcome,progressionfree survival,outcome,34057299
overall survival,outcome,overall survival,outcome,34057299
Serum C-reactive protein (CRP),biomarker,Serum C-reactive protein (CRP),biomarker,34054056
Melanoma patient,patient,Melanoma patient,patient,34054056
Immune-related adverse event (irAE),adverse event,Immune-related adverse event (irAE),adverse event,34054056
Immune checkpoint inhibitor (ICI),drug,Immune checkpoint inhibitor (ICI),drug,34054056
Relapse-free survival (RFS),outcome measure,Relapse-free survival (RFS),outcome measure,34054056
patient,class_id,patient,class_id,34052929
germ cell tumour,class_id,germ cell tumour,class_id,34052929
PARP,preferred_label,PARP,preferred_label,34052929
gemcitabine,preferred_label,gemcitabine,preferred_label,34052929
carboplatin,preferred_label,carboplatin,preferred_label,34052929
veliparib,preferred_label,veliparib,preferred_label,34052929
neutropenia,preferred_label,neutropenia,preferred_label,34052929
thrombocytopenia,preferred_label,thrombocytopenia,preferred_label,34052929
anaemia,preferred_label,anaemia,preferred_label,34052929
febrile neutropenia,preferred_label,febrile neutropenia,preferred_label,34052929
sorafenib,drug,sorafenib,drug,34052550
lenvatinib,drug,lenvatinib,drug,34052550
apatinib,drug,apatinib,drug,34052550
hepatocellular carcinoma,disease,hepatocellular carcinoma,disease,34052550
therapeutic drug monitoring,procedure,therapeutic drug monitoring,procedure,34052550
human plasma,biological sample,human plasma,biological sample,34052550
uplcmsms system,instrument,uplcmsms system,instrument,34052550
c18 column,instrument,c18 column,instrument,34052550
water,substance,water,substance,34052550
acetonitrile,substance,acetonitrile,substance,34052550
whole blood,biological sample,whole blood,biological sample,34052550
Chronic myeloid leukemia,class_id,Chronic myeloid leukemia,class_id,34052176
Imatinib,class_id,Imatinib,class_id,34052176
Elderly patients,class_id,Elderly patients,class_id,34052176
Younger patients,class_id,Younger patients,class_id,34052176
Charlson comorbidity index (CCI),class_id,Charlson comorbidity index (CCI),class_id,34052176
Hematologic adverse events (AEs),class_id,Hematologic adverse events (AEs),class_id,34052176
Nonhematologic AEs,class_id,Nonhematologic AEs,class_id,34052176
Imatinib dose reduction,class_id,Imatinib dose reduction,class_id,34052176
Cumulative response rate,class_id,Cumulative response rate,class_id,34052176
Event-free survival,class_id,Event-free survival,class_id,34052176
Overall survival,class_id,Overall survival,class_id,34052176
Patient,class_id,Patient,class_id,34051880
Cancer Treatment,class_id,Cancer Treatment,class_id,34051880
Atezolizumab,class_id,Atezolizumab,class_id,34051880
Bevacizumab,class_id,Bevacizumab,class_id,34051880
Sorafenib,class_id,Sorafenib,class_id,34051880
Hepatocellular Carcinoma,class_id,Hepatocellular Carcinoma,class_id,34051880
Trial,class_id,Trial,class_id,34051880
Quality of Life,class_id,Quality of Life,class_id,34051880
Functioning,class_id,Functioning,class_id,34051880
Disease Symptom,class_id,Disease Symptom,class_id,34051880
gold nanoparticles,class_id,gold nanoparticles,class_id,34051217
influenza a virus,class_id,influenza a virus,class_id,34051217
human glioblastoma gmb u87,class_id,human glioblastoma gmb u87,class_id,34051217
human glioblastoma u251,class_id,human glioblastoma u251,class_id,34051217
citrate reduction method,class_id,citrate reduction method,class_id,34051217
uvvis spectrum,class_id,uvvis spectrum,class_id,34051217
electron microscopy analysis,class_id,electron microscopy analysis,class_id,34051217
hemagglutination inhibition,class_id,hemagglutination inhibition,class_id,34051217
tissue culture infectious dose 50,class_id,tissue culture infectious dose 50,class_id,34051217
realtime pcr,class_id,realtime pcr,class_id,34051217
mtt,class_id,mtt,class_id,34051217
flow cytometry,class_id,flow cytometry,class_id,34051217
scratch assay,class_id,scratch assay,class_id,34051217
apoptosis,class_id,apoptosis,class_id,34051217
high-risk non-muscle-invasive bladder cancer,semantic_types,high-risk non-muscle-invasive bladder cancer,semantic_types,34051177
transurethral resection of bladder tumour,preferred_label,transurethral resection of bladder tumour,preferred_label,34051177
intravesical bcg immunotherapy,preferred_label,intravesical bcg immunotherapy,preferred_label,34051177
pd1 pathway activation,preferred_label,pd1 pathway activation,preferred_label,34051177
pembrolizumab,preferred_label,pembrolizumab,preferred_label,34051177
singlearm multicentre phase 2 study,preferred_label,singlearm multicentre phase 2 study,preferred_label,34051177
site hospital and cancer centre,preferred_label,site hospital and cancer centre,preferred_label,34051177
cohort A,preferred_label,cohort A,preferred_label,34051177
carcinoma in situ of the bladder,preferred_label,carcinoma in situ of the bladder,preferred_label,34051177
Eastern Cooperative Oncology Group performance status,preferred_label,Eastern Cooperative Oncology Group performance status,preferred_label,34051177
radical cystectomy,preferred_label,radical cystectomy,preferred_label,34051177
clinical complete response rate,preferred_label,clinical complete response rate,preferred_label,34051177
high-grade ta or any grade t1 papillary disease,preferred_label,high-grade ta or any grade t1 papillary disease,preferred_label,34051177
treatment-related adverse event,preferred_label,treatment-related adverse event,preferred_label,34051177
arthralgia,preferred_label,arthralgia,preferred_label,34051177
hyponatremia,preferred_label,hyponatremia,preferred_label,34051177
death,preferred_label,death,preferred_label,34051177
oxaliplatin,drug,oxaliplatin,drug,34050586
irinotecan,drug,irinotecan,drug,34050586
S-1,drug,S-1,drug,34050586
unresectable pancreatic ductal adenocarcinoma,disease,unresectable pancreatic ductal adenocarcinoma,disease,34050586
adenocarcinoma,disease,adenocarcinoma,disease,34050586
adenosquamous histology,disease,adenosquamous histology,disease,34050586
anemia,adverse event,anemia,adverse event,34050586
thrombocytopenia,adverse event,thrombocytopenia,adverse event,34050586
fatigue,adverse event,fatigue,adverse event,34050586
nausea,adverse event,nausea,adverse event,34050586
anorexia,adverse event,anorexia,adverse event,34050586
diarrhea,adverse event,diarrhea,adverse event,34050586
peripheral sensory neuropathy,adverse event,peripheral sensory neuropathy,adverse event,34050586
pazopanib,drug,pazopanib,drug,34050255
soft tissue sarcoma,disease,soft tissue sarcoma,disease,34050255
topotecan,drug,topotecan,drug,34050255
metastatic nonadipocytic STS,disease,metastatic nonadipocytic STS,disease,34050255
osteosarcoma,disease,osteosarcoma,disease,34050255
liposarcoma,disease,liposarcoma,disease,34050255
toxicity,adverse event,toxicity,adverse event,34050255
programmed cell death ligand 1,biomarker,programmed cell death ligand 1,biomarker,34049821
immune checkpoint inhibitor icis,treatment,immune checkpoint inhibitor icis,treatment,34049821
advanced nonsmallcell lung cancer nsclc,disease,advanced nonsmallcell lung cancer nsclc,disease,34049821
serum protein,biomarker,serum protein,biomarker,34049821
immunerelated adverse event iraes,adverse event,immunerelated adverse event iraes,adverse event,34049821
nivolumab,drug,nivolumab,drug,34049821
pembrolizumab,drug,pembrolizumab,drug,34049821
growthregulated oncogene 1 gro1,protein,growthregulated oncogene 1 gro1,protein,34049821
monocyte chemoattractant protein 1 mcp1,protein,monocyte chemoattractant protein 1 mcp1,protein,34049821
progressionfree survival pfs,outcome,progressionfree survival pfs,outcome,34049821
overall survival o,outcome,overall survival o,outcome,34049821
chimeric antigen receptor car,class_id,chimeric antigen receptor car,class_id,34048683
antigenrecognition domain,class_id,antigenrecognition domain,class_id,34048683
tcell activation domain,class_id,tcell activation domain,class_id,34048683
cd3,class_id,cd3,class_id,34048683
cd247,class_id,cd247,class_id,34048683
costimulatory domain,class_id,costimulatory domain,class_id,34048683
cd28,class_id,cd28,class_id,34048683
bb tnfrsf,class_id,bb tnfrsf,class_id,34048683
cd137,class_id,cd137,class_id,34048683
bcell maturation antigen bcma,class_id,bcell maturation antigen bcma,class_id,34048683
tnfrsf17,class_id,tnfrsf17,class_id,34048683
plasma cell,class_id,plasma cell,class_id,34048683
mature b cell,class_id,mature b cell,class_id,34048683
multiple myeloma,class_id,multiple myeloma,class_id,34048683
antibcma car t cell,class_id,antibcma car t cell,class_id,34048683
cytokinerelease syndrome,class_id,cytokinerelease syndrome,class_id,34048683
cytopenia,class_id,cytopenia,class_id,34048683
infection,class_id,infection,class_id,34048683
neurotoxicity,class_id,neurotoxicity,class_id,34048683
immunosuppressive microenvironment,class_id,immunosuppressive microenvironment,class_id,34048683
suicide gene safety system,class_id,suicide gene safety system,class_id,34048683
lenalidomide maintenance,drug associated with AE,lenalidomide maintenance,drug associated with AE,34048681
multiple myeloma,has disease,multiple myeloma,has disease,34048681
minimal residual disease,drug AE occurs in,minimal residual disease,drug AE occurs in,34048681
bone marrow,located_in,bone marrow,located_in,34048681
progression-free survival,adverse event outcome,progression-free survival,adverse event outcome,34048681
mrd status,drug AE occurs in,mrd status,drug AE occurs in,34048681
flow cytometry,may diagnose,flow cytometry,may diagnose,34048681
adverse event,has disease,adverse event,has disease,34048681
sepsis,adverse event,sepsis,adverse event,34048681
heart failure,adverse event,heart failure,adverse event,34048681
methotrexate,drug,methotrexate,drug,34047177
mercaptopurine,drug,mercaptopurine,drug,34047177
acute lymphoblastic leukemia,disease,acute lymphoblastic leukemia,disease,34047177
thioguanine,drug,thioguanine,drug,34047177
thioguanine nucleotide,chemical compound,thioguanine nucleotide,chemical compound,34047177
DNA,biomolecule,DNA,biomolecule,34047177
thiopurine enhanced ALL maintenance therapy team,treatment approach,thiopurine enhanced ALL maintenance therapy team,treatment approach,34047177
temozolomide,drug,temozolomide,drug,34045849
tumor,disease,tumor,disease,34045849
patient,class_id,patient,class_id,34045849
radiotherapy,treatment,radiotherapy,treatment,34045849
chemotherapy,treatment,chemotherapy,treatment,34045849
clinical stage,class_id,clinical stage,class_id,34045849
hematological system,anatomical entity,hematological system,anatomical entity,34045849
gastrointestinal system,anatomical entity,gastrointestinal system,anatomical entity,34045849
liver,anatomical entity,liver,anatomical entity,34045849
doxorubicin,drug,doxorubicin,drug,34044928
antimir21,drug,antimir21,drug,34044928
mesoporous silica nanoparticles,drug delivery system,mesoporous silica nanoparticles,drug delivery system,34044928
chitosan,material,chitosan,material,34044928
AS1411 aptamer,targeting molecule,AS1411 aptamer,targeting molecule,34044928
nucleolin,protein,nucleolin,protein,34044928
C26 tumor,disease,C26 tumor,disease,34044928
cancer,disease,cancer,disease,34044797
chemoresistance,adverse event outcome,chemoresistance,adverse event outcome,34044797
toxic side effects,adverse event outcome,toxic side effects,adverse event outcome,34044797
metformin,drug,metformin,drug,34044797
chemotherapy,drug treatment,chemotherapy,drug treatment,34044797
doxorubicin,drug,doxorubicin,drug,34044797
docetaxel,drug,docetaxel,drug,34044797
mitomycin c,drug,mitomycin c,drug,34044797
fluorouracil,drug,fluorouracil,drug,34044797
glucose consumption,biomarker,glucose consumption,biomarker,34044797
immune checkpoint inhibitor,drug,immune checkpoint inhibitor,drug,34044546
antitumor drug,drug,antitumor drug,drug,34044546
chemotherapy,drug,chemotherapy,drug,34044546
immunotoxicity,adverse event,immunotoxicity,adverse event,34044546
immunerelated adverse event,adverse event,immunerelated adverse event,adverse event,34044546
immune thrombocytopenia,adverse event,immune thrombocytopenia,adverse event,34044546
nivolumab,drug,nivolumab,drug,34044546
small cell lung cancer,disease,small cell lung cancer,disease,34044546
thrombocytopenia,adverse event,thrombocytopenia,adverse event,34044546
platelet antibody,antibody,platelet antibody,antibody,34044546
autoantibody,antibody,autoantibody,antibody,34044546
thyroglobulin antibody,antibody,thyroglobulin antibody,antibody,34044546
helper T cell,cell,helper T cell,cell,34044546
regulatory T cell,cell,regulatory T cell,cell,34044546
cytokine,biomarker,cytokine,biomarker,34044546
capecitabine,drug,capecitabine,drug,34043412
oxaliplatin,drug,oxaliplatin,drug,34043412
rectal cancer,disease,rectal cancer,disease,34043412
neoadjuvant chemotherapy,treatment,neoadjuvant chemotherapy,treatment,34043412
radiation,treatment,radiation,treatment,34043412
surgery,treatment,surgery,treatment,34043412
diarrhea,adverse event,diarrhea,adverse event,34043412
neuropathy,adverse event,neuropathy,adverse event,34043412
oral mucositis,adverse event,oral mucositis,adverse event,34043412
pathologic complete response,outcome,pathologic complete response,outcome,34043412
negative circumferential resection margin,outcome,negative circumferential resection margin,outcome,34043412
arsenic trioxide,drug,arsenic trioxide,drug,34042274
acute promyelocytic leukemia,disease,acute promyelocytic leukemia,disease,34042274
e2f1,protein,e2f1,protein,34042274
cyclin E,protein,cyclin E,protein,34042274
pRB,protein,pRB,protein,34042274
PI3K,protein,PI3K,protein,34042274
p53,protein,p53,protein,34042274
chemodynamic therapy,semantic_types,chemodynamic therapy,semantic_types,34041833
h2 o2,preferred_label,h2 o2,preferred_label,34041833
tumor tissue,preferred_label,tumor tissue,preferred_label,34041833
supramolecular nanoparticle,preferred_label,supramolecular nanoparticle,preferred_label,34041833
platinum iv complexmodified cyclodextrinferrocene conjugate,preferred_label,platinum iv complexmodified cyclodextrinferrocene conjugate,preferred_label,34041833
hydroxyl radical,preferred_label,hydroxyl radical,preferred_label,34041833
cisplatin,preferred_label,cisplatin,preferred_label,34041833
renal clearance,preferred_label,renal clearance,preferred_label,34041833
systemic toxicity,preferred_label,systemic toxicity,preferred_label,34041833
biocompatibility,preferred_label,biocompatibility,preferred_label,34041833
supramolecular nanoassemblies,preferred_label,supramolecular nanoassemblies,preferred_label,34041833
cascade chemochemodynamic therapy,preferred_label,cascade chemochemodynamic therapy,preferred_label,34041833
everolimus,drug,everolimus,drug,34041638
metastatic breast cancer,disease,metastatic breast cancer,disease,34041638
exemestane,drug,exemestane,drug,34041638
mammalian target of rapamycin (mtor),protein,mammalian target of rapamycin (mtor),protein,34041638
peripheral blood mononuclear cell (pbmcs),cell,peripheral blood mononuclear cell (pbmcs),cell,34041638
stomatitis,adverse event,stomatitis,adverse event,34041638
berzosertib,preferred_label,berzosertib,preferred_label,34040175
gemcitabine,preferred_label,gemcitabine,preferred_label,34040175
cisplatin,preferred_label,cisplatin,preferred_label,34040175
ataxia telangiectasia and radrelated protein kinase,preferred_label,ataxia telangiectasia and radrelated protein kinase,preferred_label,34040175
solid tumour,preferred_label,solid tumour,preferred_label,34040175
partial response,preferred_label,partial response,preferred_label,34040175
stable disease,preferred_label,stable disease,preferred_label,34040175
berzosertib,preferred_label,berzosertib,preferred_label,34040174
cisplatin,preferred_label,cisplatin,preferred_label,34040174
neutropenia,preferred_label,neutropenia,preferred_label,34040174
anaemia,preferred_label,anaemia,preferred_label,34040174
hypersensitivity reaction,preferred_label,hypersensitivity reaction,preferred_label,34040174
increase in alanine aminotransferase,preferred_label,increase in alanine aminotransferase,preferred_label,34040174
partial response,preferred_label,partial response,preferred_label,34040174
platinumbased chemotherapy,preferred_label,platinumbased chemotherapy,preferred_label,34040174
locally advanced esophageal squamous cell carcinoma,semantic_types,locally advanced esophageal squamous cell carcinoma,semantic_types,34039375
chemoradiotherapy,semantic_types,chemoradiotherapy,semantic_types,34039375
s1,preferred_label,s1,preferred_label,34039375
docetaxel,preferred_label,docetaxel,preferred_label,34039375
cisplatin,preferred_label,cisplatin,preferred_label,34039375
adverse event,preferred_label,adverse event,preferred_label,34039375
elderly patient,preferred_label,elderly patient,preferred_label,34039375
overall response rate,preferred_label,overall response rate,preferred_label,34039375
survival outcome,preferred_label,survival outcome,preferred_label,34039375
cc chemokine receptor 4,class_id,cc chemokine receptor 4,class_id,34039310
mogamulizumab,preferred_label,mogamulizumab,preferred_label,34039310
effector tregs,preferred_label,effector tregs,preferred_label,34039310
antitumor immune response,preferred_label,antitumor immune response,preferred_label,34039310
tumor cell,preferred_label,tumor cell,preferred_label,34039310
adult tcell leukemialymphoma,preferred_label,adult tcell leukemialymphoma,preferred_label,34039310
peripheral tcell lymphoma,preferred_label,peripheral tcell lymphoma,preferred_label,34039310
cutaneous tcell lymphoma,preferred_label,cutaneous tcell lymphoma,preferred_label,34039310
lymphopenia,preferred_label,lymphopenia,preferred_label,34039310
infusion reaction,preferred_label,infusion reaction,preferred_label,34039310
fever,preferred_label,fever,preferred_label,34039310
rash,preferred_label,rash,preferred_label,34039310
neutropenia,preferred_label,neutropenia,preferred_label,34039310
anaemia,preferred_label,anaemia,preferred_label,34039310
gastrointestinal disorder,preferred_label,gastrointestinal disorder,preferred_label,34039310
immune checkpoint inhibitor,preferred_label,immune checkpoint inhibitor,preferred_label,34036513
cancer,preferred_label,cancer,preferred_label,34036513
antipd1 molecule nivolumab,preferred_label,antipd1 molecule nivolumab,preferred_label,34036513
pembrolizumab,preferred_label,pembrolizumab,preferred_label,34036513
endocrine system,preferred_label,endocrine system,preferred_label,34036513
antipd1 drug,preferred_label,antipd1 drug,preferred_label,34036513
thyroid dysfunction,preferred_label,thyroid dysfunction,preferred_label,34036513
progressionfree survival,preferred_label,progressionfree survival,preferred_label,34036513
overall survival,preferred_label,overall survival,preferred_label,34036513
woman,preferred_label,woman,preferred_label,34036513
endocrinopathy,preferred_label,endocrinopathy,preferred_label,34036513
side effect,preferred_label,side effect,preferred_label,34036513
cancer drug,drug,cancer drug,drug,34035370
safety,adverse event outcome,safety,adverse event outcome,34035370
tolerability,adverse event outcome,tolerability,adverse event outcome,34035370
control arm,treatment arm,control arm,treatment arm,34035370
efficacy,adverse event outcome,efficacy,adverse event outcome,34035370
toxicity,adverse event outcome,toxicity,adverse event outcome,34035370
phase 3 randomized controlled trial,clinical trial,phase 3 randomized controlled trial,clinical trial,34035370
advanced breast cancer,disease,advanced breast cancer,disease,34035370
colorectal cancer,disease,colorectal cancer,disease,34035370
lung cancer,disease,lung cancer,disease,34035370
prostate cancer,disease,prostate cancer,disease,34035370
progression-free survival,adverse event outcome,progression-free survival,adverse event outcome,34035370
overall survival,adverse event outcome,overall survival,adverse event outcome,34035370
toxic death,adverse event outcome,toxic death,adverse event outcome,34035370
treatment discontinuation without progression,adverse event outcome,treatment discontinuation without progression,adverse event outcome,34035370
grade adverse event,adverse event,grade adverse event,adverse event,34035370
experimental cancer vaccine,class_id,experimental cancer vaccine,class_id,34035112
melanoma-derived peptide,class_id,melanoma-derived peptide,class_id,34035112
t cell,class_id,t cell,class_id,34035112
skin epidermal langerhans cell,class_id,skin epidermal langerhans cell,class_id,34035112
granulocyte macrophage colony stimulating factor,class_id,granulocyte macrophage colony stimulating factor,class_id,34035112
tlr7 agonist,class_id,tlr7 agonist,class_id,34035112
tetanus helper peptide,class_id,tetanus helper peptide,class_id,34035112
dimethyl sulfoxide,class_id,dimethyl sulfoxide,class_id,34035112
concurrent chemoradiotherapy,preferred_label,concurrent chemoradiotherapy,preferred_label,34032710
adjuvant chemotherapy,preferred_label,adjuvant chemotherapy,preferred_label,34032710
gemcitabine,preferred_label,gemcitabine,preferred_label,34032710
cisplatin,preferred_label,cisplatin,preferred_label,34032710
fluorouracil,preferred_label,fluorouracil,preferred_label,34032710
nasopharyngeal carcinoma,preferred_label,nasopharyngeal carcinoma,preferred_label,34032710
NPC,synonyms,NPC,synonyms,34032710
progression-free survival,preferred_label,progression-free survival,preferred_label,34032710
overall survival,preferred_label,overall survival,preferred_label,34032710
overall response rate,preferred_label,overall response rate,preferred_label,34032710
acute toxicity,preferred_label,acute toxicity,preferred_label,34032710
late toxicity,preferred_label,late toxicity,preferred_label,34032710
adverse event,preferred_label,adverse event,preferred_label,34032710
cd30,semantic_types,cd30,semantic_types,34031784
brentuximab vedotin,preferred_label,brentuximab vedotin,preferred_label,34031784
nonseminomatous germcell tumor,semantic_types,nonseminomatous germcell tumor,semantic_types,34031784
antibodydrug conjugate,semantic_types,antibodydrug conjugate,semantic_types,34031784
phase 2 trial,semantic_types,phase 2 trial,semantic_types,34031784
chemorefractory gct,semantic_types,chemorefractory gct,semantic_types,34031784
cisplatinbased chemotherapy,semantic_types,cisplatinbased chemotherapy,semantic_types,34031784
salvage regimen,semantic_types,salvage regimen,semantic_types,34031784
highdose chemotherapy,semantic_types,highdose chemotherapy,semantic_types,34031784
treatment-related adverse event,semantic_types,treatment-related adverse event,semantic_types,34031784
radiographic stable disease,semantic_types,radiographic stable disease,semantic_types,34031784
progression of disease,semantic_types,progression of disease,semantic_types,34031784
ly01610,preferred_label,ly01610,preferred_label,34031756
irinotecan,preferred_label,irinotecan,preferred_label,34031756
esophageal squamous cell carcinoma,preferred_label,esophageal squamous cell carcinoma,preferred_label,34031756
patient,preferred_label,patient,preferred_label,34031756
vomiting,preferred_label,vomiting,preferred_label,34031756
febrile neutropenia,preferred_label,febrile neutropenia,preferred_label,34031756
leukopenia,preferred_label,leukopenia,preferred_label,34031756
anemia,preferred_label,anemia,preferred_label,34031756
neutropenia,preferred_label,neutropenia,preferred_label,34031756
complete response,preferred_label,complete response,preferred_label,34031756
partial response,preferred_label,partial response,preferred_label,34031756
antitumor activity,preferred_label,antitumor activity,preferred_label,34031756
clinical development,preferred_label,clinical development,preferred_label,34031756
anticancer agent,preferred_label,anticancer agent,preferred_label,34031756
immunotherapy,preferred_label,immunotherapy,preferred_label,34031312
immune checkpoint pathway,preferred_label,immune checkpoint pathway,preferred_label,34031312
adverse reaction,preferred_label,adverse reaction,preferred_label,34031312
immune-related adverse event,preferred_label,immune-related adverse event,preferred_label,34031312
immune system,preferred_label,immune system,preferred_label,34031312
organ,preferred_label,organ,preferred_label,34031312
patient,preferred_label,patient,preferred_label,34031312
toxicity,preferred_label,toxicity,preferred_label,34031312
Epidermal Growth Factor Receptor,class_id,Epidermal Growth Factor Receptor,class_id,34031056
Afatinib,preferred_label,Afatinib,preferred_label,34031056
Cetuximab,preferred_label,Cetuximab,preferred_label,34031056
Non-Small Cell Lung Cancer,class_id,Non-Small Cell Lung Cancer,class_id,34031056
Tyrosine Kinase Inhibitor,class_id,Tyrosine Kinase Inhibitor,class_id,34031056
Monoclonal Antibody,class_id,Monoclonal Antibody,class_id,34031056
irinotecan,drug,irinotecan,drug,34030768
topoisomerase inhibitor,drug class,topoisomerase inhibitor,drug class,34030768
metastatic colorectal cancer,disease,metastatic colorectal cancer,disease,34030768
diarrhea,adverse event,diarrhea,adverse event,34030768
sn38,active metabolite,sn38,active metabolite,34030768
bacterial glucuronidase,enzyme,bacterial glucuronidase,enzyme,34030768
silymarin,supplement,silymarin,supplement,34030768
folfiri,chemotherapy regimen,folfiri,chemotherapy regimen,34030768
bevacizumab,drug,bevacizumab,drug,34030768
graftversushost disease gvhd,preferred_label,graftversushost disease gvhd,preferred_label,34029766
ixazomib,preferred_label,ixazomib,preferred_label,34029766
calcineurin inhibitor,preferred_label,calcineurin inhibitor,preferred_label,34029766
proteasome inhibitor,preferred_label,proteasome inhibitor,preferred_label,34029766
hematologic malignancy,preferred_label,hematologic malignancy,preferred_label,34029766
paronychia,class_id,paronychia,class_id,34029250
antibiotic,class_id,antibiotic,class_id,34029250
steroid,class_id,steroid,class_id,34029250
cancer therapy,class_id,cancer therapy,class_id,34029250
nail surgery,class_id,nail surgery,class_id,34029250
surgical intervention,class_id,surgical intervention,class_id,34029250
partial matricectomy,class_id,partial matricectomy,class_id,34029250
highrisk neuroblastoma,semantic_types,highrisk neuroblastoma,semantic_types,34028986
131 imibg,preferred_label,131 imibg,preferred_label,34028986
sinusoidal obstruction syndrome,preferred_label,sinusoidal obstruction syndrome,preferred_label,34028986
18 mcikg,preferred_label,18 mcikg,preferred_label,34028986
induction chemotherapy,preferred_label,induction chemotherapy,preferred_label,34028986
myeloablative therapy,preferred_label,myeloablative therapy,preferred_label,34028986
bumel,preferred_label,bumel,preferred_label,34028986
cooperative randomized trial,preferred_label,cooperative randomized trial,preferred_label,34028986
etoposide ifosfamide and cisplatin,preferred_label,etoposide ifosfamide and cisplatin,preferred_label,34028113
pegfilgrastim,preferred_label,pegfilgrastim,preferred_label,34028113
disseminated germ cell cancer,preferred_label,disseminated germ cell cancer,preferred_label,34028113
patient,preferred_label,patient,preferred_label,34028113
short-acting granulocyte colony-stimulating factor,preferred_label,short-acting granulocyte colony-stimulating factor,preferred_label,34028113
myelosuppression,preferred_label,myelosuppression,preferred_label,34028113
metastatic clear cell renal cell carcinoma,class_id,metastatic clear cell renal cell carcinoma,class_id,34027908
nivolumab therapy,preferred_label,nivolumab therapy,preferred_label,34027908
late-onset ocular toxicity,preferred_label,late-onset ocular toxicity,preferred_label,34027908
choroidal metastasis,preferred_label,choroidal metastasis,preferred_label,34027908
choroidal thickening,preferred_label,choroidal thickening,preferred_label,34027908
choroidal fold,preferred_label,choroidal fold,preferred_label,34027908
uveitis,synonyms,uveitis,synonyms,34027908
systemic corticosteroid,preferred_label,systemic corticosteroid,preferred_label,34027908
neoadjuvant immunotherapy,semantic_types,neoadjuvant immunotherapy,semantic_types,34024062
chemotherapy,semantic_types,chemotherapy,semantic_types,34024062
nonsmall cell lung cancer,semantic_types,nonsmall cell lung cancer,semantic_types,34024062
clinical trial,semantic_types,clinical trial,semantic_types,34024062
neoadjuvant chemoimmunotherapy,semantic_types,neoadjuvant chemoimmunotherapy,semantic_types,34024062
China,semantic_types,China,semantic_types,34024062
antitumour activity,semantic_types,antitumour activity,semantic_types,34024062
safety,semantic_types,safety,semantic_types,34024062
stage ibiiib nsclc,semantic_types,stage ibiiib nsclc,semantic_types,34024062
patient,semantic_types,patient,semantic_types,34024062
surgical resection,semantic_types,surgical resection,semantic_types,34024062
residual tumor resection,semantic_types,residual tumor resection,semantic_types,34024062
radiographic objective response rate,semantic_types,radiographic objective response rate,semantic_types,34024062
pathologic response,semantic_types,pathologic response,semantic_types,34024062
immunerelated pneumonia,semantic_types,immunerelated pneumonia,semantic_types,34024062
hematologic toxicity,semantic_types,hematologic toxicity,semantic_types,34024062
actinomycin D,preferred_label,actinomycin D,preferred_label,34023919
vincristine,preferred_label,vincristine,preferred_label,34023919
cancer,semantic_types,cancer,semantic_types,34023919
child,semantic_types,child,semantic_types,34023919
blood sample,preferred_label,blood sample,preferred_label,34023919
patient,preferred_label,patient,preferred_label,34023919
pharmacokinetic variability,preferred_label,pharmacokinetic variability,preferred_label,34023919
toxicity,semantic_types,toxicity,semantic_types,34023919
high-performance liquid chromatography-tandem mass spectrometry,preferred_label,high-performance liquid chromatography-tandem mass spectrometry,preferred_label,34023919
noncompartmental method,preferred_label,noncompartmental method,preferred_label,34023919
myelosuppression,semantic_types,myelosuppression,semantic_types,34023919
hepatotoxicity,semantic_types,hepatotoxicity,semantic_types,34023919
neuropathy,semantic_types,neuropathy,semantic_types,34023919
age,preferred_label,age,preferred_label,34023919
body surface area (BSA),preferred_label,body surface area (BSA),preferred_label,34023919
infant,semantic_types,infant,semantic_types,34023919
dose reduction,preferred_label,dose reduction,preferred_label,34023919
BSA-based dosing,preferred_label,BSA-based dosing,preferred_label,34023919
induction chemotherapy,preferred_label,induction chemotherapy,preferred_label,34022697
cisplatin,preferred_label,cisplatin,preferred_label,34022697
fluorouracil,preferred_label,fluorouracil,preferred_label,34022697
taxanes,preferred_label,taxanes,preferred_label,34022697
squamous cell carcinoma of the head and neck (SCCHN),preferred_label,squamous cell carcinoma of the head and neck (SCCHN),preferred_label,34022697
cetuximab,preferred_label,cetuximab,preferred_label,34022697
radiotherapy,preferred_label,radiotherapy,preferred_label,34022697
patient,preferred_label,patient,preferred_label,34022697
adverse event,preferred_label,adverse event,preferred_label,34022697
diffuse large b-cell lymphoma,class_id,diffuse large b-cell lymphoma,class_id,34022150
rituximab,preferred_label,rituximab,preferred_label,34022150
cyclophosphamide,preferred_label,cyclophosphamide,preferred_label,34022150
doxorubicin,preferred_label,doxorubicin,preferred_label,34022150
vincristine,preferred_label,vincristine,preferred_label,34022150
prednisone,preferred_label,prednisone,preferred_label,34022150
malawi,class_id,malawi,class_id,34022150
Kamuzu Central Hospital,class_id,Kamuzu Central Hospital,class_id,34022150
HIV,semantic_types,HIV,semantic_types,34022150
Eastern Cooperative Oncology Group,class_id,Eastern Cooperative Oncology Group,class_id,34022150
CD4 count,preferred_label,CD4 count,preferred_label,34022150
neutrophil count,preferred_label,neutrophil count,preferred_label,34022150
platelet count,preferred_label,platelet count,preferred_label,34022150
serum creatinine concentration,preferred_label,serum creatinine concentration,preferred_label,34022150
bilirubin concentration,preferred_label,bilirubin concentration,preferred_label,34022150
urine pregnancy test,preferred_label,urine pregnancy test,preferred_label,34022150
cytotoxic therapy,preferred_label,cytotoxic therapy,preferred_label,34022150
complete response,preferred_label,complete response,preferred_label,34022150
progression-free survival,preferred_label,progression-free survival,preferred_label,34022150
Influenza vaccination,drug,Influenza vaccination,drug,34021591
Immunerelated adverse event,adverse event,Immunerelated adverse event,adverse event,34021591
Patient receiving immune checkpoint inhibitor (ICIs),patient,Patient receiving immune checkpoint inhibitor (ICIs),patient,34021591
Cancer patient,patient,Cancer patient,patient,34021591
Melanoma,disease,Melanoma,disease,34021591
Lung cancer,disease,Lung cancer,disease,34021591
Antipd,drug,Antipd,drug,34021591
Sarscov2 pandemic,event,Sarscov2 pandemic,event,34021591
clarithromycin,drug,clarithromycin,drug,34021118
lenalidomide,drug,lenalidomide,drug,34021118
dexamethasone,drug,dexamethasone,drug,34021118
multiple myeloma,disease,multiple myeloma,disease,34021118
neutropenia,adverse event,neutropenia,adverse event,34021118
infection,adverse event,infection,adverse event,34021118
toxic death,adverse event outcome,toxic death,adverse event outcome,34021118
steroid,drug,steroid,drug,34021118
elderly population,patient population,elderly population,patient population,34021118
cigb552,preferred_label,cigb552,preferred_label,34019700
commd1,preferred_label,commd1,preferred_label,34019700
lymphocyte CD4,preferred_label,lymphocyte CD4,preferred_label,34019700
lymphocyte CD8,preferred_label,lymphocyte CD8,preferred_label,34019700
tumor,preferred_label,tumor,preferred_label,34019700
pruritic maculopapular rash,preferred_label,pruritic maculopapular rash,preferred_label,34019700
metastatic soft sarcoma,preferred_label,metastatic soft sarcoma,preferred_label,34019700
folfoxiri plus bevacizumab,preferred_label,folfoxiri plus bevacizumab,preferred_label,34019214
metastatic colorectal cancer,semantic_types,metastatic colorectal cancer,semantic_types,34019214
neutropenia,preferred_label,neutropenia,preferred_label,34019214
Asian patient,preferred_label,Asian patient,preferred_label,34019214
capecitabine,preferred_label,capecitabine,preferred_label,34019214
oxaliplatin,preferred_label,oxaliplatin,preferred_label,34019214
irinotecan,preferred_label,irinotecan,preferred_label,34019214
DLTs,preferred_label,DLTs,preferred_label,34019214
febrile neutropenia,preferred_label,febrile neutropenia,preferred_label,34019214
objective response rate,preferred_label,objective response rate,preferred_label,34019214
ventricular myocytes,class_id,ventricular myocytes,class_id,34018126
abnormal prolongation and dispersion of ventricular repolarization,preferred_label,abnormal prolongation and dispersion of ventricular repolarization,preferred_label,34018126
multilead qtc measurement,preferred_label,multilead qtc measurement,preferred_label,34018126
hypokalemia,preferred_label,hypokalemia,preferred_label,34018126
hypomagnesaemia,preferred_label,hypomagnesaemia,preferred_label,34018126
hypocalcemia,preferred_label,hypocalcemia,preferred_label,34018126
torsade de point,preferred_label,torsade de point,preferred_label,34018126
arrhythmia,preferred_label,arrhythmia,preferred_label,34018126
ventricular repolarization reserve,preferred_label,ventricular repolarization reserve,preferred_label,34018126
qt prolongation,preferred_label,qt prolongation,preferred_label,34018126
lead ecg recording,preferred_label,lead ecg recording,preferred_label,34018126
breast cancer,preferred_label,breast cancer,preferred_label,34018126
tamoxifen therapy,preferred_label,tamoxifen therapy,preferred_label,34018126
holter monitoring,preferred_label,holter monitoring,preferred_label,34018126
antibiotic,preferred_label,antibiotic,preferred_label,34018126
bilateral pneumonia,preferred_label,bilateral pneumonia,preferred_label,34018126
covid,preferred_label,covid,preferred_label,34018126
trastuzumab emtansine tdm1,preferred_label,trastuzumab emtansine tdm1,preferred_label,34014777
metastatic breast cancer,semantic_types,metastatic breast cancer,semantic_types,34014777
human epidermal growth factor receptor 2 her2,preferred_label,human epidermal growth factor receptor 2 her2,preferred_label,34014777
thrombocytopenia,preferred_label,thrombocytopenia,preferred_label,34014777
increased serum gammaglutamyl transferase,preferred_label,increased serum gammaglutamyl transferase,preferred_label,34014777
pegteograstim,preferred_label,pegteograstim,preferred_label,34010932
neulapeg,preferred_label,neulapeg,preferred_label,34010932
recombinant human granulocyte colonystimulating factor,preferred_label,recombinant human granulocyte colonystimulating factor,preferred_label,34010932
methoxymaleimidepolyethylene glycol,preferred_label,methoxymaleimidepolyethylene glycol,preferred_label,34010932
filgrastim,preferred_label,filgrastim,preferred_label,34010932
child and adolescent patient,preferred_label,child and adolescent patient,preferred_label,34010932
solid tumor,preferred_label,solid tumor,preferred_label,34010932
toxicity,preferred_label,toxicity,preferred_label,34010932
absolute neutrophil count,preferred_label,absolute neutrophil count,preferred_label,34010932
adverse event,preferred_label,adverse event,preferred_label,34010932
musculoskeletal pain,preferred_label,musculoskeletal pain,preferred_label,34010932
skin nodule,preferred_label,skin nodule,preferred_label,34010932
paroxysmal cough,preferred_label,paroxysmal cough,preferred_label,34010932
urticaria,preferred_label,urticaria,preferred_label,34010932
rash,preferred_label,rash,preferred_label,34010932
itching,preferred_label,itching,preferred_label,34010932
gastroenteropancreatic neuroendocrine tumor,class_id,gastroenteropancreatic neuroendocrine tumor,class_id,34010146
177Lu-octreotate,preferred_label,177Lu-octreotate,preferred_label,34010146
capecitabine,preferred_label,capecitabine,preferred_label,34010146
temozolomide,preferred_label,temozolomide,preferred_label,34010146
hematologic toxicity,preferred_label,hematologic toxicity,preferred_label,34010146
myelodysplastic syndrome,preferred_label,myelodysplastic syndrome,preferred_label,34010146
progressive disease,preferred_label,progressive disease,preferred_label,34010146
endometrial cancer,class_id,endometrial cancer,class_id,34008039
pioglitazone,class_id,pioglitazone,class_id,34008039
peroxisome proliferator-activated receptor gamma,class_id,peroxisome proliferator-activated receptor gamma,class_id,34008039
female Swiss albino mouse,class_id,female Swiss albino mouse,class_id,34008039
nethylnnitrosourea,class_id,nethylnnitrosourea,class_id,34008039
estradiol hexadrobenzoate,class_id,estradiol hexadrobenzoate,class_id,34008039
paclitaxel,class_id,paclitaxel,class_id,34008039
childhood acute lymphoblastic leukemia,class_id,childhood acute lymphoblastic leukemia,class_id,34003566
dexamethasone,preferred_label,dexamethasone,preferred_label,34003566
prednisone,preferred_label,prednisone,preferred_label,34003566
methotrexate,preferred_label,methotrexate,preferred_label,34003566
hospitalization,preferred_label,hospitalization,preferred_label,34003566
emergency department visit,preferred_label,emergency department visit,preferred_label,34003566
cytokine,preferred_label,cytokine,preferred_label,34003395
immune system,preferred_label,immune system,preferred_label,34003395
cancer,preferred_label,cancer,preferred_label,34003395
doselimiting toxicity,preferred_label,doselimiting toxicity,preferred_label,34003395
melanoma,preferred_label,melanoma,preferred_label,34003395
pharmacokinetics,preferred_label,pharmacokinetics,preferred_label,34003395
safety,preferred_label,safety,preferred_label,34003395
efficacy,preferred_label,efficacy,preferred_label,34003395
pegylated il2,preferred_label,pegylated il2,preferred_label,34003395
nktr214,preferred_label,nktr214,preferred_label,34003395
pegylated il10,preferred_label,pegylated il10,preferred_label,34003395
am0010,preferred_label,am0010,preferred_label,34003395
il15 super agonist alt803,preferred_label,il15 super agonist alt803,preferred_label,34003395
clinical trial,preferred_label,clinical trial,preferred_label,34003395
clinical activity,preferred_label,clinical activity,preferred_label,34003395
combination therapy,preferred_label,combination therapy,preferred_label,34003395
mechanism of action,preferred_label,mechanism of action,preferred_label,34003395
gastric cancer,class_id,gastric cancer,class_id,34003074
afatinib,class_id,afatinib,class_id,34003074
cisplatin,class_id,cisplatin,class_id,34003074
5fu,class_id,5fu,class_id,34003074
erbb transmembrane receptor family,class_id,erbb transmembrane receptor family,class_id,34003074
her2,class_id,her2,class_id,34003074
tp53,class_id,tp53,class_id,34003074
brca2,class_id,brca2,class_id,34003074
smad4,class_id,smad4,class_id,34003074
neutrophil count,class_id,neutrophil count,class_id,34003074
white blood cell decrease,class_id,white blood cell decrease,class_id,34003074
anemia,class_id,anemia,class_id,34003074
hyperglycemia,class_id,hyperglycemia,class_id,34003074
diarrhea,class_id,diarrhea,class_id,34003074
lymph node metastasis,semantic_types,lymph node metastasis,semantic_types,34001158
locally advanced cervical cancer,semantic_types,locally advanced cervical cancer,semantic_types,34001158
radiotherapy approach,semantic_types,radiotherapy approach,semantic_types,34001158
dose escalation,semantic_types,dose escalation,semantic_types,34001158
simultaneous integrated boost,semantic_types,simultaneous integrated boost,semantic_types,34001158
radical chemoradiation,semantic_types,radical chemoradiation,semantic_types,34001158
weekly cisplatin,semantic_types,weekly cisplatin,semantic_types,34001158
intensity modulated radiotherapy,semantic_types,intensity modulated radiotherapy,semantic_types,34001158
volumetric modulated arc therapy,semantic_types,volumetric modulated arc therapy,semantic_types,34001158
high dose rate brachytherapy,semantic_types,high dose rate brachytherapy,semantic_types,34001158
control cohort,semantic_types,control cohort,semantic_types,34001158
treatment outcome,semantic_types,treatment outcome,semantic_types,34001158
Panitumumab,preferred_label,Panitumumab,preferred_label,34000921
Epidermal growth factor receptor,preferred_label,Epidermal growth factor receptor,preferred_label,34000921
Metastatic colorectal carcinoma,preferred_label,Metastatic colorectal carcinoma,preferred_label,34000921
Interstitial lung disease,preferred_label,Interstitial lung disease,preferred_label,34000921
Pneumomediastinum,preferred_label,Pneumomediastinum,preferred_label,34000921
Subcutaneous emphysema,preferred_label,Subcutaneous emphysema,preferred_label,34000921
FOLFIRI,preferred_label,FOLFIRI,preferred_label,34000921
Methylprednisolone,preferred_label,Methylprednisolone,preferred_label,34000921
mthfr gene,class_id,mthfr gene,class_id,34000920
methotrexate,preferred_label,methotrexate,preferred_label,34000920
acute lymphoblastic leukemia,preferred_label,acute lymphoblastic leukemia,preferred_label,34000920
northern african,preferred_label,northern african,preferred_label,34000920
genomic dna,preferred_label,genomic dna,preferred_label,34000920
haplotype,preferred_label,haplotype,preferred_label,34000920
toxicity score,preferred_label,toxicity score,preferred_label,34000920
hdmtx chemotherapyrelated adverse effect biomarker,preferred_label,hdmtx chemotherapyrelated adverse effect biomarker,preferred_label,34000920
trastuzumab emtansine tdm1,drug,trastuzumab emtansine tdm1,drug,34000917
breast cancer,disease,breast cancer,disease,34000917
pleural effusion,adverse event,pleural effusion,adverse event,34000917
pericardial effusion,adverse event,pericardial effusion,adverse event,34000917
trastuzumab,drug,trastuzumab,drug,34000917
emtansine,drug,emtansine,drug,34000917
maytansine dm1,drug,maytansine dm1,drug,34000917
Locally advanced basal cell carcinoma,preferred_label,Locally advanced basal cell carcinoma,preferred_label,34000246
Cemiplimab,preferred_label,Cemiplimab,preferred_label,34000246
PD1 antibody,synonyms,PD1 antibody,synonyms,34000246
Metastatic basal cell carcinoma,preferred_label,Metastatic basal cell carcinoma,preferred_label,34000246
Eastern Cooperative Oncology Group performance status,preferred_label,Eastern Cooperative Oncology Group performance status,preferred_label,34000246
Hedgehog inhibitor therapy,preferred_label,Hedgehog inhibitor therapy,preferred_label,34000246
Monotherapy,preferred_label,Monotherapy,preferred_label,34000246
Phase 2 trial,preferred_label,Phase 2 trial,preferred_label,34000246
Objective response,preferred_label,Objective response,preferred_label,34000246
Adverse event,preferred_label,Adverse event,preferred_label,34000246
Hypertension,preferred_label,Hypertension,preferred_label,34000246
Colitis,preferred_label,Colitis,preferred_label,34000246
Antitumour activity,preferred_label,Antitumour activity,preferred_label,34000246
catnon trial,preferred_label,catnon trial,preferred_label,34000245
temozolomide,preferred_label,temozolomide,preferred_label,34000245
radiotherapy,preferred_label,radiotherapy,preferred_label,34000245
adult,semantic_types,adult,semantic_types,34000245
glioma,preferred_label,glioma,preferred_label,34000245
idh1,preferred_label,idh1,preferred_label,34000245
idh2,preferred_label,idh2,preferred_label,34000245
mgmt promoter,preferred_label,mgmt promoter,preferred_label,34000245
Merck Sharpe Dohme,preferred_label,Merck Sharpe Dohme,preferred_label,34000245
ra gene,class_id,ra gene,class_id,33998997
human cancer,class_id,human cancer,class_id,33998997
mutation,class_id,mutation,class_id,33998997
oncogenic stress,class_id,oncogenic stress,class_id,33998997
oncoprotein activity,class_id,oncoprotein activity,class_id,33998997
kras gene,class_id,kras gene,class_id,33998997
protein expression,class_id,protein expression,class_id,33998997
tumor suppressor p53,class_id,tumor suppressor p53,class_id,33998997
antiprogrammed cell death1 pd1 antibody,drug,antiprogrammed cell death1 pd1 antibody,drug,33994435
immunerelated adverse event iraes,adverse event,immunerelated adverse event iraes,adverse event,33994435
infectious disease,disease,infectious disease,disease,33994435
tuberculosis,disease,tuberculosis,disease,33994435
nontuberculous mycobacterial infection,disease,nontuberculous mycobacterial infection,disease,33994435
mycobacterium mageritense infection,disease,mycobacterium mageritense infection,disease,33994435
capecitabine,drug,capecitabine,drug,33994039
cardiomyopathy,disease,cardiomyopathy,disease,33994039
acute coronary syndrome,disease,acute coronary syndrome,disease,33994039
arrhythmia,disease,arrhythmia,disease,33994039
coronary vasospasm,disease,coronary vasospasm,disease,33994039
endothelial injury,disease,endothelial injury,disease,33994039
oxidative stress,disease,oxidative stress,disease,33994039
pancreatic cancer,disease,pancreatic cancer,disease,33994039
mild coronary artery disease,disease,mild coronary artery disease,disease,33994039
metastatic colorectal cancer,disease,metastatic colorectal cancer,disease,33993741
regorafenib,drug,regorafenib,drug,33993741
trifluridinetipiracil,drug,trifluridinetipiracil,drug,33993741
phase ib study,clinical trial,phase ib study,clinical trial,33993741
ageritin,preferred_label,ageritin,preferred_label,33993266
ribotoxinlike protein family,class_id,ribotoxinlike protein family,class_id,33993266
basidiomycete,class_id,basidiomycete,class_id,33993266
rnase activity,preferred_label,rnase activity,preferred_label,33993266
sarcinricin loop,preferred_label,sarcinricin loop,preferred_label,33993266
large rrna,preferred_label,large rrna,preferred_label,33993266
divalent cation,preferred_label,divalent cation,preferred_label,33993266
prokaryotic cell,class_id,prokaryotic cell,class_id,33993266
eukaryotic cell,class_id,eukaryotic cell,class_id,33993266
cancer cell,class_id,cancer cell,class_id,33993266
bacterial cell,class_id,bacterial cell,class_id,33993266
liposome,class_id,liposome,class_id,33993266
cholesterol,preferred_label,cholesterol,preferred_label,33993266
chemotherapy,preferred_label,chemotherapy,preferred_label,33992717
thoracic radiation therapy,preferred_label,thoracic radiation therapy,preferred_label,33992717
prophylactic cranial irradiation,preferred_label,prophylactic cranial irradiation,preferred_label,33992717
small cell lung cancer,preferred_label,small cell lung cancer,preferred_label,33992717
etoposidecisplatin chemotherapy,preferred_label,etoposidecisplatin chemotherapy,preferred_label,33992717
patient,preferred_label,patient,preferred_label,33992717
performance status,preferred_label,performance status,preferred_label,33992717
progression-free survival,preferred_label,progression-free survival,preferred_label,33992717
locoregional progression-free survival,preferred_label,locoregional progression-free survival,preferred_label,33992717
toxicity,preferred_label,toxicity,preferred_label,33992717
acute lymphopenia,preferred_label,acute lymphopenia,preferred_label,33992717
esophagitis,preferred_label,esophagitis,preferred_label,33992717
pneumonitis,preferred_label,pneumonitis,preferred_label,33992717
treatment-related death,preferred_label,treatment-related death,preferred_label,33992717
capecitabine,drug,capecitabine,drug,33992087
stereotactic radiotherapy,treatment,stereotactic radiotherapy,treatment,33992087
breast cancer brain metastasis,disease,breast cancer brain metastasis,disease,33992087
patient,class_id,patient,class_id,33992087
lesion,class_id,lesion,class_id,33992087
neuroradiologist,class_id,neuroradiologist,class_id,33992087
metastasis,class_id,metastasis,class_id,33992087
radionecrosis,class_id,radionecrosis,class_id,33992087
adoptive cell therapy,preferred_label,adoptive cell therapy,preferred_label,33990415
tumor-infiltrating t lymphocyte,preferred_label,tumor-infiltrating t lymphocyte,preferred_label,33990415
chimeric antigen receptor,preferred_label,chimeric antigen receptor,preferred_label,33990415
cyclophosphamide,preferred_label,cyclophosphamide,preferred_label,33990415
fludarabine,preferred_label,fludarabine,preferred_label,33990415
total body irradiation,preferred_label,total body irradiation,preferred_label,33990415
metastatic melanoma,preferred_label,metastatic melanoma,preferred_label,33990415
acute lymphoblastic leukemia,preferred_label,acute lymphoblastic leukemia,preferred_label,33990415
neutrophil-to-lymphocyte ratio,preferred_label,neutrophil-to-lymphocyte ratio,preferred_label,33990415
platelet-to-lymphocyte ratio,preferred_label,platelet-to-lymphocyte ratio,preferred_label,33990415
bone marrow suppression,preferred_label,bone marrow suppression,preferred_label,33990415
clinical response,preferred_label,clinical response,preferred_label,33990415
adverse event,preferred_label,adverse event,preferred_label,33990415
hospitalization,preferred_label,hospitalization,preferred_label,33990415
doxorubicin cardiac toxicity,preferred_label,doxorubicin cardiac toxicity,preferred_label,33990361
dexrazoxane cardioprotection,preferred_label,dexrazoxane cardioprotection,preferred_label,33990361
immune checkpoint inhibitor,preferred_label,immune checkpoint inhibitor,preferred_label,33989769
lung cancer,preferred_label,lung cancer,preferred_label,33989769
atezolizumab,preferred_label,atezolizumab,preferred_label,33989769
durvalumab,preferred_label,durvalumab,preferred_label,33989769
nivolumab,preferred_label,nivolumab,preferred_label,33989769
pembrolizumab,preferred_label,pembrolizumab,preferred_label,33989769
immunotherapy,preferred_label,immunotherapy,preferred_label,33989769
chemotherapy,preferred_label,chemotherapy,preferred_label,33989769
immunerelated adverse event,preferred_label,immunerelated adverse event,preferred_label,33989769
irAEs,preferred_label,irAEs,preferred_label,33989769
toxicity,preferred_label,toxicity,preferred_label,33989769
phase iii randomized controlled trial,preferred_label,phase iii randomized controlled trial,preferred_label,33989769
patient,class_id,patient,class_id,33989558
relapsed or refractory diffuse large b-cell lymphoma dlbcl,class_id,relapsed or refractory diffuse large b-cell lymphoma dlbcl,class_id,33989558
loncastuximab tesirine,preferred_label,loncastuximab tesirine,preferred_label,33989558
cddirected antibodydrug conjugate,semantic_types,cddirected antibodydrug conjugate,semantic_types,33989558
non-hodgkin lymphoma,synonyms,non-hodgkin lymphoma,synonyms,33989558
lotis2,class_id,lotis2,class_id,33989558
neutropenia,preferred_label,neutropenia,preferred_label,33989558
thrombocytopenia,preferred_label,thrombocytopenia,preferred_label,33989558
increased gammaglutamyltransferase,preferred_label,increased gammaglutamyltransferase,preferred_label,33989558
antipd1 therapy,preferred_label,antipd1 therapy,preferred_label,33989557
ipilimumab,preferred_label,ipilimumab,preferred_label,33989557
pembrolizumab,preferred_label,pembrolizumab,preferred_label,33989557
nivolumab,preferred_label,nivolumab,preferred_label,33989557
metastatic melanoma,preferred_label,metastatic melanoma,preferred_label,33989557
patient,preferred_label,patient,preferred_label,33989557
ipilimumab monotherapy,preferred_label,ipilimumab monotherapy,preferred_label,33989557
ipilimumab plus antipd1,preferred_label,ipilimumab plus antipd1,preferred_label,33989557
adverse event,preferred_label,adverse event,preferred_label,33989557
diarrhoea,preferred_label,diarrhoea,preferred_label,33989557
colitis,preferred_label,colitis,preferred_label,33989557
alanine aminotransferase,preferred_label,alanine aminotransferase,preferred_label,33989557
aspartate aminotransferase,preferred_label,aspartate aminotransferase,preferred_label,33989557
colon perforation,preferred_label,colon perforation,preferred_label,33989557
immunerelated pancolitis,preferred_label,immunerelated pancolitis,preferred_label,33989557
antibodydrug conjugate,class_id,antibodydrug conjugate,class_id,33988833
cancer,class_id,cancer,class_id,33988833
toxin,class_id,toxin,class_id,33988833
toxicity,class_id,toxicity,class_id,33988833
peripheral neuropathy,class_id,peripheral neuropathy,class_id,33988833
pulmonary toxicity,class_id,pulmonary toxicity,class_id,33988833
skin toxicity,class_id,skin toxicity,class_id,33988833
hepatic toxicity,class_id,hepatic toxicity,class_id,33988833
ocular toxicity,class_id,ocular toxicity,class_id,33988833
hyperglycemia,class_id,hyperglycemia,class_id,33988833
left ventricular dysfunction,class_id,left ventricular dysfunction,class_id,33988833
fluidrelated event,class_id,fluidrelated event,class_id,33988833
offtarget effect,class_id,offtarget effect,class_id,33988833
risk minimization approach,class_id,risk minimization approach,class_id,33988833
physician,class_id,physician,class_id,33988833
healthcare practitioner,class_id,healthcare practitioner,class_id,33988833
apatinib,drug,apatinib,drug,33987959
cervical carcinoma,disease,cervical carcinoma,disease,33987959
patient,person,patient,person,33987959
complete response,outcome,complete response,outcome,33987959
partial response,outcome,partial response,outcome,33987959
stable disease,outcome,stable disease,outcome,33987959
progressive disease,outcome,progressive disease,outcome,33987959
objective response rate,measurement,objective response rate,measurement,33987959
disease control rate,measurement,disease control rate,measurement,33987959
adverse effect,outcome,adverse effect,outcome,33987959
handfoot syndrome,adverse event,handfoot syndrome,adverse event,33987959
hypertension,adverse event,hypertension,adverse event,33987959
fatigue,adverse event,fatigue,adverse event,33987959
grade 3 adverse event,adverse event,grade 3 adverse event,adverse event,33987959
drug-related death,adverse event,drug-related death,adverse event,33987959
progression-free survival,outcome,progression-free survival,outcome,33987959
overall survival,outcome,overall survival,outcome,33987959
phase III clinical trial,study,phase III clinical trial,study,33987959
interleukin2,class_id,interleukin2,class_id,33986267
proIL2,class_id,proIL2,class_id,33986267
cd8 T cell,class_id,cd8 T cell,class_id,33986267
IL2 receptor beta,class_id,IL2 receptor beta,class_id,33986267
tumor-associated protease,class_id,tumor-associated protease,class_id,33986267
antigen-specific CD8 T cell,class_id,antigen-specific CD8 T cell,class_id,33986267
cancer,class_id,cancer,class_id,33986267
immune checkpoint blockade,class_id,immune checkpoint blockade,class_id,33986267
sipuleucelt,drug,sipuleucelt,drug,33986125
ipilimumab,drug,ipilimumab,drug,33986125
metastatic castration-resistant prostate cancer,disease,metastatic castration-resistant prostate cancer,disease,33986125
mCRPC,disease,mCRPC,disease,33986125
antiprostatic acid phosphatase,protein,antiprostatic acid phosphatase,protein,33986125
PA2024,protein,PA2024,protein,33986125
serum prostate-specific antigen,protein,serum prostate-specific antigen,protein,33986125
CD4,cell,CD4,cell,33986125
CD8,cell,CD8,cell,33986125
CTLA4,protein,CTLA4,protein,33986125
radiation therapy,treatment,radiation therapy,treatment,33986125
pancreatic ductal adenocarcinoma,class_id,pancreatic ductal adenocarcinoma,class_id,33985455
gemcitabinenabpaclitaxels1,drug associated with AE,gemcitabinenabpaclitaxels1,drug associated with AE,33985455
patient,class_id,patient,class_id,33985455
Japan,class_id,Japan,class_id,33985455
locally advanced pancreatic cancer,class_id,locally advanced pancreatic cancer,class_id,33985455
phase I trial,class_id,phase I trial,class_id,33985455
maximum tolerated dose,class_id,maximum tolerated dose,class_id,33985455
dose-limiting toxicity,class_id,dose-limiting toxicity,class_id,33985455
Chemotherapy-induced neutropenia,class_id,Chemotherapy-induced neutropenia,class_id,33985435
Non-small cell lung cancer,class_id,Non-small cell lung cancer,class_id,33985435
Overall survival,class_id,Overall survival,class_id,33985435
Severe neutropenia,class_id,Severe neutropenia,class_id,33985435
Mild neutropenia,class_id,Mild neutropenia,class_id,33985435
targeted therapy,preferred_label,targeted therapy,preferred_label,33983833
cardiovascular toxicity,preferred_label,cardiovascular toxicity,preferred_label,33983833
her2 human epidermal growth factor receptor 2 targeted therapy,preferred_label,her2 human epidermal growth factor receptor 2 targeted therapy,preferred_label,33983833
tyrosine kinase inhibitor,preferred_label,tyrosine kinase inhibitor,preferred_label,33983833
immune checkpoint inhibitor,preferred_label,immune checkpoint inhibitor,preferred_label,33983833
proteasome inhibitor,preferred_label,proteasome inhibitor,preferred_label,33983833
androgen deprivation therapy,preferred_label,androgen deprivation therapy,preferred_label,33983833
mek mitogenactivated protein kinase kinasebraf vraf murine sarcoma viral oncogene homolog b inhibitor,preferred_label,mek mitogenactivated protein kinase kinasebraf vraf murine sarcoma viral oncogene homolog b inhibitor,preferred_label,33983833
heart failure,preferred_label,heart failure,preferred_label,33983833
incidence,preferred_label,incidence,preferred_label,33983833
cardiotoxicity,preferred_label,cardiotoxicity,preferred_label,33983833
cardioprotective strategy,preferred_label,cardioprotective strategy,preferred_label,33983833
patient,class_id,patient,class_id,33983589
tumor,class_id,tumor,class_id,33983589
chemotherapy,class_id,chemotherapy,class_id,33983589
variant,class_id,variant,class_id,33983589
drug,class_id,drug,class_id,33983589
enzyme,class_id,enzyme,class_id,33983589
response,class_id,response,class_id,33983589
somatic mutation,class_id,somatic mutation,class_id,33983589
germline variant,class_id,germline variant,class_id,33983589
cancer cell,class_id,cancer cell,class_id,33983589
immune system,class_id,immune system,class_id,33983589
toxicity,class_id,toxicity,class_id,33983589
genomic variation,class_id,genomic variation,class_id,33983589
pharmacokinetics,class_id,pharmacokinetics,class_id,33983589
biomarkers,class_id,biomarkers,class_id,33983589
older and/or frail patient,patient,older and/or frail patient,patient,33983395
landmark cancer trial,clinical trial,landmark cancer trial,clinical trial,33983395
chemotherapy dosing,treatment,chemotherapy dosing,treatment,33983395
advanced gastroesophageal cancer,cancer type,advanced gastroesophageal cancer,cancer type,33983395
geriatric assessment,medical assessment tool,geriatric assessment,medical assessment tool,33983395
chemointensity,chemotherapy regimen,chemointensity,chemotherapy regimen,33983395
chemobsc,treatment comparison,chemobsc,treatment comparison,33983395
overall survival,clinical outcome,overall survival,clinical outcome,33983395
progression-free survival,clinical outcome,progression-free survival,clinical outcome,33983395
toxic effects,side effect,toxic effects,side effect,33983395
quality of life,health-related quality,quality of life,health-related quality,33983395
neutrophil to lymphocyte ratio,biomarker,neutrophil to lymphocyte ratio,biomarker,33983395
glioblastoma gbm,class_id,glioblastoma gbm,class_id,33980886
ln u87,class_id,ln u87,class_id,33980886
t98g,class_id,t98g,class_id,33980886
oxelaidin,class_id,oxelaidin,class_id,33980886
butamirate,class_id,butamirate,class_id,33980886
ra family gtpase rasrelated associated with diabetes rrad,class_id,ra family gtpase rasrelated associated with diabetes rrad,class_id,33980886
stat3,class_id,stat3,class_id,33980886
cyclin d1,class_id,cyclin d1,class_id,33980886
survivin,class_id,survivin,class_id,33980886
pegfr,class_id,pegfr,class_id,33980886
pakt,class_id,pakt,class_id,33980886
pstat,class_id,pstat,class_id,33980886
multiple myeloma,class_id,multiple myeloma,class_id,33980053
ixazomib,class_id,ixazomib,class_id,33980053
oral proteasome inhibitor,class_id,oral proteasome inhibitor,class_id,33980053
chemotherapeutic agent,class_id,chemotherapeutic agent,class_id,33980053
patient,class_id,patient,class_id,33980053
instruction,class_id,instruction,class_id,33980053
male,class_id,male,class_id,33980053
overdose,class_id,overdose,class_id,33980053
adverse effect,class_id,adverse effect,class_id,33980053
toxicity,class_id,toxicity,class_id,33980053
reaction,class_id,reaction,class_id,33980053
antidote,class_id,antidote,class_id,33980053
supportive care,class_id,supportive care,class_id,33980053
breast cancer,class_id,breast cancer,class_id,33979647
cisplatin,class_id,cisplatin,class_id,33979647
palladium complex btc,class_id,palladium complex btc,class_id,33979647
mcf7,class_id,mcf7,class_id,33979647
mdamb231,class_id,mdamb231,class_id,33979647
DNA double strand break,class_id,DNA double strand break,class_id,33979647
h2ax,class_id,h2ax,class_id,33979647
patmpchk2,class_id,patmpchk2,class_id,33979647
ppmapk,class_id,ppmapk,class_id,33979647
cleaved caspase 9,class_id,cleaved caspase 9,class_id,33979647
cleaved caspase 8,class_id,cleaved caspase 8,class_id,33979647
prip3,class_id,prip3,class_id,33979647
pmlkl,class_id,pmlkl,class_id,33979647
paclitaxel,class_id,paclitaxel,class_id,33979647
hairycell leukemia,class_id,hairycell leukemia,class_id,33979489
braf v600e,preferred_label,braf v600e,preferred_label,33979489
bcell cancer,synonyms,bcell cancer,synonyms,33979489
vemurafenib,preferred_label,vemurafenib,preferred_label,33979489
rituximab,preferred_label,rituximab,preferred_label,33979489
thrombocytopenia,preferred_label,thrombocytopenia,preferred_label,33979489
neutropenia,preferred_label,neutropenia,preferred_label,33979489
minimal residual disease,preferred_label,minimal residual disease,preferred_label,33979489
toxic effect,preferred_label,toxic effect,preferred_label,33979489
colorectal cancer liver metastasis,class_id,colorectal cancer liver metastasis,class_id,33977607
capecitabine,preferred_label,capecitabine,preferred_label,33977607
oxaliplatin,preferred_label,oxaliplatin,preferred_label,33977607
adjuvant chemotherapy,preferred_label,adjuvant chemotherapy,preferred_label,33977607
recurrence-free survival,preferred_label,recurrence-free survival,preferred_label,33977607
overall survival,preferred_label,overall survival,preferred_label,33977607
folfirinox,preferred_label,folfirinox,preferred_label,33975561
gemcitabine plus nabpaclitaxel,preferred_label,gemcitabine plus nabpaclitaxel,preferred_label,33975561
metastatic pancreatic cancer,preferred_label,metastatic pancreatic cancer,preferred_label,33975561
chemotherapy,preferred_label,chemotherapy,preferred_label,33975561
patient,preferred_label,patient,preferred_label,33975561
overall survival,preferred_label,overall survival,preferred_label,33975561
progression free survival,preferred_label,progression free survival,preferred_label,33975561
toxicity,preferred_label,toxicity,preferred_label,33975561
adverse event,preferred_label,adverse event,preferred_label,33975561
treatment interruption,preferred_label,treatment interruption,preferred_label,33975561
mortality,preferred_label,mortality,preferred_label,33975561
oxaliplatin resistance,semantic_types,oxaliplatin resistance,semantic_types,33974471
colorectal cancer cell,semantic_types,colorectal cancer cell,semantic_types,33974471
hyaluronic acid,semantic_types,hyaluronic acid,semantic_types,33974471
cd44v6 receptor,semantic_types,cd44v6 receptor,semantic_types,33974471
oxaliplatin liposome nanoparticles,semantic_types,oxaliplatin liposome nanoparticles,semantic_types,33974471
androgen deprivation therapy,treatment,androgen deprivation therapy,treatment,33974005
prostate cancer,disease,prostate cancer,disease,33974005
fatty acid synthase,enzyme,fatty acid synthase,enzyme,33974005
enzalutamide,drug,enzalutamide,drug,33974005
orlistat,drug,orlistat,drug,33974005
PC3 cell line,cell line,PC3 cell line,cell line,33974005
NF-κB,protein,NF-κB,protein,33974005
Nivolumab,drug,Nivolumab,drug,33973307
Ipilimumab,drug,Ipilimumab,drug,33973307
Hepatocellular carcinoma,disease,Hepatocellular carcinoma,disease,33973307
Sorafenib,drug,Sorafenib,drug,33973307
FDA,organization,FDA,organization,33973307
Checkmate,clinical trial,Checkmate,clinical trial,33973307
Chemotherapy-induced toxicity,adverse event occurs in,Chemotherapy-induced toxicity,adverse event occurs in,33973301
Relative Dose Intensity (RDI),drug associated with AE,Relative Dose Intensity (RDI),drug associated with AE,33973301
Survival,adverse event outcome,Survival,adverse event outcome,33973301
Solid Tumor Cancer,has disease,Solid Tumor Cancer,has disease,33973301
Carboplatin-based regimen,may_treat,Carboplatin-based regimen,may_treat,33973301
"FOLFOX, FOLFIRI, or FOLFIRINOX-based regimen",may_treat,"FOLFOX, FOLFIRI, or FOLFIRINOX-based regimen",may_treat,33973301
metastatic colorectal cancer,class_id,metastatic colorectal cancer,class_id,33973081
skin rash,class_id,skin rash,class_id,33973081
vectibix,preferred_label,vectibix,preferred_label,33973081
quality of life,preferred_label,quality of life,preferred_label,33973081
patient education,preferred_label,patient education,preferred_label,33973081
sun protection,preferred_label,sun protection,preferred_label,33973081
oral antibiotic,preferred_label,oral antibiotic,preferred_label,33973081
dermatology life quality index,preferred_label,dermatology life quality index,preferred_label,33973081
tepotinib,drug,tepotinib,drug,33972742
hepatocellular carcinoma,disease,hepatocellular carcinoma,disease,33972742
Asian patients,patient,Asian patients,patient,33972742
MET inhibitor,drug target,MET inhibitor,drug target,33972742
sorafenib,drug,sorafenib,drug,33972742
retinoblastoma,class_id,retinoblastoma,class_id,33972235
melphalan,preferred_label,melphalan,preferred_label,33972235
topotecan,preferred_label,topotecan,preferred_label,33972235
rabbit model,preferred_label,rabbit model,preferred_label,33972235
patient cohort,preferred_label,patient cohort,preferred_label,33972235
vitreous seed,preferred_label,vitreous seed,preferred_label,33972235
toxicity,preferred_label,toxicity,preferred_label,33972235
efficacy,preferred_label,efficacy,preferred_label,33972235
pharmacokinetics,preferred_label,pharmacokinetics,preferred_label,33972235
electroretinography,preferred_label,electroretinography,preferred_label,33972235
histopathology,preferred_label,histopathology,preferred_label,33972235
tumour cell reduction,preferred_label,tumour cell reduction,preferred_label,33972235
apoptosis induction,preferred_label,apoptosis induction,preferred_label,33972235
retrospective cohort study,preferred_label,retrospective cohort study,preferred_label,33972235
intravitreal injection,preferred_label,intravitreal injection,preferred_label,33972235
ic90,preferred_label,ic90,preferred_label,33972235
werirb1 cell xenograft,preferred_label,werirb1 cell xenograft,preferred_label,33972235
oxaliplatinbased therapy,preferred_label,oxaliplatinbased therapy,preferred_label,33971834
folfox4,preferred_label,folfox4,preferred_label,33971834
capox,preferred_label,capox,preferred_label,33971834
adjuvant treatment,preferred_label,adjuvant treatment,preferred_label,33971834
stage iii colon cancer,preferred_label,stage iii colon cancer,preferred_label,33971834
patient,preferred_label,patient,preferred_label,33971834
dose reduction,preferred_label,dose reduction,preferred_label,33971834
early termination,preferred_label,early termination,preferred_label,33971834
chemotherapy,preferred_label,chemotherapy,preferred_label,33971834
oxaliplatin toxicity,preferred_label,oxaliplatin toxicity,preferred_label,33971834
risk of early recurrence,preferred_label,risk of early recurrence,preferred_label,33971834
relationship,preferred_label,relationship,preferred_label,33971834
relative dose intensity of oxaliplatin,preferred_label,relative dose intensity of oxaliplatin,preferred_label,33971834
early recurrence,preferred_label,early recurrence,preferred_label,33971834
oncology center,preferred_label,oncology center,preferred_label,33971834
Poland,preferred_label,Poland,preferred_label,33971834
survival analysis,preferred_label,survival analysis,preferred_label,33971834
Kaplan-Meier method,preferred_label,Kaplan-Meier method,preferred_label,33971834
univariate analysis,preferred_label,univariate analysis,preferred_label,33971834
multivariate analysis,preferred_label,multivariate analysis,preferred_label,33971834
stepwise forward approach,preferred_label,stepwise forward approach,preferred_label,33971834
follow-up,preferred_label,follow-up,preferred_label,33971834
lymph node harvested,preferred_label,lymph node harvested,preferred_label,33971834
adjuvant therapy,preferred_label,adjuvant therapy,preferred_label,33971834
overall survival,preferred_label,overall survival,preferred_label,33971834
neratinib,drug,neratinib,drug,33971386
extended adjuvant treatment,treatment,extended adjuvant treatment,treatment,33971386
human epidermal growth factor receptor positive hormone receptorpositive copositive early breast cancer,disease,human epidermal growth factor receptor positive hormone receptorpositive copositive early breast cancer,disease,33971386
trastuzumab,drug,trastuzumab,drug,33971386
extenet trial,clinical trial,extenet trial,clinical trial,33971386
German health technology assessment,organization,German health technology assessment,organization,33971386
disease-free survival,outcome measure,disease-free survival,outcome measure,33971386
quality of life,outcome measure,quality of life,outcome measure,33971386
gastrointestinal events,adverse event,gastrointestinal events,adverse event,33971386
immune checkpoint inhibitor,class_id,immune checkpoint inhibitor,class_id,33969772
nivolumab,preferred_label,nivolumab,preferred_label,33969772
cancer therapy,semantic_types,cancer therapy,semantic_types,33969772
patient immune system,preferred_label,patient immune system,preferred_label,33969772
toxicities,synonyms,toxicities,synonyms,33969772
pharmacist,preferred_label,pharmacist,preferred_label,33969772
adverse event,preferred_label,adverse event,preferred_label,33969772
clinical trial,semantic_types,clinical trial,semantic_types,33969772
literature data,semantic_types,literature data,semantic_types,33969772
retrospective case note review,preferred_label,retrospective case note review,preferred_label,33969772
common toxicity,synonyms,common toxicity,synonyms,33969772
symptomatic treatment,synonyms,symptomatic treatment,synonyms,33969772
prevalence of adverse event,preferred_label,prevalence of adverse event,preferred_label,33969772
pharmacy practice strategy,preferred_label,pharmacy practice strategy,preferred_label,33969772
ICI toxicity,synonyms,ICI toxicity,synonyms,33969772
gastrointestinal endocrine dermatological toxicity,synonyms,gastrointestinal endocrine dermatological toxicity,synonyms,33969772
fatigue,synonyms,fatigue,synonyms,33969772
multiple drug treatment,drug,multiple drug treatment,drug,33969525
bayesian adaptive phase i clinical trial design,clinical trial design,bayesian adaptive phase i clinical trial design,clinical trial design,33969525
normalized equivalent toxicity score,clinical endpoint,normalized equivalent toxicity score,clinical endpoint,33969525
mtd contour of two drug combination,dose,mtd contour of two drug combination,dose,33969525
logistic linear regression model,statistical model,logistic linear regression model,statistical model,33969525
four parameter in the dosetoxicity model,model parameter,four parameter in the dosetoxicity model,model parameter,33969525
markov chain monte carlo,simulation method,markov chain monte carlo,simulation method,33969525
safety trial efficiency,clinical trial outcome,safety trial efficiency,clinical trial outcome,33969525
platinum doublet,preferred_label,platinum doublet,preferred_label,33967202
gemcitabine,preferred_label,gemcitabine,preferred_label,33967202
platinum agent,preferred_label,platinum agent,preferred_label,33967202
squamous cell lung cancer,preferred_label,squamous cell lung cancer,preferred_label,33967202
cytotoxic regimen,preferred_label,cytotoxic regimen,preferred_label,33967202
maintenance chemotherapy,preferred_label,maintenance chemotherapy,preferred_label,33967202
bone marrow suppression,preferred_label,bone marrow suppression,preferred_label,33967202
htp,class_id,htp,class_id,33965731
cpbmf223,class_id,cpbmf223,class_id,33965731
human colorectal carcinoma cell hct116,class_id,human colorectal carcinoma cell hct116,class_id,33965731
fluorouracil,class_id,fluorouracil,class_id,33965731
zebrafish,class_id,zebrafish,class_id,33965731
mtorc1 inhibition,semantic_types,mtorc1 inhibition,semantic_types,33964572
everolimus,preferred_label,everolimus,preferred_label,33964572
phosphatidylinositol kinase catalytic subunit p110 blockade,preferred_label,phosphatidylinositol kinase catalytic subunit p110 blockade,preferred_label,33964572
alpelisib,preferred_label,alpelisib,preferred_label,33964572
preclinical model,semantic_types,preclinical model,semantic_types,33964572
combination therapy,semantic_types,combination therapy,semantic_types,33964572
dose escalation phase,semantic_types,dose escalation phase,semantic_types,33964572
solid tumor,semantic_types,solid tumor,semantic_types,33964572
breast cancer,semantic_types,breast cancer,semantic_types,33964572
pancreatic neuroendocrine tumor,semantic_types,pancreatic neuroendocrine tumor,semantic_types,33964572
renal cell carcinoma,semantic_types,renal cell carcinoma,semantic_types,33964572
adverse events,semantic_types,adverse events,semantic_types,33964572
pharmacokinetics,semantic_types,pharmacokinetics,semantic_types,33964572
synovial sarcoma,class_id,synovial sarcoma,class_id,33963013
myxoidround cell liposarcoma,class_id,myxoidround cell liposarcoma,class_id,33963013
adoptive cellular therapy,preferred_label,adoptive cellular therapy,preferred_label,33963013
nyeso1,preferred_label,nyeso1,preferred_label,33963013
cyclophosphamide,preferred_label,cyclophosphamide,preferred_label,33963013
peripheral blood mononuclear cell,preferred_label,peripheral blood mononuclear cell,preferred_label,33963013
IL-15,preferred_label,IL-15,preferred_label,33963013
autoimmune disease,preferred_label,autoimmune disease,preferred_label,33963010
ipilimumab,preferred_label,ipilimumab,preferred_label,33963010
antipd1 antibody,preferred_label,antipd1 antibody,preferred_label,33963010
combination therapy,preferred_label,combination therapy,preferred_label,33963010
advanced melanoma,preferred_label,advanced melanoma,preferred_label,33963010
retrospective study,preferred_label,retrospective study,preferred_label,33963010
patient,preferred_label,patient,preferred_label,33963010
toxicity,preferred_label,toxicity,preferred_label,33963010
international center,preferred_label,international center,preferred_label,33963010
rheumatoid arthritis,preferred_label,rheumatoid arthritis,preferred_label,33963010
psoriasis,preferred_label,psoriasis,preferred_label,33963010
inflammatory bowel disease,preferred_label,inflammatory bowel disease,preferred_label,33963010
thyroiditis,preferred_label,thyroiditis,preferred_label,33963010
sjogrens syndrome,preferred_label,sjogrens syndrome,preferred_label,33963010
polymyalgia,preferred_label,polymyalgia,preferred_label,33963010
behcets syndrome,preferred_label,behcets syndrome,preferred_label,33963010
immunotherapy,preferred_label,immunotherapy,preferred_label,33963010
adverse event,preferred_label,adverse event,preferred_label,33963010
immunerelated adverse event,preferred_label,immunerelated adverse event,preferred_label,33963010
adrenocortical carcinoma,class_id,adrenocortical carcinoma,class_id,33962475
mitotane,preferred_label,mitotane,preferred_label,33962475
etoposide,preferred_label,etoposide,preferred_label,33962475
doxorubicin,preferred_label,doxorubicin,preferred_label,33962475
cisplatin,preferred_label,cisplatin,preferred_label,33962475
immune checkpoint inhibitor,preferred_label,immune checkpoint inhibitor,preferred_label,33962475
multityrosine kinase inhibitor,preferred_label,multityrosine kinase inhibitor,preferred_label,33962475
pembrolizumab,preferred_label,pembrolizumab,preferred_label,33962475
microsatellite instability,preferred_label,microsatellite instability,preferred_label,33962475
Lynch syndrome,preferred_label,Lynch syndrome,preferred_label,33962475
cortisol secretion,preferred_label,cortisol secretion,preferred_label,33962475
acute myeloid leukaemia,class_id,acute myeloid leukaemia,class_id,33961292
tosedostat,preferred_label,tosedostat,preferred_label,33961292
older patient,preferred_label,older patient,preferred_label,33961292
lowdose cytosine arabinoside,synonyms,lowdose cytosine arabinoside,synonyms,33961292
pickawinner li1 trial,preferred_label,pickawinner li1 trial,preferred_label,33961292
chemotherapeutic agent,preferred_label,chemotherapeutic agent,preferred_label,33961140
nuclear cardiac imaging,preferred_label,nuclear cardiac imaging,preferred_label,33961140
cardiotoxicity,preferred_label,cardiotoxicity,preferred_label,33961140
cancer therapeuticsrelated cardiac dysfunction,preferred_label,cancer therapeuticsrelated cardiac dysfunction,preferred_label,33961140
mortality,preferred_label,mortality,preferred_label,33961140
chemotherapy,preferred_label,chemotherapy,preferred_label,33961140
cardiac function,preferred_label,cardiac function,preferred_label,33961140
adverse effect,preferred_label,adverse effect,preferred_label,33961140
nuclear imaging technique,preferred_label,nuclear imaging technique,preferred_label,33961140
radio nucleotide angiography,preferred_label,radio nucleotide angiography,preferred_label,33961140
myocardial perfusion imaging,preferred_label,myocardial perfusion imaging,preferred_label,33961140
echocardiography,preferred_label,echocardiography,preferred_label,33961140
cardiac magnetic resonance imaging,preferred_label,cardiac magnetic resonance imaging,preferred_label,33961140
obinutuzumab,drug,obinutuzumab,drug,33961019
idelalisib,drug,idelalisib,drug,33961019
waldenstrm macroglobulinemia,disease,waldenstrm macroglobulinemia,disease,33961019
patient,class_id,patient,class_id,33961019
cxcr4,class_id,cxcr4,class_id,33961019
tp53,class_id,tp53,class_id,33961019
neutropenia,adverse event,neutropenia,adverse event,33961019
diarrhea,adverse event,diarrhea,adverse event,33961019
liver toxicity,adverse event,liver toxicity,adverse event,33961019
trabectedin,drug,trabectedin,drug,33960681
cardiac dysfunction,adverse event,cardiac dysfunction,adverse event,33960681
soft tissue sarcoma,disease,soft tissue sarcoma,disease,33960681
ovarian cancer,disease,ovarian cancer,disease,33960681
pegylated liposomal doxorubicin,drug,pegylated liposomal doxorubicin,drug,33960681
cardiovascular medical history,medical history,cardiovascular medical history,medical history,33960681
age 65 years,age group,age 65 years,age group,33960681
prior cardiac medication,medication,prior cardiac medication,medication,33960681
primary central nervous system lymphoma,class_id,primary central nervous system lymphoma,class_id,33960535
rituximab,class_id,rituximab,class_id,33960535
methotrexate,class_id,methotrexate,class_id,33960535
University Hospital of Cologne,class_id,University Hospital of Cologne,class_id,33960535
anlotinib,drug,anlotinib,drug,33960145
small cell lung cancer,disease,small cell lung cancer,disease,33960145
progression-free survival,clinical parameter,progression-free survival,clinical parameter,33960145
overall survival,clinical parameter,overall survival,clinical parameter,33960145
second-line treatment,treatment type,second-line treatment,treatment type,33960145
combination therapy,treatment type,combination therapy,treatment type,33960145
adverse events,clinical parameter,adverse events,clinical parameter,33960145
hoarseness,adverse event,hoarseness,adverse event,33960145
fatigue,adverse event,fatigue,adverse event,33960145
decreased appetite,adverse event,decreased appetite,adverse event,33960145
oral mucositis,adverse event,oral mucositis,adverse event,33960145
anemia,adverse event,anemia,adverse event,33960145
Durvalumab,drug,Durvalumab,drug,33960102
Bladder cancer,disease,Bladder cancer,disease,33960102
Suburothelial injection,procedure,Suburothelial injection,procedure,33960102
Lymphocyte,cell,Lymphocyte,cell,33960102
Macrophage,cell,Macrophage,cell,33960102
Radical cystectomy,procedure,Radical cystectomy,procedure,33960102
nudt15,preferred_label,nudt15,preferred_label,33958640
tpmt variant,preferred_label,tpmt variant,preferred_label,33958640
thiopurine-induced hematological toxicity,preferred_label,thiopurine-induced hematological toxicity,preferred_label,33958640
homozygous crim1,preferred_label,homozygous crim1,preferred_label,33958640
acute lymphoblastic leukemia,preferred_label,acute lymphoblastic leukemia,preferred_label,33958640
whole-exome sequencing,preferred_label,whole-exome sequencing,preferred_label,33958640
mercaptopurine,preferred_label,mercaptopurine,preferred_label,33958640
il6 rs13306435,preferred_label,il6 rs13306435,preferred_label,33958640
pediatric all patient,preferred_label,pediatric all patient,preferred_label,33958640
four-gene-interplay model,preferred_label,four-gene-interplay model,preferred_label,33958640
pembrolizumablenvatinib,preferred_label,pembrolizumablenvatinib,preferred_label,33958211
lenvatinib,preferred_label,lenvatinib,preferred_label,33958211
endometrial cancer,preferred_label,endometrial cancer,preferred_label,33958211
reduced lenvatinib starting dose,preferred_label,reduced lenvatinib starting dose,preferred_label,33958211
recurrent endometrial cancer,preferred_label,recurrent endometrial cancer,preferred_label,33958211
carcinosarcoma histology,preferred_label,carcinosarcoma histology,preferred_label,33958211
patient,class_id,patient,class_id,33957881
adjuvant chemotherapy,preferred_label,adjuvant chemotherapy,preferred_label,33957881
s1,preferred_label,s1,preferred_label,33957881
nonsmall cell lung cancer,preferred_label,nonsmall cell lung cancer,preferred_label,33957881
adverse event,preferred_label,adverse event,preferred_label,33957881
liposomal irinotecan,preferred_label,liposomal irinotecan,preferred_label,33957442
oxaliplatin,preferred_label,oxaliplatin,preferred_label,33957442
fluorouracil,preferred_label,fluorouracil,preferred_label,33957442
leucovorin,preferred_label,leucovorin,preferred_label,33957442
pancreatic ductal adenocarcinoma,preferred_label,pancreatic ductal adenocarcinoma,preferred_label,33957442
patient,preferred_label,patient,preferred_label,33957442
metastatic disease,preferred_label,metastatic disease,preferred_label,33957442
neutropenia,preferred_label,neutropenia,preferred_label,33957442
febrile neutropenia,preferred_label,febrile neutropenia,preferred_label,33957442
hypokalaemia,preferred_label,hypokalaemia,preferred_label,33957442
progression-free survival,preferred_label,progression-free survival,preferred_label,33957442
overall survival,preferred_label,overall survival,preferred_label,33957442
randomised controlled phase iii study,preferred_label,randomised controlled phase iii study,preferred_label,33957442
primary central nervous system lymphoma,class_id,primary central nervous system lymphoma,class_id,33956047
high-dose therapy and autologous hematopoietic cell transplant,class_id,high-dose therapy and autologous hematopoietic cell transplant,class_id,33956047
thiotepa-busulfan-cyclophosphamide (TBC),class_id,thiotepa-busulfan-cyclophosphamide (TBC),class_id,33956047
thiotepa-carmustine (TTBCNU),class_id,thiotepa-carmustine (TTBCNU),class_id,33956047
carmustine-etoposide-cytarabine-melphalan (BEAM),class_id,carmustine-etoposide-cytarabine-melphalan (BEAM),class_id,33956047
regorafenib,drug,regorafenib,drug,33952483
trifluridine-tipiracil,drug,trifluridine-tipiracil,drug,33952483
metastatic colorectal cancer,disease,metastatic colorectal cancer,disease,33952483
overall survival,outcome,overall survival,outcome,33952483
patient,person,patient,person,33952483
toxicity event,adverse event,toxicity event,adverse event,33952483
disease control rate,outcome,disease control rate,outcome,33952483
cancer growth,process,cancer growth,process,33952483
pancreatic cancer,class_id,pancreatic cancer,class_id,33952409
neoadjuvant treatment,class_id,neoadjuvant treatment,class_id,33952409
overall survival,class_id,overall survival,class_id,33952409
recurrence-free survival,class_id,recurrence-free survival,class_id,33952409
borderline resectable pancreatic cancer,class_id,borderline resectable pancreatic cancer,class_id,33952409
locally advanced pancreatic cancer,class_id,locally advanced pancreatic cancer,class_id,33952409
gemcitabine,class_id,gemcitabine,class_id,33952409
Abraxane,class_id,Abraxane,class_id,33952409
FOLFIRINOX,class_id,FOLFIRINOX,class_id,33952409
radiotherapy,class_id,radiotherapy,class_id,33952409
lymph node,class_id,lymph node,class_id,33952409
tumour size,class_id,tumour size,class_id,33952409
adverse event,class_id,adverse event,class_id,33952409
pathological response,class_id,pathological response,class_id,33952409
disease biology,class_id,disease biology,class_id,33952409
surgery,class_id,surgery,class_id,33952409
toxic keratopathy,semantic_types,toxic keratopathy,semantic_types,33951900
cytarabine chemotherapy,semantic_types,cytarabine chemotherapy,semantic_types,33951900
loteprednol etabonate,preferred_label,loteprednol etabonate,preferred_label,33951900
acute myeloid leukemia,semantic_types,acute myeloid leukemia,semantic_types,33951900
ocular discomfort,semantic_types,ocular discomfort,semantic_types,33951900
photophobia,semantic_types,photophobia,semantic_types,33951900
blurred vision,semantic_types,blurred vision,semantic_types,33951900
corneal epithelial microcysts,semantic_types,corneal epithelial microcysts,semantic_types,33951900
in vivo confocal microscopy,preferred_label,in vivo confocal microscopy,preferred_label,33951900
granular opacity,semantic_types,granular opacity,semantic_types,33951900
irregular intraepithelial opacity,semantic_types,irregular intraepithelial opacity,semantic_types,33951900
basal epithelial layer,semantic_types,basal epithelial layer,semantic_types,33951900
dexamethasone,preferred_label,dexamethasone,preferred_label,33951900
prednisolone phosphate,preferred_label,prednisolone phosphate,preferred_label,33951900
sarcopenia,preferred_label,sarcopenia,preferred_label,33951292
lung cancer,preferred_label,lung cancer,preferred_label,33951292
afatinib,preferred_label,afatinib,preferred_label,33951292
epidermal growth factor receptor,preferred_label,epidermal growth factor receptor,preferred_label,33951292
nonsmall cell lung cancer,preferred_label,nonsmall cell lung cancer,preferred_label,33951292
diarrhea,preferred_label,diarrhea,preferred_label,33951292
rash,preferred_label,rash,preferred_label,33951292
paronychia,preferred_label,paronychia,preferred_label,33951292
dose reduction,preferred_label,dose reduction,preferred_label,33951292
progression-free survival,preferred_label,progression-free survival,preferred_label,33951292
cancer stem cell,class_id,cancer stem cell,class_id,33948856
prostate cancer,class_id,prostate cancer,class_id,33948856
sonic hedgehog,class_id,sonic hedgehog,class_id,33948856
zoledronic acid,class_id,zoledronic acid,class_id,33948856
hepatocellular carcinoma,class_id,hepatocellular carcinoma,class_id,33948697
transarterial chemoembolization,class_id,transarterial chemoembolization,class_id,33948697
sorafenib,class_id,sorafenib,class_id,33948697
macrovascular invasion,class_id,macrovascular invasion,class_id,33948697
radiologic response,class_id,radiologic response,class_id,33948697
sorafenib-related dermatologic toxicity,class_id,sorafenib-related dermatologic toxicity,class_id,33948697
hdac6,class_id,hdac6,class_id,33947698
ka2507,class_id,ka2507,class_id,33947698
melanoma,class_id,melanoma,class_id,33947698
colorectal cancer,class_id,colorectal cancer,class_id,33947698
syngeneic tumorbearing mouse,class_id,syngeneic tumorbearing mouse,class_id,33947698
patient,class_id,patient,class_id,33947698
adenoid cystic carcinoma,class_id,adenoid cystic carcinoma,class_id,33947698
rectal adenocarcinoma,class_id,rectal adenocarcinoma,class_id,33947698
veliparib,preferred_label,veliparib,preferred_label,33947690
carboplatin,preferred_label,carboplatin,preferred_label,33947690
etoposide,preferred_label,etoposide,preferred_label,33947690
small cell lung cancer,preferred_label,small cell lung cancer,preferred_label,33947690
edsclc,preferred_label,edsclc,preferred_label,33947690
chemotherapy,preferred_label,chemotherapy,preferred_label,33947690
progression-free survival,preferred_label,progression-free survival,preferred_label,33947690
overall survival,preferred_label,overall survival,preferred_label,33947690
adverse event,preferred_label,adverse event,preferred_label,33947690
hematologic,preferred_label,hematologic,preferred_label,33947690
platinum,preferred_label,platinum,preferred_label,33947690
first-line treatment,preferred_label,first-line treatment,preferred_label,33947690
biomarkers,preferred_label,biomarkers,preferred_label,33947690
axitinib,drug,axitinib,drug,33947608
immunooncology therapy,treatment,immunooncology therapy,treatment,33947608
renal cell carcinoma,disease,renal cell carcinoma,disease,33947608
toxicity,adverse event,toxicity,adverse event,33947608
time to resolution,clinical parameter,time to resolution,clinical parameter,33947608
diarrhea,adverse event,diarrhea,adverse event,33947608
fatigue,adverse event,fatigue,adverse event,33947608
hypertension,adverse event,hypertension,adverse event,33947608
nausea,adverse event,nausea,adverse event,33947608
palmarplantar erythrodysesthesia syndrome,adverse event,palmarplantar erythrodysesthesia syndrome,adverse event,33947608
differentiation syndrome,class_id,differentiation syndrome,class_id,33947461
acute promyelocytic leukaemia,class_id,acute promyelocytic leukaemia,class_id,33947461
alltrans retinoic acid,class_id,alltrans retinoic acid,class_id,33947461
arsenic trioxide,class_id,arsenic trioxide,class_id,33947461
inflammatory response syndrome,class_id,inflammatory response syndrome,class_id,33947461
shock,class_id,shock,class_id,33947461
lung nodule,class_id,lung nodule,class_id,33947461
groundglass opacity,class_id,groundglass opacity,class_id,33947461
total leukocyte count,class_id,total leukocyte count,class_id,33947461
Indian girl,class_id,Indian girl,class_id,33947461
chemotherapy regimen,class_id,chemotherapy regimen,class_id,33947461
dexamethasone,class_id,dexamethasone,class_id,33947461
ventilatory support,class_id,ventilatory support,class_id,33947461
chest radiograph,class_id,chest radiograph,class_id,33947461
computed tomography,class_id,computed tomography,class_id,33947461
bacterial infection,class_id,bacterial infection,class_id,33947461
viral infection,class_id,viral infection,class_id,33947461
fungal infection,class_id,fungal infection,class_id,33947461
pulmonary hemorrhage,class_id,pulmonary hemorrhage,class_id,33947461
leukostasis,class_id,leukostasis,class_id,33947461
cancer,class_id,cancer,class_id,33946916
chemotherapy,class_id,chemotherapy,class_id,33946916
drug resistance,class_id,drug resistance,class_id,33946916
multitarget chemotherapy,class_id,multitarget chemotherapy,class_id,33946916
hybrid drug,class_id,hybrid drug,class_id,33946916
signaling network,class_id,signaling network,class_id,33946916
cancer cell proliferation,class_id,cancer cell proliferation,class_id,33946916
pharmacokinetic profile,class_id,pharmacokinetic profile,class_id,33946916
drug interaction,class_id,drug interaction,class_id,33946916
patient compliance,class_id,patient compliance,class_id,33946916
adverse reaction,class_id,adverse reaction,class_id,33946916
toxicity,class_id,toxicity,class_id,33946916
drug development,class_id,drug development,class_id,33946916
Trastuzumab deruxtecan,drug,Trastuzumab deruxtecan,drug,33946310
Her2,protein,Her2,protein,33946310
Breast cancer,disease,Breast cancer,disease,33946310
Gastric cancer,disease,Gastric cancer,disease,33946310
Nonsmall cell lung cancer (NSCLC),disease,Nonsmall cell lung cancer (NSCLC),disease,33946310
Colorectal cancer,disease,Colorectal cancer,disease,33946310
Fluorouracil,drug associated with AE,Fluorouracil,drug associated with AE,33945215
Docetaxel,drug associated with AE,Docetaxel,drug associated with AE,33945215
Cisplatin,drug associated with AE,Cisplatin,drug associated with AE,33945215
Nasopharyngeal carcinoma,has disease,Nasopharyngeal carcinoma,has disease,33945215
nanozymes,class_id,nanozymes,class_id,33942817
manganese dioxide nanoparticles,class_id,manganese dioxide nanoparticles,class_id,33942817
paclitaxel,class_id,paclitaxel,class_id,33942817
chlorin e6,class_id,chlorin e6,class_id,33942817
oxygen,class_id,oxygen,class_id,33942817
tumor cell,class_id,tumor cell,class_id,33942817
liposome,class_id,liposome,class_id,33942817
chemoresistance,class_id,chemoresistance,class_id,33942817
contrast agent,class_id,contrast agent,class_id,33942817
magnetic resonance imaging,class_id,magnetic resonance imaging,class_id,33942817
chemotherapy,class_id,chemotherapy,class_id,33942817
photodynamic therapy,class_id,photodynamic therapy,class_id,33942817
bearing tumor mouse,class_id,bearing tumor mouse,class_id,33942817
atezolizumab,drug,atezolizumab,drug,33941055
nivolumab,drug,nivolumab,drug,33941055
pembrolizumab,drug,pembrolizumab,drug,33941055
nonsmall cell lung cancer,disease,nonsmall cell lung cancer,disease,33941055
metastasis,disease,metastasis,disease,33941055
vitiligo,adverse event,vitiligo,adverse event,33941055
overall survival,outcome measurement,overall survival,outcome measurement,33941055
progression free survival,outcome measurement,progression free survival,outcome measurement,33941055
pregnancy associated breast cancer,class_id,pregnancy associated breast cancer,class_id,33939895
breast cancer,class_id,breast cancer,class_id,33939895
patient,class_id,patient,class_id,33939895
tumour,class_id,tumour,class_id,33939895
international guideline,class_id,international guideline,class_id,33939895
maternal outcome,class_id,maternal outcome,class_id,33939895
institutional electronic database,class_id,institutional electronic database,class_id,33939895
case series,class_id,case series,class_id,33939895
tertiary institution,class_id,tertiary institution,class_id,33939895
treatment plan,class_id,treatment plan,class_id,33939895
systemic chemotherapy,class_id,systemic chemotherapy,class_id,33939895
delivery,class_id,delivery,class_id,33939895
adverse effect,class_id,adverse effect,class_id,33939895
complication,class_id,complication,class_id,33939895
blue dye,class_id,blue dye,class_id,33939895
unborn child,class_id,unborn child,class_id,33939895
multidisciplinary approach,class_id,multidisciplinary approach,class_id,33939895
argininelysine,preferred_label,argininelysine,preferred_label,33939662
radiolabeled somatostatin analog,preferred_label,radiolabeled somatostatin analog,preferred_label,33939662
netter1 trial,preferred_label,netter1 trial,preferred_label,33939662
commercial aa formulation,preferred_label,commercial aa formulation,preferred_label,33939662
177ludotatyroctreotate dotatate,preferred_label,177ludotatyroctreotate dotatate,preferred_label,33939662
earlyaccess program,preferred_label,earlyaccess program,preferred_label,33939662
larginine llysine,preferred_label,larginine llysine,preferred_label,33939662
nacl,preferred_label,nacl,preferred_label,33939662
nauseavomiting,preferred_label,nauseavomiting,preferred_label,33939662
eap patient,preferred_label,eap patient,preferred_label,33939662
clinisol,preferred_label,clinisol,preferred_label,33939662
infusion-related reaction,preferred_label,infusion-related reaction,preferred_label,33939662
infusion duration,preferred_label,infusion duration,preferred_label,33939662
Systemic antineoplastic agent,drug,Systemic antineoplastic agent,drug,33939491
Obese adult with cancer,patient,Obese adult with cancer,patient,33939491
Chemotherapy,treatment,Chemotherapy,treatment,33939491
Immunotherapy,treatment,Immunotherapy,treatment,33939491
Targeted therapy,treatment,Targeted therapy,treatment,33939491
idh1,class_id,idh1,class_id,33939107
idh2,class_id,idh2,class_id,33939107
acute myeloid leukemia,class_id,acute myeloid leukemia,class_id,33939107
ivosidenib,class_id,ivosidenib,class_id,33939107
enasidenib,class_id,enasidenib,class_id,33939107
differentiation syndrome,class_id,differentiation syndrome,class_id,33939107
hypomethylating agent,class_id,hypomethylating agent,class_id,33939107
venetoclax,class_id,venetoclax,class_id,33939107
intensitymodulated radiotherapy,preferred_label,intensitymodulated radiotherapy,preferred_label,33938967
cervical cancer,preferred_label,cervical cancer,preferred_label,33938967
volumetric modulated arc therapy,preferred_label,volumetric modulated arc therapy,preferred_label,33938967
3d conformal radiotherapy,preferred_label,3d conformal radiotherapy,preferred_label,33938967
patient,preferred_label,patient,preferred_label,33938967
treatment-related parameter,preferred_label,treatment-related parameter,preferred_label,33938967
side effect,preferred_label,side effect,preferred_label,33938967
late toxicity,preferred_label,late toxicity,preferred_label,33938967
small bowel toxicity,preferred_label,small bowel toxicity,preferred_label,33938967
urinary toxicity,preferred_label,urinary toxicity,preferred_label,33938967
body mass index,preferred_label,body mass index,preferred_label,33938967
multivariable model,preferred_label,multivariable model,preferred_label,33938967
nonhodgkin lymphoma,class_id,nonhodgkin lymphoma,class_id,33938097
chemotherapy,class_id,chemotherapy,class_id,33938097
hemodialysis,class_id,hemodialysis,class_id,33938097
drug,class_id,drug,class_id,33938097
kidney,class_id,kidney,class_id,33938097
metabolite,class_id,metabolite,class_id,33938097
parent drug,class_id,parent drug,class_id,33938097
chemotherapeutics,class_id,chemotherapeutics,class_id,33938097
rituximab,class_id,rituximab,class_id,33938097
cyclophosphamide,class_id,cyclophosphamide,class_id,33938097
vincristine,class_id,vincristine,class_id,33938097
prednisolone,class_id,prednisolone,class_id,33938097
chlorambucil,class_id,chlorambucil,class_id,33938097
ibrutinib,class_id,ibrutinib,class_id,33938097
bendamustine,class_id,bendamustine,class_id,33938097
methotrexate,class_id,methotrexate,class_id,33938097
platinum compound,class_id,platinum compound,class_id,33938097
cytarabine,class_id,cytarabine,class_id,33938097
gemcitabine,class_id,gemcitabine,class_id,33938097
etoposide,class_id,etoposide,class_id,33938097
ifosfamide,class_id,ifosfamide,class_id,33938097
melphalan,class_id,melphalan,class_id,33938097
busulfan,class_id,busulfan,class_id,33938097
fludarabine,class_id,fludarabine,class_id,33938097
mogamulizumab,class_id,mogamulizumab,class_id,33938097
brentuximab vedotin,class_id,brentuximab vedotin,class_id,33938097
90 yibritumomab tiuxetan,class_id,90 yibritumomab tiuxetan,class_id,33938097
immune checkpoint inhibitor,drug,immune checkpoint inhibitor,drug,33937956
cardiovascular toxicity,adverse event,cardiovascular toxicity,adverse event,33937956
myocarditis,disease,myocarditis,disease,33937956
stress cardiomyopathy,disease,stress cardiomyopathy,disease,33937956
pericardial disease,disease,pericardial disease,disease,33937956
atherosclerosis,disease,atherosclerosis,disease,33937956
corticosteroid,drug,corticosteroid,drug,33937956
immune checkpoint inhibitor therapy,treated with drug,immune checkpoint inhibitor therapy,treated with drug,33936037
thymic epithelial tumor,has disease,thymic epithelial tumor,has disease,33936037
metastatic thymoma,has disease,metastatic thymoma,has disease,33936037
antiprogrammed cell death protein 1 pd1 antibody pembrolizumab,drug associated with AE,antiprogrammed cell death protein 1 pd1 antibody pembrolizumab,drug associated with AE,33936037
liver dysfunction,adverse event occurs in,liver dysfunction,adverse event occurs in,33936037
kidney dysfunction,adverse event occurs in,kidney dysfunction,adverse event occurs in,33936037
hypothyroidism,adverse event occurs in,hypothyroidism,adverse event occurs in,33936037
myocarditis,adverse event occurs in,myocarditis,adverse event occurs in,33936037
tumor remission,adverse event outcome,tumor remission,adverse event outcome,33936037
cardiovascular toxicity,semantic_types,cardiovascular toxicity,semantic_types,33934611
chemotherapy,semantic_types,chemotherapy,semantic_types,33934611
novel targeted cancer therapy,semantic_types,novel targeted cancer therapy,semantic_types,33934611
cardiooncology,semantic_types,cardiooncology,semantic_types,33934611
heart failure,semantic_types,heart failure,semantic_types,33934611
arrhythmia,semantic_types,arrhythmia,semantic_types,33934611
myocarditis,semantic_types,myocarditis,semantic_types,33934611
vascular event,semantic_types,vascular event,semantic_types,33934611
genetic and environmental risk factors,semantic_types,genetic and environmental risk factors,semantic_types,33934611
preclinical cardiovascular model,semantic_types,preclinical cardiovascular model,semantic_types,33934611
biomarkers,semantic_types,biomarkers,semantic_types,33934611
cardioprotective therapy,semantic_types,cardioprotective therapy,semantic_types,33934611
cancer treatment,semantic_types,cancer treatment,semantic_types,33934611
pathway,semantic_types,pathway,semantic_types,33934611
cardiovascular homeostasis,semantic_types,cardiovascular homeostasis,semantic_types,33934611
mechanistic understanding,semantic_types,mechanistic understanding,semantic_types,33934611
cardiovascular disease,semantic_types,cardiovascular disease,semantic_types,33934611
scientific statement,semantic_types,scientific statement,semantic_types,33934611
immune-based therapy,preferred_label,immune-based therapy,preferred_label,33934609
cardiovascular sequela,preferred_label,cardiovascular sequela,preferred_label,33934609
treatment,preferred_label,treatment,preferred_label,33934609
complication,preferred_label,complication,preferred_label,33934609
challenge,preferred_label,challenge,preferred_label,33934609
immune therapy,preferred_label,immune therapy,preferred_label,33934609
novel drugs,preferred_label,novel drugs,preferred_label,33934609
antibody,preferred_label,antibody,preferred_label,33934609
biologics,preferred_label,biologics,preferred_label,33934609
immune checkpoint inhibitor,preferred_label,immune checkpoint inhibitor,preferred_label,33934609
bispecific T-cell engagers,preferred_label,bispecific T-cell engagers,preferred_label,33934609
cell-based therapy,preferred_label,cell-based therapy,preferred_label,33934609
chimeric antigen receptor T-cell therapy,preferred_label,chimeric antigen receptor T-cell therapy,preferred_label,33934609
immunotherapy-associated cardiovascular side effects,preferred_label,immunotherapy-associated cardiovascular side effects,preferred_label,33934609
research questions,preferred_label,research questions,preferred_label,33934609
interaction,preferred_label,interaction,preferred_label,33934609
immune system dysregulation,preferred_label,immune system dysregulation,preferred_label,33934609
mechanism of immune activation,preferred_label,mechanism of immune activation,preferred_label,33934609
cardiovascular toxicity,preferred_label,cardiovascular toxicity,preferred_label,33934609
cytokine production,preferred_label,cytokine production,preferred_label,33934609
bortezomib,drug,bortezomib,drug,33934417
peripheral neuropathy,disease,peripheral neuropathy,disease,33934417
multiple myeloma,disease,multiple myeloma,disease,33934417
melphalan,drug,melphalan,drug,33934417
prednisone,drug,prednisone,drug,33934417
VMP,drug regimen,VMP,drug regimen,33934417
patient,individual,patient,individual,33934417
cycle,treatment cycle,cycle,treatment cycle,33934417
progression-free survival,clinical outcome,progression-free survival,clinical outcome,33934417
overall survival,clinical outcome,overall survival,clinical outcome,33934417
kras mutation,semantic_types,kras mutation,semantic_types,33933896
nonsquamous nonsmall cell lung cancer nsclc,semantic_types,nonsquamous nonsmall cell lung cancer nsclc,semantic_types,33933896
therapy targeting the rasmekerk pathway,semantic_types,therapy targeting the rasmekerk pathway,semantic_types,33933896
multicenter openlabel phase 1b trial,semantic_types,multicenter openlabel phase 1b trial,semantic_types,33933896
mekinhibitor binimetinib,semantic_types,mekinhibitor binimetinib,semantic_types,33933896
cisplatin,semantic_types,cisplatin,semantic_types,33933896
pemetrexed,semantic_types,pemetrexed,semantic_types,33933896
stage iiiiv nsclc,semantic_types,stage iiiiv nsclc,semantic_types,33933896
k-ras exon 2 or 3 codon 13 or 61 mutation,semantic_types,k-ras exon 2 or 3 codon 13 or 61 mutation,semantic_types,33933896
systemic therapy,semantic_types,systemic therapy,semantic_types,33933896
part 1 3 3 design,semantic_types,part 1 3 3 design,semantic_types,33933896
dose escalation,semantic_types,dose escalation,semantic_types,33933896
maximum tolerated dose mtd,semantic_types,maximum tolerated dose mtd,semantic_types,33933896
lung infection,semantic_types,lung infection,semantic_types,33933896
fatigue,semantic_types,fatigue,semantic_types,33933896
anemia,semantic_types,anemia,semantic_types,33933896
overall response rate,semantic_types,overall response rate,semantic_types,33933896
progression-free survival,semantic_types,progression-free survival,semantic_types,33933896
overall survival,semantic_types,overall survival,semantic_types,33933896
chemotherapy,semantic_types,chemotherapy,semantic_types,33933896
cisplatin chemoradiotherapy,preferred_label,cisplatin chemoradiotherapy,preferred_label,33933569
head and neck cancer,preferred_label,head and neck cancer,preferred_label,33933569
weekly cisplatin,preferred_label,weekly cisplatin,preferred_label,33933569
threeweekly cisplatin,preferred_label,threeweekly cisplatin,preferred_label,33933569
lasparaginase,class_id,lasparaginase,class_id,33932739
acute lymphoblastic leukemia,class_id,acute lymphoblastic leukemia,class_id,33932739
l-glutaminase,class_id,l-glutaminase,class_id,33932739
pegylated version,class_id,pegylated version,class_id,33932739
dickeya chrysanthemi,class_id,dickeya chrysanthemi,class_id,33932739
nelfinavir,drug,nelfinavir,drug,33932031
cervical cancer,disease,cervical cancer,disease,33932031
radiation,treatment,radiation,treatment,33932031
apoptosis,biological process,apoptosis,biological process,33932031
tumor suppression,biological process,tumor suppression,biological process,33932031
phosphorylated akt,molecular entity,phosphorylated akt,molecular entity,33932031
epidermal growth factor receptor,preferred_label,epidermal growth factor receptor,preferred_label,33931014
tyrosine kinase inhibitor,preferred_label,tyrosine kinase inhibitor,preferred_label,33931014
stereotactic body radiation therapy,preferred_label,stereotactic body radiation therapy,preferred_label,33931014
nsclc,preferred_label,nsclc,preferred_label,33931014
egfr mutation,preferred_label,egfr mutation,preferred_label,33931014
t790m mutation,preferred_label,t790m mutation,preferred_label,33931014
redox abnormality,preferred_label,redox abnormality,preferred_label,33930514
cardiovascular disease,preferred_label,cardiovascular disease,preferred_label,33930514
cancer,preferred_label,cancer,preferred_label,33930514
cardiotoxicity,preferred_label,cardiotoxicity,preferred_label,33930514
anthracyclines,preferred_label,anthracyclines,preferred_label,33930514
oxidative stress,preferred_label,oxidative stress,preferred_label,33930514
antineoplastic targeted drug,preferred_label,antineoplastic targeted drug,preferred_label,33930514
radiotherapy,preferred_label,radiotherapy,preferred_label,33930514
cardiotoxicities,preferred_label,cardiotoxicities,preferred_label,33930514
redox-based antineoplastic treatment,preferred_label,redox-based antineoplastic treatment,preferred_label,33930514
mthfr a1298c mutation,class_id,mthfr a1298c mutation,class_id,33930029
methotrexate,drug,methotrexate,drug,33930029
csf tau,preferred_label,csf tau,preferred_label,33930029
phosphorylated tau,preferred_label,phosphorylated tau,preferred_label,33930029
folinic acid,drug,folinic acid,drug,33930029
chemotherapeutics,preferred_label,chemotherapeutics,preferred_label,33930029
antifolate chemotherapy,preferred_label,antifolate chemotherapy,preferred_label,33930029
metastatic urothelial carcinoma,class_id,metastatic urothelial carcinoma,class_id,33929895
platinum-based combination chemotherapy,preferred_label,platinum-based combination chemotherapy,preferred_label,33929895
checkpoint inhibitor,preferred_label,checkpoint inhibitor,preferred_label,33929895
sacituzumab govitecan,preferred_label,sacituzumab govitecan,preferred_label,33929895
neutropenia,preferred_label,neutropenia,preferred_label,33929895
aflibercept,drug,aflibercept,drug,33929648
arsenic trioxide,drug,arsenic trioxide,drug,33929648
oral squamous cell carcinoma,disease,oral squamous cell carcinoma,disease,33929648
endoglin,protein,endoglin,protein,33929648
VEGFA,protein,VEGFA,protein,33929648
VEGFB,protein,VEGFB,protein,33929648
angiogenesis therapy,preferred_label,angiogenesis therapy,preferred_label,33928747
vascular endothelial growth factor,preferred_label,vascular endothelial growth factor,preferred_label,33928747
VEGF family,preferred_label,VEGF family,preferred_label,33928747
antiangiogenic agent,preferred_label,antiangiogenic agent,preferred_label,33928747
thrombotic risk,preferred_label,thrombotic risk,preferred_label,33928747
bleeding risk,preferred_label,bleeding risk,preferred_label,33928747
venous thromboembolism,preferred_label,venous thromboembolism,preferred_label,33928747
arterial thrombosis,preferred_label,arterial thrombosis,preferred_label,33928747
cancer therapy,preferred_label,cancer therapy,preferred_label,33928747
nonmalignant disorder,preferred_label,nonmalignant disorder,preferred_label,33928747
hereditary hemorrhagic telangiectasia,preferred_label,hereditary hemorrhagic telangiectasia,preferred_label,33928747
neovascular age-related macular degeneration,preferred_label,neovascular age-related macular degeneration,preferred_label,33928747
fluoropyrimidines,preferred_label,fluoropyrimidines,preferred_label,33928618
cancer,preferred_label,cancer,preferred_label,33928618
chemotherapy,preferred_label,chemotherapy,preferred_label,33928618
toxicity,preferred_label,toxicity,preferred_label,33928618
dpd activity,preferred_label,dpd activity,preferred_label,33928618
adverse event,preferred_label,adverse event,preferred_label,33928618
dpyd variant,preferred_label,dpyd variant,preferred_label,33928618
mir27,preferred_label,mir27,preferred_label,33928618
miRNA,preferred_label,miRNA,preferred_label,33928618
panitumumab,drug,panitumumab,drug,33928486
trifluridinetipiracil,drug,trifluridinetipiracil,drug,33928486
wildtype ra metastatic colorectal cancer,disease,wildtype ra metastatic colorectal cancer,disease,33928486
refractory/intolerant to standard therapy,disease,refractory/intolerant to standard therapy,disease,33928486
antiepidermal growth factor receptor therapy,drug,antiepidermal growth factor receptor therapy,drug,33928486
morab202,preferred_label,morab202,preferred_label,33926914
farletuzumab,preferred_label,farletuzumab,preferred_label,33926914
eribulin,preferred_label,eribulin,preferred_label,33926914
cathepsinb,preferred_label,cathepsinb,preferred_label,33926914
folate receptor,preferred_label,folate receptor,preferred_label,33926914
solid tumor,preferred_label,solid tumor,preferred_label,33926914
leukopenia,preferred_label,leukopenia,preferred_label,33926914
neutropenia,preferred_label,neutropenia,preferred_label,33926914
interstitial lung disease,preferred_label,interstitial lung disease,preferred_label,33926914
cardamom,class_id,cardamom,class_id,33926427
cyclophosphamide,class_id,cyclophosphamide,class_id,33926427
Ehrlich solid tumor,class_id,Ehrlich solid tumor,class_id,33926427
mouse,class_id,mouse,class_id,33926427
apoptotic-related gene,class_id,apoptotic-related gene,class_id,33926427
oxidative stress biomarkers,class_id,oxidative stress biomarkers,class_id,33926427
glutathione level,class_id,glutathione level,class_id,33926427
antioxidant enzyme,class_id,antioxidant enzyme,class_id,33926427
liver function biomarkers,class_id,liver function biomarkers,class_id,33926427
kidney function biomarkers,class_id,kidney function biomarkers,class_id,33926427
chronic myeloid leukemia,class_id,chronic myeloid leukemia,class_id,33924068
bcrabl1 protein,preferred_label,bcrabl1 protein,preferred_label,33924068
tyrosine kinase inhibitor,preferred_label,tyrosine kinase inhibitor,preferred_label,33924068
imatinib,synonyms,imatinib,synonyms,33924068
oxidative stress,semantic_types,oxidative stress,semantic_types,33924068
genomic instability,semantic_types,genomic instability,semantic_types,33924068
TKI resistance,preferred_label,TKI resistance,preferred_label,33924068
antioxidant enzyme,preferred_label,antioxidant enzyme,preferred_label,33924068
glutathione,preferred_label,glutathione,preferred_label,33924068
mitochondrial potential,preferred_label,mitochondrial potential,preferred_label,33924068
melanoma,class_id,melanoma,class_id,33921050
decursinol angelate da,preferred_label,decursinol angelate da,preferred_label,33921050
b16f10 cell line,preferred_label,b16f10 cell line,preferred_label,33921050
autophagyrelated protein,preferred_label,autophagyrelated protein,preferred_label,33921050
apoptotic event,preferred_label,apoptotic event,preferred_label,33921050
reactive oxygen specie ro,preferred_label,reactive oxygen specie ro,preferred_label,33921050
mitochondrial membrane potential,preferred_label,mitochondrial membrane potential,preferred_label,33921050
proapoptotic protein bax,preferred_label,proapoptotic protein bax,preferred_label,33921050
bcl2 expression,preferred_label,bcl2 expression,preferred_label,33921050
cytochrome c expression,preferred_label,cytochrome c expression,preferred_label,33921050
nacetyllcysteine nac,preferred_label,nacetyllcysteine nac,preferred_label,33921050
cdk2 protein,preferred_label,cdk2 protein,preferred_label,33921050
cdk4 protein,preferred_label,cdk4 protein,preferred_label,33921050
cyclin d1 protein,preferred_label,cyclin d1 protein,preferred_label,33921050
cyclin e protein,preferred_label,cyclin e protein,preferred_label,33921050
cleaved caspase-9 protein,preferred_label,cleaved caspase-9 protein,preferred_label,33921050
cleaved caspase-3 protein,preferred_label,cleaved caspase-3 protein,preferred_label,33921050
growth factor,preferred_label,growth factor,preferred_label,33915323
chemotherapy-based stem cell mobilization strategy,preferred_label,chemotherapy-based stem cell mobilization strategy,preferred_label,33915323
multiple myeloma,preferred_label,multiple myeloma,preferred_label,33915323
398 patient,preferred_label,398 patient,preferred_label,33915323
cyclophosphamide,preferred_label,cyclophosphamide,preferred_label,33915323
granulocyte colony-stimulating factor (GCSF),preferred_label,granulocyte colony-stimulating factor (GCSF),preferred_label,33915323
plerixafor (PXF),preferred_label,plerixafor (PXF),preferred_label,33915323
CD cell,preferred_label,CD cell,preferred_label,33915323
lenalidomide,preferred_label,lenalidomide,preferred_label,33915323
lurbinectedin,preferred_label,lurbinectedin,preferred_label,33914350
oncogenic transcription,semantic_types,oncogenic transcription,semantic_types,33914350
myelosuppression,preferred_label,myelosuppression,preferred_label,33914350
absolute neutrophil count,preferred_label,absolute neutrophil count,preferred_label,33914350
platelet count,preferred_label,platelet count,preferred_label,33914350
granulocyte colonystimulating factor,preferred_label,granulocyte colonystimulating factor,preferred_label,33914350
gcsf,synonyms,gcsf,synonyms,33914350
cancer patient,semantic_types,cancer patient,semantic_types,33914350
platelet transfusion,preferred_label,platelet transfusion,preferred_label,33914350
cyp3a inhibitor,preferred_label,cyp3a inhibitor,preferred_label,33914350
mb02,preferred_label,mb02,preferred_label,33914256
bevacizumab biosimilar,preferred_label,bevacizumab biosimilar,preferred_label,33914256
reference bevacizumab,preferred_label,reference bevacizumab,preferred_label,33914256
avastin,preferred_label,avastin,preferred_label,33914256
eubevacizumab,preferred_label,eubevacizumab,preferred_label,33914256
stage iiibiv nonsquamous nonsmall cell lung cancer,preferred_label,stage iiibiv nonsquamous nonsmall cell lung cancer,preferred_label,33914256
paclitaxel,preferred_label,paclitaxel,preferred_label,33914256
carboplatin,preferred_label,carboplatin,preferred_label,33914256
radiological review committee,preferred_label,radiological review committee,preferred_label,33914256
progressionfree survival,preferred_label,progressionfree survival,preferred_label,33914256
overall survival,preferred_label,overall survival,preferred_label,33914256
adverse event,preferred_label,adverse event,preferred_label,33914256
hypertension,preferred_label,hypertension,preferred_label,33914256
anemia,preferred_label,anemia,preferred_label,33914256
antidrug antibody,preferred_label,antidrug antibody,preferred_label,33914256
neutralizing antibody,preferred_label,neutralizing antibody,preferred_label,33914256
advanced nonsquamous nsclc,preferred_label,advanced nonsquamous nsclc,preferred_label,33914256
relapsed or refractory acute myeloid leukemia,class_id,relapsed or refractory acute myeloid leukemia,class_id,33914097
selinexor,preferred_label,selinexor,preferred_label,33914097
exportin1 inhibitor,synonyms,exportin1 inhibitor,synonyms,33914097
flagida,preferred_label,flagida,preferred_label,33914097
patient,semantic_types,patient,semantic_types,33914097
dose-limiting toxicity,semantic_types,dose-limiting toxicity,semantic_types,33914097
non-hematologic adverse event,semantic_types,non-hematologic adverse event,semantic_types,33914097
complete remission,preferred_label,complete remission,preferred_label,33914097
allogeneic transplantation,preferred_label,allogeneic transplantation,preferred_label,33914097
overall survival,preferred_label,overall survival,preferred_label,33914097
event-free survival,preferred_label,event-free survival,preferred_label,33914097
tetraarsenic tetrasulfide,preferred_label,tetraarsenic tetrasulfide,preferred_label,33911851
acute promyelocytic leukemia,preferred_label,acute promyelocytic leukemia,preferred_label,33911851
pediatric patient,preferred_label,pediatric patient,preferred_label,33911851
arsenic concentration,preferred_label,arsenic concentration,preferred_label,33911851
pharmacokinetic analysis,preferred_label,pharmacokinetic analysis,preferred_label,33911851
adverse event,preferred_label,adverse event,preferred_label,33911851
EGFR inhibitor,drug,EGFR inhibitor,drug,33910927
MAPK pathway,biological pathway,MAPK pathway,biological pathway,33910927
BRAF inhibitor,drug,BRAF inhibitor,drug,33910927
human skin keratinocytes,cell type,human skin keratinocytes,cell type,33910927
phase I clinical trial,clinical trial phase,phase I clinical trial,clinical trial phase,33910927
LUT014,drug,LUT014,drug,33910927
metastatic colorectal cancer,disease,metastatic colorectal cancer,disease,33910927
acneiform rash,adverse event,acneiform rash,adverse event,33910927
cetuximab,drug,cetuximab,drug,33910927
panitumumab,drug,panitumumab,drug,33910927
grade 2 rash,adverse event outcome,grade 2 rash,adverse event outcome,33910927
smallcell lung cancer,class_id,smallcell lung cancer,class_id,33910796
cisplatin and etoposide chemotherapy,preferred_label,cisplatin and etoposide chemotherapy,preferred_label,33910796
platinumcontaining combination regimen,synonyms,platinumcontaining combination regimen,synonyms,33910796
severe refractory headache,preferred_label,severe refractory headache,preferred_label,33910796
selinexor,preferred_label,selinexor,preferred_label,33909232
nuclear export sine compound,class_id,nuclear export sine compound,class_id,33909232
exportin1xpo1,class_id,exportin1xpo1,class_id,33909232
chemotherapy,preferred_label,chemotherapy,preferred_label,33909232
topotecan,preferred_label,topotecan,preferred_label,33909232
solid tumor,preferred_label,solid tumor,preferred_label,33909232
gynecological cancer,preferred_label,gynecological cancer,preferred_label,33909232
ovarian cancer,preferred_label,ovarian cancer,preferred_label,33909232
endometrial cancer,preferred_label,endometrial cancer,preferred_label,33909232
fallopian tube cancer,preferred_label,fallopian tube cancer,preferred_label,33909232
vaginal cancer,preferred_label,vaginal cancer,preferred_label,33909232
anemia,preferred_label,anemia,preferred_label,33909232
thrombocytopenia,preferred_label,thrombocytopenia,preferred_label,33909232
hyponatremia,preferred_label,hyponatremia,preferred_label,33909232
vomiting,preferred_label,vomiting,preferred_label,33909232
fatigue,preferred_label,fatigue,preferred_label,33909232
nausea,preferred_label,nausea,preferred_label,33909232
neutropenia,preferred_label,neutropenia,preferred_label,33909232
partial response,preferred_label,partial response,preferred_label,33909232
time-to-treatment failure,preferred_label,time-to-treatment failure,preferred_label,33909232
dose limiting toxicity,preferred_label,dose limiting toxicity,preferred_label,33909232
clinical benefit rate,preferred_label,clinical benefit rate,preferred_label,33909232
phase 2 dose,preferred_label,phase 2 dose,preferred_label,33909232
immunogenic cell death,preferred_label,immunogenic cell death,preferred_label,33909000
adaptive immune response,preferred_label,adaptive immune response,preferred_label,33909000
danger-associated molecular pattern,preferred_label,danger-associated molecular pattern,preferred_label,33909000
nanoparticle-based therapeutic,preferred_label,nanoparticle-based therapeutic,preferred_label,33909000
cancer immunotherapy,preferred_label,cancer immunotherapy,preferred_label,33909000
vemurafenib,drug,vemurafenib,drug,33908053
cobimetinib,drug,cobimetinib,drug,33908053
melanoma,disease,melanoma,disease,33908053
skin rash,adverse event,skin rash,adverse event,33908053
toxicity,adverse event,toxicity,adverse event,33908053
patient,class_id,patient,class_id,33908053
bruton tyrosine kinase btk inhibition,preferred_label,bruton tyrosine kinase btk inhibition,preferred_label,33907299
bcell malignancy,preferred_label,bcell malignancy,preferred_label,33907299
acalabrutinib,preferred_label,acalabrutinib,preferred_label,33907299
adverse event,preferred_label,adverse event,preferred_label,33907299
headache,preferred_label,headache,preferred_label,33907299
diarrhea,preferred_label,diarrhea,preferred_label,33907299
upper respiratory tract infection,preferred_label,upper respiratory tract infection,preferred_label,33907299
contusion,preferred_label,contusion,preferred_label,33907299
nausea,preferred_label,nausea,preferred_label,33907299
fatigue,preferred_label,fatigue,preferred_label,33907299
cough,preferred_label,cough,preferred_label,33907299
serious aes,preferred_label,serious aes,preferred_label,33907299
pneumonia,preferred_label,pneumonia,preferred_label,33907299
death,preferred_label,death,preferred_label,33907299
infection,preferred_label,infection,preferred_label,33907299
hemorrhage,preferred_label,hemorrhage,preferred_label,33907299
neutropenia,preferred_label,neutropenia,preferred_label,33907299
anemia,preferred_label,anemia,preferred_label,33907299
second primary malignancy,preferred_label,second primary malignancy,preferred_label,33907299
thrombocytopenia,preferred_label,thrombocytopenia,preferred_label,33907299
hypertension,preferred_label,hypertension,preferred_label,33907299
atrial fibrillation,preferred_label,atrial fibrillation,preferred_label,33907299
immune checkpoint inhibitor,drug,immune checkpoint inhibitor,drug,33906378
adverse immune event,adverse event,adverse immune event,adverse event,33906378
hypopharynx cancer,disease,hypopharynx cancer,disease,33906378
oropharynx cancer,disease,oropharynx cancer,disease,33906378
nivolumab,drug,nivolumab,drug,33906378
diarrhea,adverse event,diarrhea,adverse event,33906378
abdominal pain,adverse event,abdominal pain,adverse event,33906378
corticosteroid,drug,corticosteroid,drug,33906378
lymphocyte infiltration,biological process,lymphocyte infiltration,biological process,33906378
immune checkpoint inhibitor,drug,immune checkpoint inhibitor,drug,33906146
endocrine dysfunction,disease,endocrine dysfunction,disease,33906146
thyroid dysfunction,disease,thyroid dysfunction,disease,33906146
hypophysitis,disease,hypophysitis,disease,33906146
type 1 diabetes,disease,type 1 diabetes,disease,33906146
primary adrenal insufficiency,disease,primary adrenal insufficiency,disease,33906146
hypoparathyroidism,disease,hypoparathyroidism,disease,33906146
Immunotherapy,drug,Immunotherapy,drug,33906139
Cutaneous manifestation,adverse event,Cutaneous manifestation,adverse event,33906139
Hypothyroidism,disease,Hypothyroidism,disease,33906139
Colitis,disease,Colitis,disease,33906139
Pneumonitis,disease,Pneumonitis,disease,33906139
Neurologic disorder,disease,Neurologic disorder,disease,33906139
Hepatitis,disease,Hepatitis,disease,33906139
Glucocorticoid,drug,Glucocorticoid,drug,33906139
Mycophenolate,drug,Mycophenolate,drug,33906139
Intravenous immunoglobulin,drug,Intravenous immunoglobulin,drug,33906139
egfr mutationpositive nsclc,semantic_types,egfr mutationpositive nsclc,semantic_types,33905962
ramucirumab,preferred_label,ramucirumab,preferred_label,33905962
erlotinib,preferred_label,erlotinib,preferred_label,33905962
relay trial,class_id,relay trial,class_id,33905962
east asia,class_id,east asia,class_id,33905962
euus,class_id,euus,class_id,33905962
immune-related adverse event (irAE),preferred_label,immune-related adverse event (irAE),preferred_label,33904518
immune checkpoint inhibitor,preferred_label,immune checkpoint inhibitor,preferred_label,33904518
melanoma,preferred_label,melanoma,preferred_label,33904518
PD-1 inhibitor,preferred_label,PD-1 inhibitor,preferred_label,33904518
BRAF mutated,preferred_label,BRAF mutated,preferred_label,33904518
brain metastasis,preferred_label,brain metastasis,preferred_label,33904518
dermatologic toxicity,preferred_label,dermatologic toxicity,preferred_label,33904518
endocrine toxicity,preferred_label,endocrine toxicity,preferred_label,33904518
overall survival,preferred_label,overall survival,preferred_label,33904518
antibodydrug conjugate,class_id,antibodydrug conjugate,class_id,33904380
cytotoxic drug,class_id,cytotoxic drug,class_id,33904380
tumor cell,class_id,tumor cell,class_id,33904380
cancerspecific antibody,class_id,cancerspecific antibody,class_id,33904380
reductive alkylation,class_id,reductive alkylation,class_id,33904380
trastuzumab,class_id,trastuzumab,class_id,33904380
monomethyl auristatin,class_id,monomethyl auristatin,class_id,33904380
pembrolizumab,drug,pembrolizumab,drug,33902379
extensive sclc,disease,extensive sclc,disease,33902379
phase iii clinical trial,clinical trial,phase iii clinical trial,clinical trial,33902379
atezolizumab,drug,atezolizumab,drug,33902379
durvalumab,drug,durvalumab,drug,33902379
checkpoint inhibitor,drug,checkpoint inhibitor,drug,33902379
adjuvant axitinib,drug,adjuvant axitinib,drug,33901868
renal cell carcinoma,disease,renal cell carcinoma,disease,33901868
Asian patients,ethnicity,Asian patients,ethnicity,33901868
non-Asian patients,ethnicity,non-Asian patients,ethnicity,33901868
Japanese patients,ethnicity,Japanese patients,ethnicity,33901868
Korean patients,ethnicity,Korean patients,ethnicity,33901868
Chinese patients,ethnicity,Chinese patients,ethnicity,33901868
nasopharyngitis,adverse event,nasopharyngitis,adverse event,33901868
fatigue,adverse event,fatigue,adverse event,33901868
asthenia,adverse event,asthenia,adverse event,33901868
proteinuria,adverse event,proteinuria,adverse event,33901868
hypothyroidism,adverse event,hypothyroidism,adverse event,33901868
hypertension,adverse event,hypertension,adverse event,33901868
l19tnf,recombinant fusion protein,l19tnf,recombinant fusion protein,33901793
human tumour necrosis factor,protein,human tumour necrosis factor,protein,33901793
oncofetal fibronectin,protein,oncofetal fibronectin,protein,33901793
doxorubicin,drug,doxorubicin,drug,33901793
soft tissue sarcoma,disease,soft tissue sarcoma,disease,33901793
ibrutinib,drug,ibrutinib,drug,33900450
venetoclax,drug,venetoclax,drug,33900450
diffuse large b cell lymphoma,disease,diffuse large b cell lymphoma,disease,33900450
nongcb subtype,subtype,nongcb subtype,subtype,33900450
BCL2,gene,BCL2,gene,33900450
hcc,class_id,hcc,class_id,33896016
myc oncogene,class_id,myc oncogene,class_id,33896016
dimethylarginine,class_id,dimethylarginine,class_id,33896016
sdma,class_id,sdma,class_id,33896016
prmt,class_id,prmt,class_id,33896016
cdkn1bp,class_id,cdkn1bp,class_id,33896016
gsk3326595,class_id,gsk3326595,class_id,33896016
pd1,class_id,pd1,class_id,33896016
ribosome inactivating protein,class_id,ribosome inactivating protein,class_id,33895972
drug resistance transporter,class_id,drug resistance transporter,class_id,33895972
trichosanthin,class_id,trichosanthin,class_id,33895972
gelonin,class_id,gelonin,class_id,33895972
scorpion venom-derived rip,class_id,scorpion venom-derived rip,class_id,33895972
cancer therapy,class_id,cancer therapy,class_id,33895972
